Page last updated: 2024-12-04

uric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

uric acid : An oxopurine that is the final oxidation product of purine metabolism. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1175
CHEMBL ID792
CHEBI ID17775
CHEBI ID46817
CHEBI ID46811
CHEBI ID46814
CHEBI ID46823
CHEBI ID62589
CHEBI ID27226
SCHEMBL ID7933
SCHEMBL ID15777793
SCHEMBL ID17081907
MeSH IDM0022340

Synonyms (110)

Synonym
nsc3975
2,8-trihydroxypurine
2,8-trioxypurine
purine-2,8(1h,3h,9h)-trione
1h-purine-2,8(3h)-trione, 7,9-dihydro-
1h-purine-2,8-triol
nsc-3975
lithic acid
2,8-trioxopurine
purine-2,6,8(1h,3h,9h)-trione
2,6,8-trioxopurine
6,8-dioxo-6,7,8,9-tetrahydro-1h-purin-2-olate
CHEBI:17775 ,
NCGC00181032-01
7,9-dihydro-3h-purine-2,6,8-trione
1h-purine-2,6,8(3h)-trione, 7,9-dihydro-
inchi=1/c5h4n4o3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h(h4,6,7,8,9,10,11,12
1h-purine-2,6,8(3h)-trione, 7,9-dihydro- (9ci)
8-hydroxyxanthine
2,6,8-trihydroxypurine
1h-purine-2,6,8-triol 2,6,8-trihydroxypurine
ai3-15432
uric acid (8ci)
trioxopurine
1h-purine-2,6,8-triol
purine-2,6,8-(1h,3h,9h)-trione
C00366
uric acid
2,6,8-trioxypurine
7,9-dihydro-1h-purine-2,6,8(3h)-trione
69-93-2
URATE ,
urc ,
uric acid, bioxtra, >=99% (hplc)
uric acid, >=99%, crystalline
1L5S
CHEBI:46817
9h-purine-2,6,8-triol
CHEBI:46811
7h-purine-2,6,8-triol
2,6-dihydroxy-7,9-dihydro-8h-purin-8-one
CHEBI:46814
CHEBI:46823 ,
nsc 3975
einecs 200-720-7
acid, uric
U-6050
565FF3AF-8AFA-4EE9-9FC4-6B119784A5BB
uricum acidum
idelalisib metabolite m54
CHEMBL792 ,
AKOS000118731
BMSE000126
U0018
dtxsid3042508 ,
dtxcid1022508
tox21_113563
cas-69-93-2
7,9-dihydro-3h-purine-2,6,8-trione(urate)
7,9-dihydro-3h-purine-2,6,8-trione(uric acid)
bdbm50325824
1h-purine-2,6,8(3h,7h,9h)-trione
S3955
CHEBI:62589
6-hydroxy-1h-purine-2,8(7h,9h)-dione
unii-268b43mj25
268b43mj25 ,
FT-0631301
8-hydroxy-3,9-dihydro-1h-purine-2,6-dione
8hx ,
uricum acidum [hpus]
uric acid [inci]
uric acid [mi]
2,3,6,7,8,9-hexahydro-1h-purine-2,6,8-trione
gtpl4731
DB08844
SCHEMBL7933
SCHEMBL15777793
purine-2,6,8-triol
purine-3,6,8(1h,3h,9h)-trione
HMS3604N17
mfcd00005712
SCHEMBL17081907
SR-01000945208-1
sr-01000945208
hypoxanthinediol
uric acid, 99.0%
uric acid, nist(r) srm(r) 913b
2,6,8-trihydroxypurin
lithate
'7,9-dihydro-1h-purine-2,6,8(3h)-trione'
HY-B2130
BCP28980
Z104473370
2,6-dihydroxy-7,9-dihydropurin-8-one
CCG-339700
CS-0020287
Q105522
AMY23430
STL185577
uric-acid
SY057305
A866713
AS-56119
(s)-3-aminoquinuclidine hcl
2,6,8-trioxypurine;2,6,8-trihydroxypurine
EN300-19268
chebi:27226
uric acid1547
uric acids

Research Excerpts

Overview

Uric acid is a waste metabolite produced from the breakdown of purines. Elevated serum uric acid levels are associated with higher risk of hypertension, cardiovascular disease, and mortality and progression of chronic kidney disease (CKD) Uric acid has been reported to be a potential risk factor in the development of nervous system diseases.

ExcerptReferenceRelevance
"Uric acid is an important indicator of the insect infestation assessment in flour. "( An Analytical Method Based on Electrochemical Sensor for the Assessment of Insect Infestation in Flour.
Fu, L; Karimi-Maleh, H; Zhu, J, 2021
)
2.06
"High uric acid levels are a risk factor for cardiovascular disorders, and metabolic diseases; however, the role of serum uric acid (sUA) during the mycoplasma pneumoniae pneumonia (MPP) of children is poorly known. "( The study of routine laboratory factors in children with mycoplasma pneumoniae pneumonia: serum uric acid may have anti-inflammatory effect.
Chen, Y; Li, M; Pan, C; Qu, S; Wang, S, 2021
)
1.35
"Uric acid is an effective antioxidant. "( Protective Effect of Uric Acid on ox-LDL-Induced HUVECs Injury via Keap1-Nrf2-ARE Pathway.
Bi, H; Hao, Z; Lin, Y; Liu, Y; Xia, Y; Xie, Y; Yang, X, 2021
)
2.38
"Uric acid (UA) is a product of the catabolism of purines, and its increase in blood may be related to the development of cardiometabolic diseases. "( Uricaemia and associated health determinants in a paediatric population in Mexico.
Aradillas-García, C; Cossío-Torres, PE; Lares-Villaseñor, E; Portales-Pérez, DP; Salazar-García, S; Vargas-Morales, JM, 2022
)
2.16
"Uric acid (UA) is a risk factor associated with cardiometabolic diseases. "( Serum Uric Acid Levels and Cardiometabolic Profile in Middle-Aged, Treatment-Naïve Hypertensive Patients.
Kalaitzidis, RG; Theofilis, P; Tsimihodimos, V; Vordoni, A, 2022
)
2.64
"Uric acid is a waste metabolite produced from the breakdown of purines, and elevated serum uric acid levels are associated with higher risk of hypertension, cardiovascular disease, and mortality and progression of chronic kidney disease (CKD). "( Association of Uric Acid-Lowering Therapy With Incident Chronic Kidney Disease.
Hassan, W; Kalantar-Zadeh, K; Kovesdy, CP; Potukuchi, PK; Rhee, CM; Shrestha, P; Streja, E; Sumida, K; Sweeney, PL; Thomas, F, 2022
)
2.52
"Uric acid is a natural antioxidant, and low levels of uric acid have been reported to be a potential risk factor in the development of nervous system diseases. "( Low serum uric acid levels are associated with incidence and severity in trigeminal neuralgia.
Chang, B; Chen, P; Guan, H; Ni, C; Niu, C; Wang, X, 2022
)
2.57
"Uric acid (UA) is an important biomarker for many diseases. "( Digital Quantification Method for Sensitive Point-of-Care Detection of Salivary Uric Acid Using Smartphone-Assisted μPADs.
Deng, Y; Fan, K; Lian, K; Liu, G; Wang, G; Yang, C; Zeng, J; Zhou, X, 2022
)
2.39
"Uric acid is an independent risk factor for the formation of thyroid nodules. "( The association of uric acid with the development of thyroid nodules: a retrospective cohort study.
Huang, Y; Li, Z; Wei, C; Xu, W; Yang, K; Yang, P; Zhang, L, 2022
)
2.49
"Uric acid (UA) is an important endogenous antioxidant that protects against oxidative stress, yet its exact role in neurodegeneration remains unclear."( Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study.
Aerqin, Q; Chen, KL; Chen, SF; Dong, Q; Huang, YY; Jia, SS; Li, Q; Ou, YN; Shen, XN; Yu, JT, 2022
)
1.92
"Uric acid (UA) is an endogenous antioxidant, low levels of which are also implicated in neurodegenerative disease."( The Influence of Agricultural Work and Plasma Uric Acid on Hospital Admission for Alzheimer's Disease.
Liu, H; Reynolds, GP; Wei, X, 2023
)
1.89
"Uric acid is an emerging biomarker for cardiovascular morbidity and mortality, but its association with all-cause mortality and ECG findings remains unestablished, specifically among older adults. "( Sex specific serum uric acid levels are associated with ischemic changes on ECG and with 20-year all-cause mortality among older adults.
Chetrit, A; Dankner, R; Goldman, A; Moshkovits, Y, 2023
)
2.68
"Uric acid which is a purine metabolite is one of the serum inflammation markers."( The Role Of Serum Uric Acid And Uric Acid To Albumin Ratio For Predicting Of Lymph Node Metastasis In Lung Cancer Treated Surgically By Vats.
Celik, A; Kankoc, A; Ozkan, D; Satir Turk, M; Sayan, M; Tombul, I, 2023
)
1.97
"Uric acid is a kind of natural antioxidant that plays a major role in the antioxidant capacity against oxidative stress."( Serum Uric Acid Levels Are Related to Diabetic Peripheral Neuropathy, Especially for Motor Conduction Velocity of Tibial Nerve in Type 2 Diabetes Mellitus Patients.
Chen, Y; He, M; Vladmir, C; Wang, W; Xu, J; Zhang, H; Zhang, Y; Zhang, Z; Zhao, W; Zhou, W, 2023
)
2.11
"Uric acid (UA) is an important antioxidant that has been positively associated with muscle strength in older adults."( Association between serum uric acid and muscle strength in older adults with or without gout diagnosis: NHANES 2011-2014.
de Oliveira, EP; Nahas, PC; Nehme, R, 2023
)
1.93
"Uric acid (UA) is a strong endogenous antioxidant that neutralizes the toxicity of peroxynitrite and other reactive species on the neurovascular unit generated during and after acute brain ischemia. "( Uric Acid: A Translational Journey in Cerebroprotection That Spanned Preclinical and Human Data.
Chamorro, A; Chauhan, AK; Leira, EC; Planas, AM, 2023
)
3.8
"Uric acid (UA) is an important natural antioxidant and strong peroxynitrite scavenger, but little is known about central nervous system (CNS) levels of UA in patients with anti-N-methyl-d-aspartate receptor encephalitis (NMDARE)."( Cerebrospinal fluid uric acid levels associated with disease severity in patients with anti-N-methyl-d-aspartate receptor encephalitis.
Cao, B; Huang, Y; Li, H; Li, Q; Lu, Y; Luo, M; Peng, F; Ruan, H; Shu, Y; Xiong, L, 2023
)
2.68
"Uric acid (UA) is an independent prognostic factor for cardiovascular events, but there are no data demonstrating a different risk profile between women and men. "( Sex-related differences for uric acid in the prediction of cardiovascular events in essential hypertension. A population prospective study.
Andreozzi, F; Caroleo, B; Gigliotti, S; Maio, R; Perticone, F; Perticone, M; Sciacqua, A; Shehaj, E; Suraci, E, 2023
)
2.65
"Uric acid (UA) is an antioxidant with neuroprotective effects in experimental stroke models. "( Serum Uric Acid and Risk of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke.
Cheng, Y; Liu, J; Liu, M; Song, Q; Wang, Y; Wei, C, 2020
)
2.48
"Uric acid is a purine degradation product but also an important antioxidant and reactive oxygen species (ROS) scavenger. "( Human concentrations of uric acid scavenges adaptive and maladaptive reactive oxygen species in isolated rat hearts subjected to ischemic stress.
Boardman, NT; Chu, X; Falck, AT; Jenssen, TG; Lund, T; Martin-Armas, M; Norvik, JV; Ytrehus, K, 2020
)
2.31
"Uric acid is a danger signal contributing to inflammation. "( Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working Party.
Basak, GW; Blau, IW; Clausen, J; Cortelezzi, A; Duarte, RF; Finke, J; Ganser, A; Greinix, H; Kaynar, L; Moreira, MC; Niittyvuopio, R; Ozkurt, Z; Pascual-Cascon, MJ; Pavlu, J; Peczynski, C; Penack, O; Rovira, M; Schoemans, H; Schroyens, W; Sierra, J; Turlure, P; van der Velden, W; van der Werf, S; Wulf, G, 2020
)
2.35
"Uric acid (UA) is an end-product of purine catabolism and its increase in blood is a risk factor for several diseases. "( Influence of muscle mass on the serum uric acid levels in children and adolescents.
Alvim, RO; Dutra, DM; Mill, JG; Oliosa, PR; Siqueira, JH; Zaniqueli, D, 2020
)
2.27
"Uric acid (UA) is a major contributor to naturally-occurring antioxidant activity and is thought to have protective effects against neurodegenerative processes. "( Uric Acid and High-Density Lipoprotein Cholesterol Are Differently Associated with Alzheimer's Disease and Vascular Dementia.
Liu, H; Reynolds, GP; Wei, X, 2020
)
3.44
"Uric acid is a potential metabolite that serves as a danger-associated molecular pattern (DAMP) and induces inflammatory responses in sterile environments. "( Inflammatory response of uric acid produced by Porphyromonas gingivalis gingipains.
An, SJ; Choi, BK; Jun, HK; Kim, HY, 2020
)
2.3
"Uric acid (UA) acts as an antioxidant and scavenges free radicals, upregulates glutamate transporters on astrocytes, and preserves neuronal viability in in vitro and in vivo SCI models, making it a promising therapeutic candidate."( Uric acid released from poly(ε-caprolactone) fibers as a treatment platform for spinal cord injury.
Firestein, BL; Freeman, JW; Khaliq, S; Patel, M; Singh, NK; Vedula, S; Wheeler, N, 2021
)
2.79
"Uric acid (UA) is an important endogenous free radical scavenger that has been found to have a neuroprotective effect. "( Prognostic significance of uric acid change in acute ischemic stroke patients with reperfusion therapy.
Cui, T; Hao, Z; Wang, A; Wang, C; Wang, L; Wu, B; Yuan, Y; Zhu, Q, 2021
)
2.36
"Uric acid level is a risk factor for kidney disease."( Uric acid level and kidney function: a cross-sectional study of the Korean national health and nutrition examination survey (2016-2017).
Choi, DW; Joo, HJ; Joo, JH; Kim, GR; Park, EC, 2020
)
2.72
"Uric acid (UA) is an important antioxidant and it seems to be positively associated with muscle strength in older adults; however, the current evidence is still limited."( Serum uric acid is positively associated with muscle strength in older men and women: Findings from NHANES 1999-2002.
Azeredo, CM; de Branco, FMS; de Oliveira, EP; Nahas, PC; Rinaldi, AEM; Rossato, LT, 2021
)
1.82
"Uric acid is an end product of purine metabolism in human beings. "( Uric Acid and Urate in Urolithiasis: The Innocent Bystander, Instigator, and Perpetrator.
Adomako, E; Moe, OW, 2020
)
3.44
"Uric acid is a powerful antioxidant. "( Detrimental effects of long-term elevated serum uric acid on cognitive function in rats.
Gu, CW; Jia, H; Li, SJ; Li, TT; Liu, XR; Nie, ZC; Tang, Y; Tian, T; Xu, WD, 2021
)
2.32
"Uric acid acts as an antioxidant as well as a prooxidant under different conditions, thus, its role in disease also varies."( Purine metabolites and complex diseases: role of genes and nutrients.
Nelson, KL; Voruganti, VS, 2021
)
1.34
"Uric acid renal stones are a frequent and important part of our clinical practice. "( [Medical management of uric acid renal stones, case description.]
Cano García, MC; Melgarejo Segura, MT; Morales Martínez, A, 2021
)
2.37
"Uric acid is a metabolic product of nucleic acid and protein. "( Fine-needle aspiration cytology finding uric acid crystals produced by
Khairwa, A, 2021
)
2.33
"Uric acid is a degradation product of purines, which is an indicator of insect infestation and the state of stored grains and pulses."( Validation and comparison of analytical methods for the determination of uric acid in pulses and cereals by salting out assisted extraction by Rapid resolution liquid chromatography.
Chandra Ir, A; Das, L; Das, S; Gupta, A; Kumar Mallick, A, 2021
)
1.57
"Uric acid is an endogenous antioxidant making it a drug candidate to improve stroke outcomes."( Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy.
Amaro, S; Arenillas, JF; Blasco, J; Cánovas, D; Castellanos, M; Chamorro, Á; Gomis, M; Leira, EC; Macho, J; Marti-Fabregas, J; Muñoz, R; Planas, AM; Román, LS; Urra, X, 2017
)
2.62
"Uric acid (UA) is an important anti-oxidant in plasma."( Roles of serum uric acid, prolactin levels, and psychosocial factors in oral lichen planus.
Goel, S; Gupta, A; Gupta, S; Kamarthi, N; Malik, SS; Mohan, RP, 2017
)
1.53
"Uric acid (UA) is a powerful antioxidant that may have neuroprotective properties, yet it is also a risk factor of vascular disease that predisposes individuals to cognitive impairment. "( A Prospective Study on the Association between Uric Acid and Cognitive Function among Middle-Aged and Older Chinese.
Sun, Y; Wang, T; Wu, Y; Zhai, L; Zhang, D, 2017
)
2.15
"High uric acid levels are a risk factor for cardiovascular disorders and gout; however, the role of physiological concentrations of soluble uric acid (sUA) is poorly understood. "( Physiological concentrations of soluble uric acid are chondroprotective and anti-inflammatory.
Ho, LJ; Huang, CY; Hung, LF; Lai, JH; Lien, SB; Lin, LC; Liu, FC; Luo, SF; Yen, BL, 2017
)
1.24
"Uric acid (UA) is a kind of purine metabolism product and important in clinical diagnosis. "( Study of ZnS Nanostructures Based Electrochemical and Photoelectrochemical Biosensors for Uric Acid Detection.
Jiang, Z; Peng, N; Wang, J; Wei, X; Zhao, Y, 2017
)
2.12
"Uric acid is a final breakdown product of purine catabolism in humans. "( Correlation of retinal nerve fibre layer and macular thickness with serum uric acid among type 2 diabetes mellitus.
Azreen-Redzal, A; Nyi-Nyi, N; Vinuthinee-Naidu, MN; Zunaina, E, 2017
)
2.13
"Uric acid is a significant predictor of systolic BP and hypertension prevalence in the general adult population in Germany independently of several known dietary BP influences."( Diet-independent relevance of serum uric acid for blood pressure in a representative population sample.
Esche, J; Krupp, D; Mensink, GB; Neuhauser, HK; Remer, T, 2017
)
1.45
"Uric acid is a product of purine catabolism formed by the activity of xanthine-oxidase and prevalently excreted by the kidney. "( [The uric acid cardio-nephropathy].
Bonino, B; Cappadona, F; Pontremoli, R; Viazzi, F, 2017
)
2.41
"Uric acid (UA) is a potent scavenger of oxidants in most mammalian and avian species. "( Unexpected effect of urate on hydrogen peroxide-induced oxidative damage in embryonic chicken cardiac cells.
Jiao, H; Lin, H; Sun, X; Wang, X; Zhao, J,
)
1.57
"Uric acid is a product of purine metabolism. "( High serum uric acid concentration predicts poor survival in patients with breast cancer.
Feng, PN; Guo, YM; Li, LS; Lin, WB; Liu, M; Qian, YM; Yao, ZR; Yu, XG; Yue, CF, 2017
)
2.29
"Uric acid (UA) is an end product of purine metabolism by the enzyme xanthine oxidase (XOD). "( Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study.
Chen, HM; Chen, MH; Chen, RJ; Chen, SJ; Chen, YL; Hsiao, CM; Wang, YJ; Wu, MD; Yech, YJ; Yuan, GF, 2017
)
1.9
"If uric acid is shown to be a mediator of incident type 2 diabetes in humans, then lowering serum uric acid would represent a simple and inexpensive way to help prevent the development of diabetes and to slow the epidemic."( Uric Acid as a Cause of the Metabolic Syndrome.
Jensen, T; Johnson, RJ; King, C; Lanaspa, MA; Sánchez-Lozada, LG; Tolan, DR, 2018
)
2.44
"Uric acid (UA) is an end product of purine metabolism in humans and great apes. "( Uric acid and cardiovascular disease.
Ndrepepa, G, 2018
)
3.37
"Uric acid is a strong antioxidant and might be a biomarker in neurodegenerative process."( Uric acid level may not be reduced in essential tremor.
Hong, JY; Kang, SY; Lee, CY; Park, JH; Sunwoo, MK; Yoon, JH, 2018
)
2.64
"Uric acid (UA) is an important biomarker for clinical diagnosis. "( A novel signal transduction system for development of uric acid biosensors.
Cao, J; Li, S; Liu, W; Qi, F; Wang, W; Xiang, W; Yang, K; Yao, Y; Zhang, L, 2018
)
2.17
"Uric acid (UA) is a metabolite of purine degradation and is involved in gout flairs and kidney stones formation. "( SLC2A9 (GLUT9) mediates urate reabsorption in the mouse kidney.
Auberson, M; Bonny, O; Koesters, R; Seuwen, K; Stadelmann, S; Stoudmann, C; Thorens, B, 2018
)
1.92
"Uric acid is a molecule that is known to act as a natural antioxidant in acute oxidative stress conditions such as acute ischemic stroke (AIS). "( Can high uric acid levels be an independent risk factor for acute ischemic stroke due to large-artery atherosclerosis?
Acar, AB; Acar, T; Gül, SS; Güzey Aras, Y, 2018
)
2.34
"Uric acid (UA) is a byproduct of the high-energy purine metabolism and is conventionally regarded as a marker of cardio-metabolic impairment. "( Serum uric acid potentially links metabolic health to measures of fuel use in lean and obese individuals.
Aimaretti, G; Mai, S; Marzullo, P; Mele, C; Saraceno, G; Scacchi, M; Tagliaferri, MA; Vietti, R; Zavattaro, M, 2018
)
2.4
"Uric acid is a major non-enzymatic antioxidant in the blood, and it exerts a protective action on vitamin C."( The Association Between Serum Uric Acid Level and Prognosis in Critically Ill Patients, Uric Acid as a Prognosis Predictor.
Er, MC; Kucuk, AO; Ozturk, CE; Pehlivanlar-Kucuk, M; Ulger, F, 2018
)
1.49
"Uric acid (UA) is a risk marker of CKD and SUA level in CKD 3-4 patients closely correlates with hyperuricemic nephropathy (HN) morbidity. "( Risk factors analysis for hyperuricemic nephropathy among CKD stages 3-4 patients: an epidemiological study of hyperuricemia in CKD stages 3-4 patients in Ningbo, China.
Gao, C; Qiu, XH; Wu, F; Wu, YY; Xia, G; Ye, Y, 2018
)
1.92
"Uric acid is a soluble final product of endogenous and dietary purine metabolism, which is freely filtered in kidney glomeruli where approximately 90% of filtered uric acid is reabsorbed."( Mechanistic Insights of Soluble Uric Acid-related Kidney Disease.
Fu, P; Ma, L; Pan, J; Shi, M, 2020
)
1.56
"Uric acid (UA) is an end product of this process in terrestrial insects."( Identification of a novel function of the silkworm integument in nitrogen metabolism: Uric acid is synthesized within the epidermal cells in B. mori.
Banno, Y; Fujii, T, 2019
)
1.46
"Uric acid is an endogenous danger signal and activator of the inflammasome, and has been independently associated with an increased risk of cirrhosis."( Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
Aller, R; Ampuero, J; Andrade, RJ; Aspichueta, P; Buque, X; Burgos-Santamaría, D; Fernández Rodríguez, CM; Gómez-Camarero, J; Gutiérrez García, ML; Hernández-Guerra, M; Latorre, M; Martín-Mateos, RMª; Romero-Gómez, M; Rosales, JM, 2019
)
1.55
"Uric acid (UA) is a promising protective treatment in ischaemic stroke, but the precise molecular targets underlying its in vivo beneficial actions remain unclear. "( Uric acid treatment after stroke modulates the Krüppel-like factor 2-VEGF-A axis to protect brain endothelial cell functions: Impact of hypertension.
Amaro, S; Chamorro, Á; D'Ocon, P; Dantas, AP; Jiménez-Altayó, F; Masip, N; Planas, AM; Puertas-Umbert, L; Solé, M; Unzeta, M; Vila, E, 2019
)
3.4
"Uric acid (UA) is a major antioxidant molecule in the human blood, and it has been linked with cell longevity. "( Uric Acid Provides Protective Role in Red Blood Cells by Antioxidant Defense: A Hypothetical Analysis.
Bian, X; Cao, W; Gao, Y; Ge, W; Han, J; Huang, X; Li, S; Shao, M; Song, Y; Tang, B; Tang, L; Yao, T; Yuan, W; Zhang, H, 2019
)
3.4
"Uric acid (UA) is a major antioxidant molecule that has been hypothesized to have a protective effect against cancer-induced oxidative damage. "( Pretreatment Serum Uric Acid as an Efficient Predictor of Prognosis in Men with Laryngeal Squamous Cell Cancer: A Retrospective Cohort Study.
Cao, W; Hsueh, CY; Li, S; Shao, M; Zhou, L, 2019
)
2.29
"Uric acid (UA) is a hydrophilic antioxidant product associated with multiple sclerosis (MS). "( Serum uric acid level in patients with relapsing-remitting multiple sclerosis.
Aghaei, M; Ashtari, F; Bahar, M; Zahed, A, 2013
)
2.31
"Uric acid did not seem to be an independent risk factor for coronary artery calcium, although the prevalence and extent of coronary artery calcium increased along with the increasing trend of uric acid."( [Relation between uric acid and coronary artery calcification:a community-based cross-sectional survey among Beijing natural population].
Cao, HL; Chen, XB; Chen, Y; Gao, Y; Gu, DF; Hou, ZH; Jiang, SL; Li, Y; Lu, JG; LV, B; Tang, X; Yu, FF; Zhao, LC, 2013
)
2.17
"Uric acid acts as a leukocyte chemoattractant in the GI tract."( Pro-inflammatory effects of uric acid in the gastrointestinal tract.
Crane, JK; Mongiardo, KM, 2014
)
1.42
"Uric acid is an important contributor to inflammatory cytokine secretion, dendritic cell and T cell responses induced by Plasmodium, suggesting uric acid as a novel molecular target for anti-inflammatory therapies in malaria."( A surprising role for uric acid: the inflammatory malaria response.
Gallego-Delgado, J; Orengo, JM; Rodriguez, A; Ty, M; van de Hoef, D, 2014
)
1.44
"Uric acid (UA) is a natural antioxidant, and may have a beneficial role in neurodegenerative diseases."( Lower serum uric acid levels in cerebral amyloid angiopathy: a pilot study.
Cheng, L; Hu, Q; Huang, M; Jiang, H; Kang, H; Lian, L; Liang, Q; Liu, A; Liu, X; Xu, F; Zhang, C; Zhu, S, 2014
)
1.5
"Uric acid (UA) is a complex phenotype influenced by both genetic and environmental factors as well as their interactions. "( A genome-wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population.
Dai, X; Deng, Q; Feng, Y; Guan, L; Gui, L; Guo, H; He, M; He, Y; Hu, D; Hu, FB; Huang, S; Lang, M; Li, D; Li, J; Lin, D; Min, X; Mo, Z; Qiu, G; Wang, T; Wu, C; Wu, T; Yang, B; Yang, H; Yang, X; Yuan, J; Zhang, X; Zhou, L; Zhu, J, 2014
)
2.07
"Uric acid is an antioxidant with neuroprotective effects in experimental models of stroke. "( Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial.
Amaro, S; Arenillas, J; Cánovas, D; Carné, X; Castellanos, M; Chamorro, A; Deulofeu, R; Gállego, J; Gomis, M; Krupinski, J; Martí-Fábregas, J; Oleaga, L; Planas, AM; Román, LS; Segura, T; Torres, F, 2014
)
2.16
"Uric acid stones are a consequence of the excessively acidic urine that results from insulin resistance."( Metabolic syndrome: a multifaceted risk factor for kidney stones.
Domingos, F; Serra, A, 2014
)
1.12
"Uric acid (UA) is a marker of endothelial dysfunction."( The relationship between uric acid and erectile dysfunction in hypertensive subjects.
Akilli, H; Alibasic, H; Aribas, A; Avci, A; Demir, K; Kanbay, M; Katlandur, H; Kaya, Z; Kayrak, M; Keser, A; Solak, Y; Turan, Y; Ulucan, S, 2014
)
1.43
"Uric acid (UA) is a known danger signal and is released from injured cells during conditioning for allogeneic hematopoietic stem cell transplantation (HSCT), but its role in GVHD is unclear."( Association between low uric acid levels and acute graft-versus-host disease.
Blau, IW; Blau, O; Ostendorf, BN; Penack, O; Uharek, L, 2015
)
1.45
"Uric acid (UA) is a strong natural scavenger of reactive oxygen and nitrogen species, with evidence of possible use in the treatment of animal models of multiple sclerosis (MS). "( Uric acid: a potential biomarker of multiple sclerosis and of its disability.
Carotenuto, A; Lanzillo, R; Massarelli, M; Moccia, M; Morra, VB; Nardone, A; Palladino, R; Russo, C; Triassi, M; Vacca, G; Vacchiano, V, 2015
)
3.3
"High uric acid level is a known risk factor for deterioration of renal function in chronic kidney disease (CKD), but its influence on the progression of IgA nephropathy (IgAN) remains unclear."( High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a.
Itabashi, M; Iwabuchi, Y; Kataoka, H; Moriyama, T; Nishida, M; Nitta, K; Sato, M; Shimizu, A; Takei, T; Uchida, K, 2015
)
1.44
"Uric acid (UA) is a strong marker of cardiovascular disease. "( The association between serum uric acid level and heart failure and mortality in the early period of ST-elevation acute myocardial infarction.
Altun, B; Barutçu, A; Bekler, A; Gazi, E; Gazi, S; Güngör, O; Kurt, T; Ozcan, S; Temiz, A; Yener, AU, 2014
)
2.13
"Uric acid (UA) is an endogenous antioxidant which is known to reduce oxidative stress and also chelate iron ion. "( Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study.
Kim, TH; Lee, JH, 2014
)
2.33
"Uric acid is a potential important biomarker in urine and serum samples for early diagnosis of preeclampsia, a life-threatening hypertensive disorder that occurs during pregnancy. "( Quantitative detection of uric acid by electrochemical-surface enhanced Raman spectroscopy using a multilayered Au/Ag substrate.
Blackburn, J; Brosseau, CL; Zhao, L, 2015
)
2.16
"Uric acid (UA) serves as an antioxidant in vascular endothelial cells. "( Depletion of Uric Acid Due to SLC22A12 (URAT1) Loss-of-Function Mutation Causes Endothelial Dysfunction in Hypouricemia.
Hamada, T; Higashi, Y; Hisatome, I; Ichida, K; Kato, M; Kuwabara, M; Maharani, N; Ninomiya, H; Niwa, K; Ogino, K; Sugihara, S; Yamamoto, K, 2015
)
2.23
"Uric acid is a terminal metabolite of the degradation of nucleotides, which increases their blood levels in patients with preeclampsia increasing its synthesis by damage and death of trophoblastic cells and proliferation."( Serum uric acid level in normal pregnant and preeclamptic ladies: a comparative study.
Khatiwada, B; Pradhan, P; Pramanik, T, 2014
)
1.6
"Uric acid is a promising hydrophobic nitrogen source for biostimulation of microbial activities in oil-impacted marine environments. "( Conversion of Uric Acid into Ammonium in Oil-Degrading Marine Microbial Communities: a Possible Role of Halomonads.
Abdel-Fattah, YR; Amer, RA; Bargiela, R; Chen, J; Cherif, A; Daffonchio, D; Ferrer, M; Gertler, C; Golyshin, PN; Hai, T; Han, X; Kalogerakis, N; Magagnini, M; Mahjoubi, M; Malkawi, H; Mapelli, F, 2015
)
2.22
"Uric acid (UA) is a risk factor for cardiovascular (CV) disease. "( Uric acid is an independent predictor of cardiovascular events in post-menopausal women.
Cimellaro, A; Maio, R; Miceli, S; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G; Tassone, EJ, 2015
)
3.3
"Uric acid is a natural antioxidant, and it has been shown that low levels of uric acid could be a risk factor for the development of PD. "( Low serum uric acid levels in progressive supranuclear palsy.
Cáceres-Redondo, MT; Carballo, M; Carrillo, F; Gómez-Garre, P; Huertas-Fernández, I; Jesús, S; Mir, P; Oropesa-Ruiz, JM; Vargas-Gonzalez, L, 2016
)
2.28
"Uric acid is a known antioxidant, and one proposed mechanism of neurodegeneration in PD is oxidative damage of dopamine neurons."( Potential mechanisms for low uric acid in Parkinson disease.
Bernhard, D; Factor, S; Jinnah, HA; Millington, D; Rosen, A; Sampat, R; Young, S, 2016
)
1.45
"Uric acid is an oxidative stress marker."( Relationship between uric acid levels and progressive supranuclear palsy.
Brody, DM; Cunningham, CR; Hall, DA; Kluger, BM; Litvan, I; Riley, DE; Shprecher, DR; Warner, S, 2016
)
1.47
"Uric acid is a powerful determinant of blood pressure over time, independent of lifestyle modifications."( Increased Serum Uric Acid Levels Blunt the Antihypertensive Efficacy of Lifestyle Modifications in Children at Cardiovascular Risk.
Antolini, L; Genovesi, S; Giussani, M; Orlando, A; Pontremoli, R; Rebora, P; Stella, A; Valsecchi, MG; Viazzi, F, 2016
)
1.5
"Uric acid is a product of purine metabolism and has been linked to gout and kidney calculi. "( Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
Al Kattar, S; Jurjus, A; Mallat, SG; Tanios, BY, 2016
)
1.88
"Uric acid is a metabolite obtained from purine by xanthine oxidase activity (XO) and high levels of serum uric acid leads to hyperuricemia and gout. "( Hypouricemic effects of Mesona procumbens Hemsl. through modulating xanthine oxidase activity in vitro and in vivo.
Hsu, CL; Jhang, JJ; Liao, JW; Lin, JH; Lu, CC; Ong, JW; Yen, GC, 2016
)
1.88
"Uric acid is a naturally occurring, endogenous compound that impacts mental health. "( The hippocampal response to psychosocial stress varies with salivary uric acid level.
Goodman, AM; Granger, DA; Harnett, NG; Knight, DC; Mrug, S; Wheelock, MD, 2016
)
2.11
"Uric acid (UA) is a purine metabolite that in most mammals is degraded by the hepatic enzyme uricase to allantoin. "( Uric Acid Induces Cognitive Dysfunction through Hippocampal Inflammation in Rodents and Humans.
Cen, X; Gao, F; Hu, J; Jie, H; Li, D; Li, Y; Lu, W; Shao, X; Zhao, Y; Zuo, Z, 2016
)
3.32
"Uric acid (UA) is a potential risk factor of the progression of chronic kidney disease (CKD). "( Uric acid metabolism of kidney and intestine in a rat model of chronic kidney disease.
Hosoyamada, M; Kumagai, T; Nagura, M; Tamura, Y; Uchida, S, 2016
)
3.32
"Uric acid (UA) is a major antioxidant molecule and has been hypothesized to have a protective effect on the central nervous system against oxidative damage. "( The association between serum uric acid and glaucoma severity in primary angle closure glaucoma: a retrospective case-control study.
Cao, W; Li, S; Shao, M; Sun, X; Tang, B; Zhang, A, 2017
)
2.19
"Uric acid is a risk factor for coronary artery disease in postmenopausal women, but the association with inflammation and coronary endothelial dysfunction (CED) is not well defined. "( Uric Acid Is Associated With Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women.
Gulati, R; Herrmann, J; Lerman, A; Lerman, LO; Matteson, EL; Prasad, M; Rihal, CS, 2017
)
3.34
"Uric acid (UA) is an antioxidant found in human serum. "( Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations.
Cai, G; Chen, X; Cui, S; Feng, Z; Hong, Q; Huang, Z; Lv, Y; Wang, L; Wu, D; Xiao, W; Zhang, X, 2017
)
2.13
"Uric acid is a damage-associated molecular pattern (DAMP), released from ischemic tissues and dying cells which, when crystalized, is able to activate the NLRP3 inflammasome. "( Soluble Uric Acid Activates the NLRP3 Inflammasome.
Barbuto, JA; Braga, TT; Branco, P; Camara, NO; Castoldi, A; Correa-Costa, M; Davanso, MR; Forni, MF; Franklin, BS; Hiyane, MI; Kowaltowski, AJ; Latz, E; Ramos, RN, 2017
)
2.33
"Uric acid (UA) is a strong immunological danger signal."( Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.
Bethge, WA; Eyb, V; Faul, C; Haen, SP; Heni, M; Kanz, L; Löffler, MW; Mirza, N; Naumann, A; Peter, A; Rammensee, HG; Vogel, W, 2017
)
2.62
"Uric acid (UA) is a natural antioxidant and iron scavenger in the human body, which has been hypothesized to exert an anti-oxidative effect in Parkinson's disease (PD). "( Serum uric acid levels and freezing of gait in Parkinson's disease.
Cao, B; Hou, Y; Ou, R; Shang, H; Song, W; Wei, Q; Xu, Y; Zhao, B, 2017
)
2.38
"Uric acid is a natural antioxidant. "( Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Ahuja, W; Jaruvongvanich, V; Ungprasert, P; Wijarnpreecha, K, 2017
)
1.9
"Uric acid is an important antioxidant, as proven by its contribution to TAS as determined by the Randox test."( Determination of uric acid concentrations in human tear fluid, aqueous humour and serum.
Faschinger, C; Horwath-Winter, J; Kirchengast, S; Meinitzer, A; Schmut, O; Wachswender, C, 2009
)
1.41
"Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD."( Uric acid in Parkinson's disease.
Schlesinger, I; Schlesinger, N, 2008
)
2.51
"Uric acid is an antioxidant and perhaps helps to control blood pressure during a low Na+ diet through stimulation of the renin-angiotensin system."( Uric acid: bystander or culprit in hypertension and progressive renal disease?
Menè, P; Punzo, G, 2008
)
2.51
"Uric acid (UA) crystals are a potent stimulator of inflammation, but how they activate immune cells is not known. "( "Dangerous crystals".
DeFranco, AL, 2008
)
1.79
"Uric acid is a risk factor of cardiovascular disease, as well as a major natural antioxidant, prohibiting the occurrence of cellular damage. "( Serum uric acid and cognitive function and dementia.
Breteler, MM; Euser, SM; Hofman, A; Westendorp, RG, 2009
)
2.28
"Uric acid is a major contributor of the inflammatory response triggered by P. "( Uric acid is a mediator of the Plasmodium falciparum-induced inflammatory response.
Day, K; Evans, B; Evans, JE; Leliwa-Sytek, A; Nyako, M; Orengo, JM; Rodriguez, A; van de Hoef, D, 2009
)
3.24
"Uric acid (UA) is known to be a major biological antioxidant in plasma. "( A sensitive and specific liquid chromatography-tandem mass spectrometry method for the determination of intracellular and extracellular uric acid.
Feig, DI; Frye, RF; Henderson, GN; Johnson, RJ; Kim, KM; Ouyang, X; Sautin, YY, 2009
)
2
"Uric acid (UA) is an emerging cardiovascular (CV) risk factor that is associated with hypertension and CV disease (CVD) in the general population, but whose role in renal transplant recipients (RTR) has not been defined. "( Role of uric acid in post-renal transplantation hypertension.
Bandukwala, F; Huang, M; Prasad, GV, 2009
)
2.23
"Uric acid is an important natural antioxidant that may reduce oxidative stress."( Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?
Artamonov, I; Berliner, S; Drory, VE; Ish-Shalom, M; Keizman, D; Maimon, N; Nefussy, B; Tsehori, J; Vered, Y, 2009
)
1.63
"Uric acid (UA) is a potent hydrophilic antioxidant that is modified by diet and drug."( Uric acid as a CNS antioxidant.
Bowman, GL; Frei, B; Kaye, JA; Quinn, JF; Shannon, J, 2010
)
2.52
"Uric acid is a risk factor for hypertension and possibly other cardiovascular outcomes."( Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA.
Ducatman, A; Shankar, A; Steenland, K; Tinker, S, 2010
)
1.3
"Uric acid is a key nitrogenous end product of purine metabolism."( Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode.
Luckenbaugh, DA; Machado-Vieira, R; Portela, LV; Salvadore, G; Souza, DO; Viale, CI; Zanatto, VC; Zarate, CA, 2010
)
1.48
"Uric acid (UA) is an efficient free radical scavenger, but has a very low solubility and poor tissue penetrability."( A synthetic uric acid analog accelerates cutaneous wound healing in mice.
Arumugam, TV; Baharani, A; Chan, SL; Chigurupati, S; Greig, NH; Holloway, HW; Mattson, MP; Mughal, MR; Poosala, S; Tang, SC; Wheeler, R; Yu, QS, 2010
)
1.46
"Uric acid is a cardiovascular risk marker associated with oxidative stress and inflammation. "( Uric acid elevation in atrial fibrillation.
Efremidis, M; Filippatos, GS; Gavrielatos, G; Kardaras, F; Korantzopoulos, P; Letsas, KP; Markou, V; Mihas, CC; Sideris, A,
)
3.02
"Uric acid (UA) is a potent endogenous antioxidant molecule."( The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4.5 h of onset of symptoms.
Amaro, S; Cánovas, D; Castellanos, M; Chamorro, A; Gállego, J; Martí-Fèbregas, J; Segura, T, 2010
)
1.32
"Uric acid is a major hydrophilic acceptor of ROS; monoenic oleic fatty acid acts as its major lipophilic acceptor."( [Plasma antioxidant activity--a test for impaired biological functions of endoecology, exotrophy, and inflammation reactions].
Dmitriev, VA; Iashin, IaI; Krylin, VV; Titov, VN, 2010
)
1.08
"Uric acid is a major product of purine metabolism in humans. "( Uric acid and the development of hypertension.
Hwu, CM; Lin, KH, 2010
)
3.25
"Uric acid is an independent predictor of diabetes in primary hypertension."( Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study.
Deferrari, G; Leoncini, G; Pontremoli, R; Vercelli, M; Viazzi, F, 2011
)
2.29
"Uric acid (UA) is a neuroprotective antioxidant that improves the benefits of alteplase in experimental ischemia. "( Uric acid levels are relevant in patients with stroke treated with thrombolysis.
Amaro, S; Cervera, A; Chamorro, A; Gómez-Choco, M; Obach, V; Planas, AM; Rios, J; Torres, F; Urra, X; Vargas, M, 2011
)
3.25
"Uric acid is a potent antioxidant in several systems and it is stored in specialized tissues of P."( Uric acid deposits and estivation in the invasive apple-snail, Pomacea canaliculata.
Abud, MA; Castro-Vazquez, A; Cueto, JA; Giraud-Billoud, M; Vega, IA, 2011
)
2.53
"Uric acid is an important prognostic marker for all-cause mortality in HF."( Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis.
Hare, J; Harzand, A; Jones, J; Palacio, A; Tamariz, L; Verma, S,
)
2.3
"Uric acid is a novel cardiovascular disease (CVD) factor, but its use as an independent risk factor for CVD remains controversial. "( An increase in serum uric acid concentrations is associated with an increase in the Framingham risk score in Korean adults.
Cho, KH; Kim, DH; Ko, BJ; Lee, KS; Lee, SH; Nam, GE; Park, YG, 2011
)
2.13
"Uric acid (UA) is an endogenous antioxidant. "( Serum uric acid levels in multiple sclerosis patients inversely correlate with disability.
Guerrero, AL; Gutiérrez, F; Iglesias, F; Laherrán, E; Martín-Polo, J; Martín-Serradilla, JI; Merino, S; Tejero, MA, 2011
)
2.29
"Uric acid is an independent predictor of future development of CKD. "( Uric acid levels predict future development of chronic kidney disease.
Dohi, Y; Kimura, G; Sonoda, H; Takase, H, 2011
)
3.25
"Uric acid (UA) is a cardiovascular risk marker associated with oxidative stress and inflammation. "( Uric acid levels and atrial fibrillation in hypertensive patients.
Korantzopoulos, P; Li, G; Liu, T; Wang, S; Zhang, X, 2011
)
3.25
"Uric acid is a terminal metabolite of the degradation of nucleotides, which increases their blood levels in patients with preeclampsia-eclampsia, increasing its synthesis by damage and death of trophoblastic cells in proliferation and decreased urinary excretion due a lower glomerular filtration rate and increased absorption in the proximal tubule. "( [Role of uric acid in preeclampsia-eclampsia].
Rico-Trejo, EI; Vázquez-Rodríguez, JG, 2011
)
2.23
"Uric acid is an independent risk factor for incidence of kidney diseases and poor prognosis of patients with kidney diseases. "( [The correlation between uric acid and the incidence and prognosis of kidney diseases: a systematic review and meta-analysis of cohort studies].
Huang, Y; Li, J; Li, YL; Wang, L; Yuan, WM, 2011
)
2.12
"Uric acid (UA) is a product of purine metabolism and is a natural antioxidant that can relieve the oxidative stress that occurs in PD."( Lower serum UA levels in Parkinson's disease patients in the Chinese population.
Guo, JF; He, D; Lei, LF; Shen, L; Tan, LM; Tang, BS; Wang, CY; Wang, YQ; Yan, XX; Zhang, HN, 2012
)
1.1
"Uric acid (UA) is an independent marker of mortality and associated with increased oxidative stress in patients with congestive heart failure (CHF). "( Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy.
Dogan, A; Erdogan, D; Icli, A; Karabacak, M; Ozaydin, M; Tayyar, S; Uysal, BA,
)
1.57
"Uric acid is a waste product of purine catabolism. "( Uric acid as a danger signal in gout and its comorbidities.
Kataoka, H; Lai, JJ; Rock, KL, 2013
)
3.28
"Uric acid is an independent risk factor in fructose-induced fatty liver, but whether it is a marker or a cause remains unknown."( Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver.
Choi, YJ; Cicerchi, C; Duranay, M; Ishimoto, T; Johnson, RJ; Kanbay, M; Kang, DH; Lanaspa, MA; Li, N; Marek, G; Nakagawa, T; Rodriguez-Iturbe, B; Roncal-Jimenez, CA; Sanchez-Lozada, LG; Sautin, YY; Schreiner, G, 2012
)
3.26
"Uric acid is an end product of the purine metabolism. "( [Uric acid and the prevention of renal and cardiovascular disease in CKD].
Teatini, U,
)
2.48
"Uric acid (UA) is a purine metabolite that selectively inhibits peroxynitrite-mediated reactions implicated in the pathogenesis of multiple sclerosis (MS) and other neurodegenerative diseases. "( Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors.
Hooper, DC; Kean, RB; Koprowski, H; Mikheeva, T; Scott, GS; Spitsin, SV, 2002
)
1.98
"Uric acid is a strong scavenger of reactive oxygen species, which are known to contribute to the development of atherosclerosis, while the incidence of atherosclerotic diseases is rather high in patients with gout. "( Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy.
Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2004
)
1.77
"Uric acid is an important antioxidant and methods to elevate its plasma concentration may be important in animal health. "( Increased dietary protein elevates plasma uric acid and is associated with decreased oxidative stress in rapidly-growing broilers.
Blemings, KP; Klandorf, H; Machín, M; Simoyi, MF, 2004
)
2.03
"Uric acid is a nontraditional risk factor implicated in the development of coronary artery disease (CAD). "( Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease.
Anderson, JL; Bair, TL; Carlquist, JF; Horne, BD; Jackson, JD; Lappe, JM; Madsen, TE; Muhlestein, JB; Pearson, RR,
)
2.05
"Uric acid is a scavenger of peroxynitrite, which is the product of nitric oxide (NO) and superoxide."( Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses.
De Keyser, J; Heerings, M; Heersema, DJ; Mostert, JP; Ramsaransing, GS; Wilczak, N, 2005
)
1.53
"Uric acid is a metabolic product synthesized from nucleic acids, amino acids and the Krebs cycle, reflecting a multiple metabolic associations in humans."( The serum uric acid and related cardiovascular risk factors in south Taiwan.
Chang, YY; Chen, SS; Chen, WH; Huang, CC; Liu, JS; Peng, MC; Tsai, WC, 2005
)
1.45
"Uric acid is a well known antioxidant; however, the relationship between serum uric acid levels and oxidative stress-caused disorders including cardiovascular diseases is not clear yet. "( Coronary flow reserve and coronary microvascular functions are strongly related to serum uric acid concentrations in healthy adults.
Bilgi, M; Caliskan, M; Erdogan, D; Gullu, H; Muderrisoglu, H; Ulus, T; Yildirim, I; Yilmaz, S, 2006
)
2
"Uric acid is an inducer of apoptosis on U937 cell line, and therefore it may be a component of the mosaic of uremic toxins both in acute and chronic renal disease."( Protective effect of urate oxidase on uric acid induced-monocyte apoptosis.
Andrikos, E; Bellomo, R; Bolgan, I; Bonello, M; Bordoni, V; Cazzavillan, S; De Cal, M; Galloni, E; Levin, N; Ranishta, R; Rassu, M; Ronco, C; Salvatori, G; Segala, C; Yavuz, A, 2005
)
1.32
"Uric acid is a natural antioxidant that protects the brain in a model of transient focal ischemia in rats. "( Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke.
Amaro, S; Chamorro, A; Planas, AM; Romanos, E, 2007
)
3.23
"Uric acid is a strong risk factor for myocardial infarction and stroke."( Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study.
Bos, MJ; Breteler, MM; Hofman, A; Koudstaal, PJ; Witteman, JC, 2006
)
3.22
"Uric acid is a well-established scavenger of reactive oxygen and nitrogen species such as hydroxyl radical and peroxynitrite. "( Nitrosation of uric acid induced by nitric oxide under aerobic conditions.
Suzuki, T, 2007
)
2.14
"The uric acid showed to be an inducer for uricase production."( Production of a thermostable uricase by a novel Bacillus thermocatenulatus strain.
Lotfy, WA, 2008
)
0.83
"Uric acid is an important diagnostic marker of catabolism of the purine nucleosides, and accurate measurements of serum uric acid are necessary for proper diagnosis of gout or renal disease appearance. "( Determination of serum uric acid using high-performance liquid chromatography (HPLC)/isotope dilution mass spectrometry (ID-MS) as a candidate reference method.
Dai, X; Fang, X; Xu, B; Xu, R; Zhang, C, 2007
)
2.09
"Uric acid is a major antioxidant in the blood of humans that can protect cultured neurons against oxidative and metabolic insults. "( Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice.
Arumugam, TV; Cutler, RG; Greig, NH; Guo, Z; Haberman, F; Holloway, HW; Hyun, DH; Mattson, MP; Tang, SC; Yu, QS, 2007
)
2.06
"Uric acid (UA) is an endogenous danger signal recently identified to be released from dying cells."( The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity.
Behrens, MD; Disis, ML; Erskine, CL; Gad, EA; Kalli, KR; Knutson, KL; Krco, CJ; Krempski, J; Wagner, WM, 2008
)
1.33
"Uric acid is a product of the activity of xanthine oxidase, an enzyme linked to oxidative stress, endothelial dysfunction, and heart failure. "( Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study.
Brennan, DM; Hazen, SL; Hoar, BM; Hoogwerf, BJ; Ioachimescu, AG, 2008
)
2.27
"Uric acid is a weak acid that exists largely as MSU, the ionized form, in urate pool at physiologic pH."( [Physiology and dynamics of uric acid in hyperuricemia].
Nakamura, T; Takagi, K; Ueda, T, 2008
)
1.36
"Uric acid is a powerful antioxidant and is a scavenger of singlet oxygen and radicals."( Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.
Ames, BN; Cathcart, R; Hochstein, P; Schwiers, E, 1981
)
2.43
"Uric acid is a weak acid that ionizes with a Pka at pH 5.75."( Uric acid nephrolithiasis.
Halabe, A; Sperling, O, 1994
)
2.45
"Uric acid is a potent antioxidant and thus might protect against cancer. "( Relationship of serum uric acid to cancer occurrence in a prospective male cohort.
Kolonel, LN; Nomura, AM; Stemmermann, GN; Yoshizawa, C,
)
1.89
"Uric acid is a useful diagnostic tool as screening for most of purine metabolic disorders."( The importance of uric acid examination.
Krijt, J; Schneiderka, P; Sebesta, I, 1994
)
1.34
"Uric acid is a possible cause of the renal hyper-echogenicity."( The possible role of uric acid in renal hyper-echogenicity in neonatal hypoxic acute shock.
Horváth, I; Mulugeta, Z; Pintér, S; Streitman, K; Surányi, A; Tálosi, G, 1996
)
1.33
"Uric acid, which is an endogenous antioxidant was statistically significantly decreased in the urine and plasma of SDZ ICT 322 VE/SeD treated rats."( Enhancement of SDZ ICT 322-induced cataracts and skin changes in rats following vitamin E- and selenium-deficient diet.
Cordier, A; Längle, UW; Wolf, A, 1997
)
1.02
"Uric acid (UA) is a water-soluble antioxidant in human body fluids. "( Possible role of uric acid as an antioxidant in premature infants.
Girschick, H; Neuhaus, T; Schrod, L; Speer, CP, 1997
)
2.08
"Uric acid was found to be an important component of the low molecular weight fraction responsible for the paradoxical effect of Cu concentration on serum oxidation."( Unexpected dose response of copper concentration on lipoprotein oxidation in serum: discovery of a unique peroxidase-like activity of urate/albumin in the presence of high copper concentrations.
Beilin, LJ; Croft, KD; Proudfoot, JM; Puddey, IB; Stocker, R, 1997
)
1.02
"Uric acid is a well-known natural antioxidant present in fluids and tissues throughout the body. "( Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo.
Bruce-Keller, AJ; Goodman, Y; Mattson, MP; Yu, ZF, 1998
)
3.19
"Uric acid is considered to be a naturally occuring antioxidant and is present in plasma at a relatively high concentration."( Uric acid inhibits L-DOPA-CU(II) mediated DNA cleavage.
Farhan Asad, S; Hadi, SM; Singh, S, 1998
)
2.46
"Uric acid is a significant UV-absorbing substance in the aqueous humor of diurnal birds with its peak absorbance at 292 nm. "( UV absorption by uric acid in diurnal bird aqueous humor.
Anderssen, E; Kjønniksen, I; Ringvold, A, 2000
)
2.09
"Uric acid (UA) is a natural scavenger of ONOO(-) that is present at high levels in the sera of humans and other higher order primates relative to most lower mammals."( Protection of myelin basic protein immunized mice from free-radical mediated inflammatory cell invasion of the central nervous system by the natural peroxynitrite scavenger uric acid.
Hooper, DC; Kean, RB; Mikheeva, T; Scott, GS; Spitsin, SV, 2000
)
1.22
"Uric acid is known to be an end product of purine metabolism. "( Diagnostic value of uric acid to differentiate transudates and exudates.
Imecik, O; Ozer, F; Uzun, K; Vural, H, 2000
)
2.07
"Uric acid in vitro acts as a potent antioxidant capable of scavenging hydroxy radicals and peroxynitrite and reacting with nitric oxide."( Renal regulation of plasma total antioxidant capacity.
Kirschbaum, B, 2001
)
1.03
"High uric acid concentration is a common finding in subjects with risk factors for cardiovascular disease (CVD), including some characteristics of the metabolic syndrome. "( Uric acid concentration in subjects at risk of type 2 diabetes mellitus: relationship to components of the metabolic syndrome.
Bedini, J; Conget, I; Costa, A; Igualá, I; Quintó, L, 2002
)
2.27
"Uric acid is an end-product of purine metabolism in Man, and has been suggested to act as an antioxidant in vivo. "( Action of biologically-relevant oxidizing species upon uric acid. Identification of uric acid oxidation products.
Halliwell, B; Kaur, H, 1990
)
1.97

Effects

Uric acid (UA) has an enormous competence to aggregate over melamine (Mel), producing large UA clusters that "drag" Mel toward them. Uric acid has a contradictory effect on cognitive function and several lines of evidence suggest that UA may modulate outcome in neurological diseases.

Uric acid (UA) has antioxidant properties yet when elevated is associated with vascular disease and stroke. Uric acid in blood has been widely accepted as a reliable indicator of hyperuricemia and gout.

ExcerptReferenceRelevance
"Uric acid (UA) has an enormous competence to aggregate over melamine (Mel), producing large UA clusters that "drag" Mel toward them. "( Investigation on the Mechanisms of Synchronous Interaction of K
Chattaraj, KG; Paul, S, 2020
)
2
"Uric acid has a role in several physiological and pathophysiological processes. "( Uric acid and allopurinol aggravate absence epileptic activity in Wistar Albino Glaxo Rijswijk rats.
Dobolyi, Á; Kovács, Z; Lakatos, RK, 2018
)
3.37
"Uric acid has an antioxidative effect."( Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population.
Cao, B; Chen, K; Guo, X; Huang, R; Shang, HF; Song, W; Wei, QQ; Zhao, B, 2013
)
2.55
"Uric acid (UA) has a contradictory effect on cognitive function and several lines of evidence suggest that UA may modulate outcome in neurological diseases."( Relation between uric acid and Alzheimer's disease in elderly Jordanians.
Al-khateeb, E; Al-khateeb, M; Al-Musawi, H; Al-Shweiki, S; Althaher, A; Azzouqah, O; Shafagoj, Y, 2015
)
1.48
"Uric acid has a stimulating effect on the cerebral cortex, and this could have allowed humans, compared with other animals, to develop higher brain mass volume, better intellectual performances, and maybe evolutionary supremacy. "( Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple".
De Giorgi, A; Fabbian, F; Manfredini, R; Misurati, E; Pala, M; Parisi, C; Tiseo, R, 2015
)
3.3
"Uric acid has an anti-oxidative effect."( Association of serum uric acid level with cognitive function among patients with multiple system atrophy.
Cao, B; Ou, R; Shang, HF; Wei, QQ; Yang, J, 2015
)
1.46
"Uric acid stone disease has a rich and fascinating medical history and probably is the oldest known stone disease."( Uric acid stone disease.
Moran, ME, 2003
)
2.48
"Uric acid, which has an antioxidant effect, is present at very high serum levels in hemodialysis patients, but its effect has not yet been clarified. "( Predictive value of uric acid in gastric mucosal damage in hemodialysis patients.
Fukai, Y; Hasegawa, T; Kamiyama, Y; Katoh, H; Kuwano, H; Masuda, N; Miyazaki, T; Nakajima, M; Ojima, H; Tajima, K; Tsukada, K; Tsukada, O; Yamamoto, Y; Yoshikawa, M,
)
1.9
"The uric acid biosensor has a linear response range of 4.0-640 microM with a detection limit of 2.0 microM (S/N=3)."( Development and analytical application of an uric acid biosensor using an uricase-immobilized eggshell membrane.
Choi, MM; Dong, C; Shuang, S; Wen, G; Zhang, Y; Zhou, Y, 2007
)
1.08
"Uric acid (UA) has both antioxidative and pro-oxidative properties. "( U-Shaped Association Between Serum Uric Acid and Hemorrhagic Transformation After Intravenous Thrombolysis.
Chen, H; Cheng, Z; Fu, Y; Han, Z; Xia, L; Xu, T; Zhan, Z; Zhang, WY, 2022
)
2.44
"Uric acid has been shown to provide a neuroprotective effect in various neurodegenerative diseases through its antioxidant properties."( Lower preoperative serum uric acid level may be a risk factor for postoperative delirium in older patients undergoing hip fracture surgery: a matched retrospective case-control study.
Li, C; Li, J; Lyu, W; Wei, P; Xu, L; Zhang, Z; Zheng, Q, 2022
)
1.75
"Uric acid has promoted renal fibrosis and inflammation in experimental studies, but some studies have shown nephroprotective effects due to alleviated oxidative stress. "( Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency.
Eräranta, A; Honkanen, T; Kurra, V; Lakkisto, P; Mustonen, J; Myllymäki, J; Paavonen, T; Pörsti, I; Riutta, A; Tikkanen, I, 2023
)
2.35
"Uric acid has antioxidant and neuroprotective properties. "( [The influence of uric acid on the course of amyotrophic lateral sclerosis].
Areprintseva, DK; Kutlubaev, MA; Pervushina, EV, 2023
)
2.69
"High uric acid (UA) levels have been shown to exert a neuroprotective effect in Parkinson's disease (PD) by inhibiting oxidative stress in the nigrostriatal pathway. "( Gender difference in the effect of uric acid on striatal dopamine in early Parkinson's disease.
Hwang, EJ; Kim, JS; Lee, KS; Lyoo, CH; Oh, YS; Yoo, SW, 2020
)
1.35
"Uric acid has been reported to activate Nod-like receptor protein 3 (NLRP3)-inflammasome and alter vascular smooth muscle cells (VSMC)."( Elevated Uric Acid Levels Promote Vascular Smooth Muscle Cells (VSMC) Proliferation via an Nod-Like Receptor Protein 3 (NLRP3)-Inflammasome-Dependent Mechanism.
Li, H; Liu, H; Qian, F; Zhang, Z, 2019
)
1.65
"Uric acid has anti-oxidant properties, but high levels predispose to gout and may play a role in metabolic syndrome."( Management of hyperuricemia in asymptomatic patients: A critical appraisal.
Brucato, A; Carnovale, C; Cianci, F, 2020
)
1.28
"Uric acid has been identified as an important factor in the development of hypertension. "( Association between pre-and postnatal growth and longitudinal trends in serum uric acid levels and blood pressure in children aged 3 to 7 years.
Cho, SJ; Ha, EH; Han, H; Kim, HS; Kim, YJ; Lee, HA; Lee, S; Park, B; Park, E; Park, H, 2020
)
2.23
"Uric acid has been considered a key molecule in the pathogenesis of some conditions such as metabolic syndrome, hypertension, and kidney disease as it is produced by injured cells and promotes immune-inflammatory responses."( Uric acid and kidney damage in systemic lupus erythematosus.
Dos Santos, M; Moresco, RN; Veronese, FV, 2020
)
2.72
"Uric acid (UA) has been suggested as a possible biomarker of bipolar disorder (BD) in recent studies. "( Comparison of Serum Uric Acid in Major Depressive Disorder and Bipolar Disorder: a Retrospective Chart Review Study.
Ahn, YM; Kim, S; Rhee, SJ; Song, Y, 2020
)
2.32
"Uric acid (UA) has an enormous competence to aggregate over melamine (Mel), producing large UA clusters that "drag" Mel toward them. "( Investigation on the Mechanisms of Synchronous Interaction of K
Chattaraj, KG; Paul, S, 2020
)
2
"Uric acid has been shown to be related to the severity of obstructive sleep apnoea syndrome (OSAS) in adults. "( Uric acid as a marker of severity of obstructive sleep apnoea syndrome in older patients.
Aydin, Ş; Kahya, Ö; ÖnÜr, ST; Özdemİr, C; SÖkÜcÜ, SN, 2020
)
3.44
"Uric acid (UA) has anti- and pro-inflammatory properties. "( Protective Effect of Luminal Uric Acid Against Indomethacin-Induced Enteropathy: Role of Antioxidant Effect and Gut Microbiota.
Akiyama, M; Hanawa, Y; Higashiyama, M; Hokari, R; Horiuchi, K; Inaba, K; Ito, S; Komoto, S; Kurihara, C; Mizoguchi, A; Nishii, S; Okada, Y; Shibuya, N; Sugihara, N; Takei, F; Tanemoto, R; Tomita, K; Wada, A; Watanabe, C, 2022
)
2.46
"Uric acid has long been considered responsible for a single specific disease, namely gout. "( The URRAH study.
Carubbi, F; Del Pinto, R; Ferri, C; Pontremoli, R; Russo, E; Viazzi, F, 2021
)
2.06
"Uric acid has both antioxidant and pro-oxidant properties in vitro by scavenging and production of reactive oxygen species (ROS). "( Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry.
Akari, S; Emoto, M; Fukumoto, S; Hirata, K; Imanishi, Y; Ishii, H; Kurajoh, M; Mori, K; Morioka, T; Murase, T; Nagata, Y; Nakamura, T; Yoshida, H; Yoshida, S, 2021
)
3.51
"Uric Acid (UA) has been related to the development of Cardio-Vascular (CV) events in patients affected by Chronic Coronary Syndromes (CCS). "( Uric acid in chronic coronary syndromes: Relationship with coronary artery disease severity and left ventricular diastolic parameter.
Bossi, I; De Chiara, B; Giannattasio, C; Maloberti, A; Moreo, A; Nava, S; Oliva, F; Oreglia, J; Piccalò, G; Piccaluga, E; Pirola, R; Racioppi, A; Rebora, P; Soriano, F; Tassistro, E; Vallerio, P; Valsecchi, MG, 2021
)
3.51
"Uric acid has strong antioxidant activity, whereas its oxidative damage is closely related to many diseases. "( The protective role of serum uric acid against premature membrane rupture in gestational diabetes: a cross-sectional study.
Guo, M; Hou, W; Hu, X; Lu, J; Pang, S; Yu, X, 2021
)
2.36
"Uric acid (UA) has been associated with renal fibrosis and progression of chronic kidney disease. "( Uric acid activates NRLP3 inflammasome in an in-vivo model of epithelial to mesenchymal transition in the kidney.
De Paul, AL; Latini, A; Mukdsi, JH; Remor, A; Romero, CA; Torres, AI, 2017
)
3.34
"Uric acid (UA) has been suggested as a novel risk factor for diabetes. "( Visceral fat mass: is it the link between uric acid and diabetes risk?
Berg, J; Bilgin, AA; Grant, R; Seyed-Sadjadi, N, 2017
)
2.16
"Uric acid has been shown to be a predictor of elevated effort HR."( Relationship between Cardiometabolic Parameters and Elevated Resting and Effort Heart Rate in Schoolchildren.
Burgos, LT; Burgos, MS; Horta, JA; Mello, ED; Reuter, CP; Sehn, AP; Silva, CFD; Silva, PTD; Welser, L, 2017
)
1.18
"Uric acid has been linked with increased risk of chronic disease such as cardiovascular disease and this association has been attributed to a pro-inflammatory effect. "( A double blind placebo controlled randomized trial of the effect of acute uric acid changes on inflammatory markers in humans: A pilot study.
Becker, KG; Ferrucci, L; Milaneschi, Y; Tanaka, T; Zhang, Y; Zukley, L, 2017
)
2.13
"Uric acid has been detected in the respiratory tract and can function as an antioxidant or damage associated molecular pattern."( Regulation of xanthine dehydrogensase gene expression and uric acid production in human airway epithelial cells.
Hansbro, PM; Hirota, JA; Hsu, AC; Huff, RD; Jones, B; Knight, DA; Nichol, KS; Wark, PAB, 2017
)
1.42
"Uric acid has neuroprotective effects, owing to its antioxidant properties. "( Uric acid in major depressive and anxiety disorders.
Black, CN; Bot, M; Penninx, BWJH; Scheffer, PG; Snieder, H, 2018
)
3.37
"Uric acid has neuroprotective effect on Parkinson's disease (PD) by inhibiting oxidative damage and neuronal cell death. "( Uric acid demonstrates neuroprotective effect on Parkinson's disease mice through Nrf2-ARE signaling pathway.
Hao, DL; Huang, TT; Mao, LL; Wu, BN; Zhang, J, 2017
)
3.34
"Uric acid (UA) has been associated with the presence and severity of coronary artery disease. "( The association between uric acid levels and different clinical manifestations of coronary artery disease.
Antonsen, S; Diederichsen, ACP; Gerke, O; Lambrechtsen, J; Larsen, TR; Mickley, H; Saaby, L; Sand, NP; Steffensen, FH, 2018
)
2.23
"Uric acid has been recognised as a potential marker of endothelial dysfunction and kidney disease but there are scarce data about its importance in systemic lupus erythematosus (SLE) nephritis. "( Serum uric acid levels are associated with lupus nephritis in patients with normal renal function.
Bonfá, E; Borba, EF; Calich, AL; da Rocha, LF; Fuller, R; Ugolini-Lopes, MR, 2018
)
2.4
"Uric acid (UA) has been proposed as an important risk factor for cardiovascular and renal morbidity. "( Effect of Salt Intake on Plasma and Urinary Uric Acid Levels in Chinese Adults: An Interventional Trial.
Cao, YM; Chen, W; Chu, C; Dang, XL; Hu, JW; Lv, YB; Mu, JJ; Wang, KK; Wang, Y; Xu, JT; Yan, Y; Yuan, ZY; Zheng, WL, 2018
)
2.18
"Uric acid has been found to be the most potent inhibitor of AChE, with a binding affinity higher than the known inhibitors of the enzyme."( Disturbed purine nucleotide metabolism in chronic kidney disease is a risk factor for cognitive impairment.
Bhattacharjee, A; Borah, A; Mazumder, MK; Phukan, BC, 2018
)
1.2
"Uric acid has a role in several physiological and pathophysiological processes. "( Uric acid and allopurinol aggravate absence epileptic activity in Wistar Albino Glaxo Rijswijk rats.
Dobolyi, Á; Kovács, Z; Lakatos, RK, 2018
)
3.37
"Uric acid has been known since long ago for its implication in gout and in certain kinds of nephrolithiasis. "( [Acid uric : key player in a recently recognized devastating nephropathy and in the development of chronic kidney disease.]
Humbert, A; Stucker, F, 2018
)
1.92
"Uric acid has neuroprotective properties in experimental and clinical studies of neurodegenerative disease. "( Lower uric acid is associated with poor short-term outcome and a higher frequency of posterior arterial involvement in ischemic stroke.
Liu, H; Reynolds, GP; Wang, W; Wei, X, 2018
)
2.4
"Uric acid has pKa ≤5.5, and it is solubilized at pH ≥5.5."( Potassium Citrate is Better in Reducing Salt and Increasing Urine pH than Oral Intake of Lemonade: A Cross-Over Study.
Shen, J; Zhang, X, 2018
)
1.2
"Uric acid has been found to be potentially neuroprotective in Parkinson's disease (PD). "( Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson's disease: PALS study.
Acharyya, S; Au, WL; Chia, NS; Huang, X; Lu, ZH; Ng, E; Ng, SY; Setiawan, F; Tan, EK; Tan, LC; Tay, KY, 2018
)
2.4
"Uric acid has been proposed as an independent risk factor of diabetic retinopathy. "( The role of uric acid in the pathogenesis of diabetic retinopathy based on Notch pathway.
She, XP; Wang, YZ; Zheng, Z; Zhu, DD; Zou, C, 2018
)
2.3
"Uric acid has been reported as a key factor contributing to the pathogenesis of PE."( The Role of Uric Acid in Preeclampsia: Is Uric Acid a Causative Factor or a Sign of Preeclampsia?
Khaliq, OP; Konoshita, T; Moodley, J; Naicker, T, 2018
)
1.58
"Uric acid has been shown to associate with vascular calcification and with carotid intima-media thickness (CIMT) and to suppress the 1 α-hydroxylase enzyme leading to lower 1,25-dihydroxyvitamin D (1,25(OH)2D) and higher intact parathyroid hormone (iPTH) levels."( Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.
Andrews, ES; Chonchol, M; Jalal, D; Kendrick, J; Nowak, KL; Pasch, A; Perrenoud, L; You, Z, 2018
)
1.51
"Uric Acid (UA) has been known to play a neuroprotective role in ischemic stroke patients. "( Gender-Specific Relationship Between Uric Acid Levels and Prognosis After Cerebral Venous Thrombosis.
Coates, G; Fang, H; Gao, Y; Li, S; Li, Y; Liu, K; Song, B; Wang, A; Wang, Y; Xu, Y; Zhao, L, 2018
)
2.2
"Uric acid (UA) has been found to stimulate macrophage migration inhibitory factor (MIF) up-regulation in renal tubules from rats subjected to UA-induced nephropathy."( Blockage of macrophage migration inhibitory factor (MIF) suppressed uric acid-induced vascular inflammation, smooth muscle cell de-differentiation, and remodeling.
Fu, X; Li, G; Liu, Q; Lou, Y; Mei, J; Niu, N; Qu, P; Sui, Z; Sun, J; Xu, M, 2019
)
1.47
"Uric acid has gained considerable attention as a potential neuroprotective agent in stroke during the last decades, however, its role in the pathophysiology of ischemic stroke remains poorly understood. "( Relationship between infarct size and serum uric acid levels during the acute phase of stroke.
Bustamante, G; Cavada, G; Cortés-Fuentes, IA; Fernández-Gajardo, R; Feuerhake, W; Guerrero, R; Gutiérrez, R; Lozano, P; Matamala, JM; Pasten, JA; Reyes, P; Rodrigo, R; Sotomayor, CG; Vargas, G, 2019
)
2.22
"Uric acid has an antioxidative effect."( Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population.
Cao, B; Chen, K; Guo, X; Huang, R; Shang, HF; Song, W; Wei, QQ; Zhao, B, 2013
)
2.55
"Uric acid (UA) has shown to be a causal risk factor for the development and progression of renal disease. "( Increased uric acid promotes decline of the renal function in hypertensive patients: a 10-year observational study.
Kiyohara, K; Ohta, Y; Oniki, H; Tsuchihashi, T, 2013
)
2.23
"Uric acid (UA) has been suggested to be a marker of multiple sclerosis (MS) activity. "( Long-term effects of whole body cryostimulation on uric acid concentration in plasma of secondary progressive multiple sclerosis patients.
Miller, E; Morel, A; Saluk, J; Wachowicz, B, 2013
)
2.08
"Uric acid (UA) has been known to be a neuroprotective antioxidant because of its free radical scavenger activity. "( Effects of uric acid levels on outcome in severe ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator.
Chang, DI; Heo, SH; Kim, HY; Kim, JH; Kim, YS; Koh, SH; Lee, D; Lee, JS; Lee, SH, 2014
)
2.23
"Uric acid has been linked to the progression of native kidney disease. "( Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial.
Hart, A; Ibrahim, HN; Jackson, S; Kasiske, BL; Matas, AJ; Mauer, MS; Najafian, B; Spong, R, 2014
)
3.29
"Uric acid has ever been considered as one of contrast induced acute kidney injury's risk factors. "( Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure.
Cong, H; Fu, N; Jin, D; Li, H; Li, X; Ma, H; Wang, Y, 2014
)
2.08
"Uric acid measurement has become increasingly important, and electrochemically modified detection method based portable devices hold a dominant position in the market for point of care and self-monitoring of uric acid blood levels. "( Evaluation of an electrochemical biosensor for uric acid measurement in human whole blood samples.
Liao, CC; Liao, LT; Liu, CC; Wang, GC; Yang, TY, 2014
)
2.1
"Uric acid (UA) has been studied extensively as a valuable biomarker of Parkinson's disease (PD), but its relationship with non-motor symptoms (NMS) in de novo PD has been poorly investigated. "( Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease.
Amboni, M; Barone, P; Capo, G; Erro, R; Longo, K; Moccia, M; Orefice, G; Palladino, R; Pellecchia, MT; Picillo, M; Santangelo, G; Vitale, C, 2015
)
2.1
"Uric acid (UA) has been identified as one major risk factor for cardiovascular diseases. "( A global proteome approach in uric acid stimulated human aortic endothelial cells revealed regulation of multiple major cellular pathways.
Adams, V; Baumann, S; Heinrich, M; Jehmlich, N; Kugler, J; Kullnick, Y; Mohr, FW; Neuhaus, J; Oberbach, A; Schlichting, N; Völker, U, 2014
)
2.13
"Uric acid (UA) has a contradictory effect on cognitive function and several lines of evidence suggest that UA may modulate outcome in neurological diseases."( Relation between uric acid and Alzheimer's disease in elderly Jordanians.
Al-khateeb, E; Al-khateeb, M; Al-Musawi, H; Al-Shweiki, S; Althaher, A; Azzouqah, O; Shafagoj, Y, 2015
)
1.48
"Uric acid (UA) has been reported to be associated with cardiovascular disease (CVD) in caucasians. "( Serum Uric Acid, Gender, and Low Ankle Brachial Index in Adults With High Cardiovascular Risk.
Dong, Y; Hu, D; Tang, Z; Yu, J; Zhan, Y; Zhang, F, 2015
)
2.34
"Uric acid has a stimulating effect on the cerebral cortex, and this could have allowed humans, compared with other animals, to develop higher brain mass volume, better intellectual performances, and maybe evolutionary supremacy. "( Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple".
De Giorgi, A; Fabbian, F; Manfredini, R; Misurati, E; Pala, M; Parisi, C; Tiseo, R, 2015
)
3.3
"Uric acid (UA) has antiosteoporotic effects in postmenopausal women. "( Low levels of serum uric Acid increase the risk of low bone mineral density in young male patients with ankylosing spondylitis.
Hong, YS; Ju, JH; Kang, KY; Park, SH, 2015
)
2.18
"Uric acid has antioxidant effects on neurons. "( Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies.
Goldacre, MJ; Pakpoor, J; Ramagopalan, SV; Seminog, OO, 2015
)
1.86
"Uric acid has emerged as a novel and potential modifiable risk factor for the incidence and progression of kidney diseases, however, the deteriorate effect of uric acid on renal mesangial cells remains unclear. "( Soluble monosodium urate, but not its crystal, induces toll like receptor 4-dependent immune activation in renal mesangial cells.
Chen, W; Fu, C; Lu, Y; Xiao, J; Ye, Z; Zhang, X; Zhu, D, 2015
)
1.86
"Uric acid has been associated as a risk factor for cardiovascular disease. "( Lower uric Acid linked with cognitive dysfunction in the elderly.
Arias-Carrión, O; Barraza-Salas, M; Cisneros-Martínez, J; Méndez-Hernández, E; Ruano-Calderón, L; Salas-Pacheco, J; Téllez-Valencia, A, 2015
)
2.34
"High uric acid (UA levels have been correlated with a reduced risk of many neurodegenerative diseases through mechanisms involving chelating Fenton reaction transitional metals, antioxidant quenching of superoxide and hydroxyl free radicals, and as an electron donor that increases antioxidant enzyme activity (e.g. "( The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders.
Camandola, S; Cutler, RG; Edelhauser, MA; Malott, KF; Mattson, MP, 2015
)
1.31
"Uric acid has been implicated in the pathophysiology of renal disease; however renal clearance makes a causal relationship difficult to prove. "( Uric Acid as a Marker of Kidney Disease: Review of the Current Literature.
Asmar, A; Giordano, C; Karasik, O; King-Morris, K, 2015
)
3.3
"Uric acid (UA) has been shown to be an independent risk factor for various cardiovascular diseases. "( Plasma Uric Acid as a Prognostic Marker in Patients With Hypertrophic Cardiomyopathy.
Hui, R; Jia, L; Liu, Y; Song, L; Sun, K; Tian, T; Wang, H; Wang, J; Wang, Y; Yuan, Z; Zhu, L; Zou, J; Zou, Y, 2015
)
2.31
"High uric acid (UA) has been found to be correlated with renal dysfunction in some experimental and clinical studies; however, the study of the dynamic correlation between AKI and UA in severe burns is still lacking."( Elevated serum uric acid after injury correlates with the early acute kidney in severe burns.
Hu, X; Liang, J; Zhang, P; Zhi, L, 2015
)
1.23
"Uric acid has an anti-oxidative effect."( Association of serum uric acid level with cognitive function among patients with multiple system atrophy.
Cao, B; Ou, R; Shang, HF; Wei, QQ; Yang, J, 2015
)
1.46
"High uric acid blood levels have been associated with a reduced risk of PD and a decreased rate of disease progression."( Relationship between uric acid levels and progressive supranuclear palsy.
Brody, DM; Cunningham, CR; Hall, DA; Kluger, BM; Litvan, I; Riley, DE; Shprecher, DR; Warner, S, 2016
)
1.21
"Uric acid (UA) has been associated with hypertension, renal disease and cardiovascular disease. "( Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
Arima, H; Hayashi, S; Ishizuka, A; Iwashima, Y; Kawano, Y; Kishida, M; Nakamura, S; Ohta, Y; Yoshihara, F, 2017
)
2.3
"Uric acid (UA) has been proven to directly cause mesangial cell (MC) proliferation with elusive mechanisms."( COX-2/mPGES-1/PGE2 cascade activation mediates uric acid-induced mesangial cell proliferation.
Chen, Q; Ding, G; Gong, W; He, JC; Huang, S; Jia, Z; Li, S; Ruan, Y; Sun, Z; Xia, W; Yu, J; Zhang, A; Zhang, Y, 2017
)
1.43
"Uric acid has become an independent risk factor of morbidity and mortality."( [Uric acid as a risk factor for cardiovascular diseases].
Cibičková, Ľ; Karásek, D,
)
1.76
"Uric acid (UA) has long been implicated as a critical cause of cardiovascular disease."( Uric acid is associated with vascular dementia in Chinese population.
Cui, R; Liu, Y; Lu, K; Wang, Q; Xu, Y; Zhao, Y, 2017
)
2.62
"Uric acid has historically been viewed as a purine metabolic waste product excreted by the kidney and gut that is relatively unimportant other than its penchant to crystallize in joints to cause the disease gout. "( Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society?
Benner, SA; Gabriela Sanchez-Lozada, L; Johnson, RJ; Mu, W; Nakagawa, T; Oliver, WJ; Rodriguez-Iturbe, B; Roncal, C; Sautin, YY, 2009
)
2.06
"Uric acid has previously been viewed as a benign solute in serum until it exceeds its saturation level."( The role of hyperuricemia in vascular disorders.
Edwards, NL, 2009
)
1.07
"Uric acid has been long recognized as the cause of gouty arthritis and kidney stones. "( The role of hyperuricemia in vascular disorders.
Edwards, NL, 2009
)
1.8
"Uric acid (UA) has been linked to renal damage in experimental models of kidney failure. "( Uric acid levels have no significant effect on renal function in adult renal transplant recipients: evidence from the symphony study.
Ekberg, H; Halloran, PF; Meier-Kriesche, HU; Schold, JD; Vanrenterghem, Y, 2009
)
3.24
"Uric acid has been reported to be a risk factor for the development of chronic kidney disease; however, no study has examined whether uric acid may confer a risk for acute kidney injury."( Uric acid: a novel risk factor for acute kidney injury in high-risk cardiac surgery patients?
Beaver, TM; Ejaz, AA; Johnson, RJ; Kim, T; Lingegowda, V; Schold, JD; Shimada, M; Sood, P, 2009
)
3.24
"Uric acid (UA) has been reported to be reduced in the serum of patients with multiple sclerosis (MS) and optic neuritis (ON). "( Serum uric acid levels and neuromyelitis optica.
Dai, Y; Deng, X; Hu, X; Jiang, Y; Li, Q; Long, Y; Peng, F; Qiu, W; Wu, A; Zhong, X, 2010
)
2.28
"Uric acid has been identified as a danger signal that triggers a cytosolic sensor, the inflammasome."( Mechanisms of uric acid crystal-mediated autoinflammation.
Martinon, F, 2010
)
1.44
"Uric acid has neuroprotective effects in experimental models including encephalomyelitis and appears to be involved in multiple sclerosis."( Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.
D'hooghe, MB; De Deyn, PP; Gonsette, RE; Guillaume, D; Medaer, R; Michotte, A; Seeldrayers, P; Sindic, C, 2010
)
1.08
"A uric acid biosensor has been fabricated through the immobilization of uricase on glassy carbon electrode modified by biomimetic titanate nanotubes of high specific surface area synthesized by hydrothermal decomposition. "( Construction of uric acid biosensor based on biomimetic titanate nanotubes.
Hu, Y; Hu, Z; Lu, Y; Ma, Y; Tao, H; Wang, X, 2010
)
1.43
"Uric acid (UA) has been shown to be elevated in patients with pulmonary hypertension (PH) and heart failure."( Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study.
Dimitroula, H; Dimitroulas, T; Giannakoulas, G; Karvounis, H; Parcharidou, D; Settas, L; Sfetsios, T, 2011
)
1.41
"Uric acid has been known to exert neuroprotective effects by acting as a free radical scavenger; however, several observational studies indicated that high levels of serum uric acid increased the risk of cardiovascular events or stroke. "( High levels of serum uric acid are associated with silent brain infarction.
Heo, SH; Lee, SH, 2010
)
2.12
"Uric acid has been associated with renal disease, even though hyperuricemia may be a marker of or by itself be responsible for microvascular disease in diabetes."( Serum uric acid as a new player in the development of diabetic nephropathy.
Hovind, P; Johnson, RJ; Parving, HH; Rossing, P, 2011
)
1.57
"Uric acid has been identified as an endogenous adjuvant that drives immune responses in the absence of microbial stimulation."( The role of uric acid as an endogenous danger signal in immunity and inflammation.
Ghaemi-Oskouie, F; Shi, Y, 2011
)
1.47
"Uric acid has been shown as a predictor and an independent risk factor for coronary heart disease, but little is known regarding the association of uric acid levels with coronary blood flow in STEMI. "( The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI.
Akpek, M; Ardic, I; Dogdu, O; Elcik, D; Ergin, A; Gibson, CM; Gunebakmaz, O; Kalay, N; Kaya, MG; Oguzhan, A; Sahin, O; Uyarel, H; Yarlioglues, M, 2011
)
2.12
"Uric acid has been shown to be involved in metabolic pathways that lead to oxidative stress, endothelial disfunction, and to a vascular and systemic inflammatory response."( Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage?
Di Giorgio, C; Gesualdo, L; Morrone, LF; Stellato, D, 2012
)
2.54
"Uric acid has been proposed to play a role in acute kidney injury. "( Elevated uric acid increases the risk for acute kidney injury.
Arif, AA; Dass, B; Ejaz, AA; Ejaz, NI; Johnson, RJ; Kambhampati, G; Lapsia, V; Shimada, M, 2012
)
2.24
"Uric acid (UA) has proven to be a causal agent in endothelial dysfunction in which ROS production plays an important role. "( Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload.
Chen, X; Cui, S; Ding, R; Feng, Z; Fu, B; Hong, Q; Huang, Z; Qi, K; Wang, L; Wu, D; Yang, J, 2012
)
1.82
"Uric acid has been formerly considered a major antioxidant in human plasma with possible beneficial anti-atherosclerotic effects."( Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Cravero, E; Muscari, A; Puddu, GM; Puddu, P; Vizioli, L, 2012
)
1.1
"Uric acid has also antioxidant properties and is a surrogate marker of metabolic syndrome."( Long-term activation of semicarbazide-sensitive amine oxidase lowers circulating levels of uric acid in diabetic conditions.
Carpéné, C; Desquesnes, A; Gomez-Ruiz, A; Iffiú-Soltész, Z; Le Gonidec, S; Mercader, J, 2012
)
1.32
"Uric acid has been suspected to be a risk factor for hypertension since the 1870s. "( The role of uric acid in the pathogenesis of hypertension in the young.
Feig, DI, 2012
)
2.2
"Uric acid (UA) has been frequently reported to be associated with MetS in the general population."( The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder.
Chen, CH; Chen, PY; Chiu, CC; Huang, MC; Lu, ML; Tsai, CJ, 2012
)
1.39
"Uric acid stone disease has a rich and fascinating medical history and probably is the oldest known stone disease."( Uric acid stone disease.
Moran, ME, 2003
)
2.48
"Uric acid, which has an antioxidant effect, is present at very high serum levels in hemodialysis patients, but its effect has not yet been clarified. "( Predictive value of uric acid in gastric mucosal damage in hemodialysis patients.
Fukai, Y; Hasegawa, T; Kamiyama, Y; Katoh, H; Kuwano, H; Masuda, N; Miyazaki, T; Nakajima, M; Ojima, H; Tajima, K; Tsukada, K; Tsukada, O; Yamamoto, Y; Yoshikawa, M,
)
1.9
"Uric acid has been suggested as a risk factor in cardiovascular disease since the beginning of the twentieth century. "( [Role of uric acid in cardiovascular diseases].
Adamiec, R; Bednarska-Chabowska, D; Wdowczyk, M, 2003
)
2.18
"Uric acid has profound beneficial effects since it scavenges potential harmful radicals in our body."( [Physiology and biochemistry of uric acid].
Hediger, MA, 2004
)
1.33
"Uric acid has been proposed as an important risk factor in the development of primary hypertension in humans. "( Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study.
Alper, AB; Berenson, GS; Chen, W; Hamm, LL; Srinivasan, SR; Yau, L, 2005
)
2.17
"Uric acid (UA) has been proposed to be the dominant antioxidant in birds. "( Free radical scavenging, DNA protection, and inhibition of lipid peroxidation mediated by uric acid.
Blemings, KP; Klandorf, H; Leonard, SS; Shi, X; Stinefelt, B, 2005
)
1.99
"Uric acid has been implicated in endothelial cell damage and decreased endothelial nitric oxide bioavailability."( The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins.
Hamed, SA; Nabeshima, T, 2005
)
1.05
"Uric acid has been shown to be heritable; however, genome-wide linkage analyses have not been reported."( Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study.
Cupples, LA; Fox, CS; Guo, CY; Levy, D; Wilson, PW; Yang, Q, 2005
)
1.31
"The uric acid biosensor has a linear response range of 4.0-640 microM with a detection limit of 2.0 microM (S/N=3)."( Development and analytical application of an uric acid biosensor using an uricase-immobilized eggshell membrane.
Choi, MM; Dong, C; Shuang, S; Wen, G; Zhang, Y; Zhou, Y, 2007
)
1.08
"Uric acid has better electrochemical behavior whereas ascorbic acid has no effective reaction on the carboxylated SWCNT electrode."( Direct electrochemistry of uric acid at chemically assembled carboxylated single-walled carbon nanotubes netlike electrode.
Choi, YK; Huang, XJ; Im, HS; Kim, HS; Kim, JH; Lee, DH; Yarimaga, O, 2006
)
1.35
"Uric acid (UA) has been demonstrated to reduce damage to neurons elicited by oxidative stress. "( Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity.
Chen, CP; Du, Y; Eisenberg, Y; Firestein, BL; Tseng, CY, 2007
)
2.07
"Uric acid (UA) has antioxidant properties yet when elevated is associated with vascular disease and stroke. "( Serum uric acid and brain ischemia in normal elderly adults.
Gordon, B; Inscore, AB; Jinnah, HA; Kraut, M; Pearlson, GD; Schretlen, DJ; Vannorsdall, TD, 2007
)
2.26
"Uric acid in blood has been widely accepted as a reliable indicator of hyperuricemia and gout, and its assay method has been established. "( [Determination of uric acid in scalp hair for non-invasive estimation of uricemic control in hyperuricemia].
Isaka, Y; Kobayashi, K; Morioka, Y; Tozawa, T, 1997
)
2.07
"Uric acid (UA) has been under intensive investigation by electrochemists owing to its important role as a metabolite in biological fluids. "( Possibilities and limitations in miniaturized sensor design for uric acid.
Brajter-Toth, A; Bravo, R; Hsueh, CC; Jaramillo, A, 1998
)
1.98
"Uric acid has been considered to be an efficient scavenger of peroxynitrite but the reaction between urate and peroxynitrite has been only partially characterized. "( Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation.
Anjos, EI; Augusto, O; Santos, CX, 1999
)
3.19
"Uric acid has been hypothesized as being one of the more important antioxidants in limiting the accumulation of glycosylated endproducts in birds. "( Accelerated tissue aging and increased oxidative stress in broiler chickens fed allopurinol.
Iqbal, M; Klandorf, H; Rathore, DS; Shi, X; Van Dyke, K, 2001
)
1.75
"Uric acid has long been associated with cardiovascular disease. "( Uric acid and cardiovascular risk.
Alderman, MH, 2002
)
3.2
"2. Uric acid interference has been eliminated by the use of a high molarity acetate buffer and by optimising the amount of TPTZ and ferric chloride used."( A rapid manual method for routine assay of ascorbic acid in serum and plasma.
Day, BR; Marsh, CA; Williams, DR, 1979
)
0.77
"Uric acid turnover, as has been reported for other New World monkeys, was several times that of normal man."( Uric acid catabolism in the woolly monkey.
Flowers, CM; Logan, DC; Sparks, PJ; Tyler, FH; Wilson, DE, 1976
)
2.42
"Uric acid has previously been shown to act as a water-soluble antioxidant. "( Free radical metabolite of uric acid.
Maples, KR; Mason, RP, 1988
)
2.01
"Uric acid has been proposed to be an important antioxidant and free radical scavenger in humans. "( Uric acid protection of nucleobases from ozone-induced degradation.
Meadows, J; Smith, RC, 1986
)
3.16

Actions

Uric acid appears to cause salting out of calcium oxalate in human urine. Uric acid may cause renal damage, whereas adiponectin in some studies has been reported to have renoprotective properties.

ExcerptReferenceRelevance
"Uric acid (UA) plays a protective role in Parkinson's disease (PD). "( Low serum uric acid levels are associated with the nonmotor symptoms and brain gray matter volume in Parkinson's disease.
Hu, S; Huang, S; Li, M; Ma, J; Shi, X; Sun, W; Wang, Z; Zheng, J, 2022
)
2.57
"Uric acid also plays important roles in primates but causes gout when present in excess in humans."( Uric acid, an important antioxidant contributing to survival in termites.
Iuchi, Y; Matsuura, K; Nitao, M; Sakurai, H; Tasaki, E, 2017
)
2.62
"Low uric acid level might cause adverse outcomes in VSA in connection with endothelial dysfunction."( Uric Acid Level Has a U-shaped Association with Clinical Outcomes in Patients with Vasospastic Angina.
Choi, JH; Choi, SH; Gwag, HB; Gwon, HC; Hahn, JY; Lee, SH; Park, TK; Song, YB; Yang, JH, 2017
)
2.38
"Uric acid plays an important role in CVD pathogenesis by inducing inflammatory COX-2 and ROS pathways."( Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells.
Çetin, A; Kırça, M; Oğuz, N; Yeşilkaya, A, 2017
)
1.58
"Uric acid (UA) plays important roles in inducing renal inflammation, intra-renal vasoconstriction and renal damage. "( Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation.
Arfian, N; Romi, MM; Sari, DCR; Setyaningsih, WAW; Tranggono, U, 2017
)
3.34
"High uric acid plays an important role in several chronic diseases including kidney diseases such as lithiasis, gout nephropathy, and preeclampsia."( Uric Acid: The Unknown Uremic Toxin.
Treviño-Becerra, A, 2018
)
2.38
"As uric acid levels increase there is a relevant clustering of metabolic risk factors, whereas elevated blood pressure is the risk factor less frequently present."( Uric acid is linked to cardiometabolic risk factors in overweight and obese youths.
Alvarez-Pitti, J; Borghi, C; Lurbe, E; Redon, J; Redon, P; Torro, MI, 2018
)
2.44
"The uric acid level was lower in the essential tremor group than in healthy subjects, but the difference did not reach statistical significance."( Uric acid level may not be reduced in essential tremor.
Hong, JY; Kang, SY; Lee, CY; Park, JH; Sunwoo, MK; Yoon, JH, 2018
)
2.4
"Uric acid could increase inflammatory cytokines and upregulate tissue RAS in rat adipocytes, which were both blocked with TLR2/4-siRNA infection."( TLR2 and TLR4 mediate an activation of adipose tissue renin-angiotensin system induced by uric acid.
Diao, B; Lin, X; Tang, F; Xu, J; Zhang, J, 2019
)
1.46
"Uric acid level was lower in DEN group than in control. "( Protective effect of omega-3 fatty acids on diethylnitrosamine toxicity in rats.
Atakisi, E; Atakisi, O; Karapehlivan, M; Kart, A; Ozcan, A, 2013
)
1.83
"Uric acid values were lower in WC compared with the PC group (p < 0.05)."( [Elevated levels of leptin and LDL-cholesterol in patients with well controlled congenital adrenal hyperplasia].
Faria, JA; Lago, R; Nunes-Silva, D; Oliveira, LM; Toralles, MB, 2013
)
1.11
"Uric acid appears to cause salting out of calcium oxalate in human urine."( Treatment of calcium nephrolithiasis in the patient with hyperuricosuria.
Arowojolu, O; Goldfarb, DS, 2014
)
1.12
"Uric acid levels were lower in the carvedilol group compared with the nebivolol group (5.8 ± 1.6 vs."( The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure.
Bas, HA; Dogan, A; Karabacak, M; Tayyar, S, 2015
)
1.14
"Uric acid (UA) plays an important role in the oxidant stress that causes inflammation. "( Association of uric acid with traditional inflammatory factors in stroke.
Xiong, G; Zhang, J; Zhu, A; Zou, T, 2016
)
2.23
"Uric acid crystals may activate an intracellular complex called inflammasome, which is important for processing and release of inflammatory cytokines."( Endogenous and Uric Acid-Induced Activation of NLRP3 Inflammasome in Pregnant Women with Preeclampsia.
Araújo, JP; Borges, VT; de Oliveira, L; Matias, ML; Nunes, PR; Peraçoli, JC; Peraçoli, MT; Ribeiro, VR; Romão, M; Weel, IC, 2015
)
1.49
"Uric acid may cause renal damage, whereas adiponectin in some studies has been reported to have renoprotective properties. "( The Association Between Adiponectin, Serum Uric Acid and Urinary Markers of Renal Damage in the General Population: Cross-Sectional Data from the Tromsø Study.
Eggen, AE; Eriksen, BO; Jenssen, TG; Kronborg, JB; Melsom, T; Norvik, JV; Solbu, MD; Storhaug, HM; Zykova, SN, 2016
)
2.14
"Uric acid was found to increase HASMC proliferation, ET-1 expression and reactive oxygen species production. "( Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells.
Chao, HH; Chen, CH; Cheng, TH; Lin, JW; Liu, JC; Wu, CH, 2008
)
3.23
"Uric acid-induced increase in MCP-1 production was blocked by scavenging superoxide or by inhibiting NADPH oxidase and by stimulating peroxisome-proliferator-activated receptor-γ with rosiglitazone."( Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome.
Baldwin, W; Baylis, C; Johnson, RJ; Marek, G; McRae, S; Pannu, V; Sautin, YY; Wymer, D, 2011
)
1.09
"Uric acid may inhibit endothelial function by inhibition of nitric oxide-function under conditions of oxidative stress."( Uric acid as one of the important factors in multifactorial disorders--facts and controversies.
Feher-Turkovic, L; Marinkovic, N; Pasalic, D, 2012
)
2.54
"Uric acid (UA) increase is considered an important risk factor for the development of cardiovascular disease (CVD) favoring oxidative stress and endothelial dysfunction and is also involved in metabolic syndrome (MS) pathophysiology."( The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome.
Dichi, I; Lozovoy, MA; Simão, AN, 2012
)
2.38
"Uric acid (UA) at the lower dose (3.75%) lacked an effect on burying behaviour but significantly increased the time spent and number of entries to the open arms; the higher UA dose (7.5%) produced a significant increase in the time spent and number of entries to the open arms and a statistically significant reduction in cumulative burying."( Influence of inflammatory nociception on the anxiolytic-like effect of diazepam and buspirone in rats.
Fernández-Guasti, A; López-Muñoz, FJ; Martínez-Mota, L; Reyes, R, 2005
)
1.05
"Uric acid also promotes endothelial dysfunction through inactivation of NO and arresting the proliferation of endothelial cells."( Hormonal and cytokine effects of uric acid.
Feig, DI; Franco, M; Herrera-Acosta, J; Johnson, RJ; Kang, DH; Nakagawa, T; Sánchez-Lozada, LG, 2006
)
1.34
"Uric acid may increase as a result of pathophysiological processes such as impaired renal sodium handling but may also contribute to renal and vascular damage, particularly endothelial dysfunction."( Uric acid and hypertension.
Schachter, M, 2005
)
2.49
"Uric acid can strongly enhance T cell immune responses induced by HBsAg-pulsed-DCs vaccine. "( Uric acid enhances T cell immune responses to hepatitis B surface antigen-pulsed-dendritic cells in mice.
Liang, ZH; Ma, XJ; Tian, DY; Xu, D; Yang, DF; Zhang, ZG; Zhu, HF, 2007
)
3.23
"Uric acid is a possible cause of the renal hyper-echogenicity."( The possible role of uric acid in renal hyper-echogenicity in neonatal hypoxic acute shock.
Horváth, I; Mulugeta, Z; Pintér, S; Streitman, K; Surányi, A; Tálosi, G, 1996
)
1.33
"The uric acid excretion was lower than in the nocturnal period before the test."( Uric acid serum concentrations in CF-children after pancreatic enzyme supplementation.
Ballke, EH; Paul, W; Wiersbitzky, S; Wolf, E, 1989
)
2.2
"Uric acid was found to suppress B[a]P quinone formation completely at a concentration lower than that of vitamin C, indicating that uric acid in an aqueous phase traps peroxyl radicals more effectively."( Quinone formation from benzo[a]pyrene by free radicals: effects of antioxidants.
Matsushita, S; Terao, J, 1988
)
1

Treatment

Uric acid-lowering treatments may be beneficial for the prevention of progression of IgAN. Uric acid treatment also was found to diminish clinical signs of a disease resembling EAE in interferon-gamma receptor knockout mice.

ExcerptReferenceRelevance
"Uric acid-treated mice exhibited significantly impaired glucose tolerance and lower insulin levels in response to glucose challenge than did control mice."( Hyperuricemia causes pancreatic β-cell death and dysfunction through NF-κB signaling pathway.
Ding, Y; Guo, J; Jia, L; Liang, X; Liu, Y; Ren, W; Shen, Y; Shi, X; Su, D; Wan, M; Xing, J; Zheng, S, 2013
)
1.11
"Uric acid-lowering treatments may be beneficial for the prevention of progression of IgAN."( Hyperuricemia is associated with progression of IgA nephropathy.
Bakan, A; Basci, S; Covic, A; Elcioglu, OC; Kanbay, M; Kostek, O; Oral, A; Ozkok, A; Ozturk, S; Sipahioglu, M; Sumnu, A; Takir, M; Turkmen, A; Voroneanu, L, 2015
)
1.14
"Uric acid treatment resulted in foam cell formation, ROS generation and expression of CD36, but not of LOX-1 or SRA."( Xanthine Oxidase Induces Foam Cell Formation through LOX-1 and NLRP3 Activation.
Cao, Y; Dai, Y; Mehta, JL; Vallurupalli, S; Zhang, Z, 2017
)
1.18
"When uric acid was treated with nitric oxide gas in a neutral solution under aerobic conditions, uric acid was consumed, yielding an unknown product."( Nitrosation of uric acid induced by nitric oxide under aerobic conditions.
Suzuki, T, 2007
)
1.15
"Uric acid, when treated with nitric acid, is stoichiometrically converted to alloxan, which is determined fluorimetrically with 1,2-phenylenediamine."( A method for quantitative wet chemical analysis of urinary calculi.
Larsson, L; Ohman, S; Sörbo, B; Tiselius, HG, 1984
)
0.99
"Uric acid treatment also was found to diminish clinical signs of a disease resembling EAE in interferon-gamma receptor knockout mice."( Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis.
Champion, JM; Chaudhry, I; Dickson, GM; Hooper, DC; Kean, RB; Koprowski, H; Spitsin, S, 1998
)
2.46
"Uric acid treatment did not increase the in vitro measurable activity of the rate-limiting biosynthetic enzyme, cyclopeptine synthetase."( Uric acid is a genuine metabolite of Penicillium cyclopium and stimulates the expression of alkaloid biosynthesis in this fungus.
Helbig, F; Roos, W; Steighardt, J, 2002
)
2.48
"Treatment with uric acid-lowering therapies has also been found to improve outcomes in patients with hypertension and kidney disease, in some but not all studies."( Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.
Agabiti-Rosei, E; Borghi, C; Johnson, RJ; Kielstein, JT; Lurbe, E; Mancia, G; Redon, J; Stack, AG; Tsioufis, KP, 2020
)
0.9
"Treatment with uric acid caused a further reduction in cell viability, while ascorbic acid improved viability."( Effects of uric acid on vascular endothelial function from bedside to bench.
Anzai, N; Fujita, T; Hayashi, K; Inoue, T; Node, K; Otani, N; Ouchi, M; Sakuma, M; Tanaka, A; Toyoda, S; Uemura, N, 2018
)
1.21
"Treatment with uric acid protected Caco-2 cells from indomethacin-induced oxidative stress, lipid peroxidation, and cytotoxicity."( Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity.
Furuhashi, H; Higashiyama, M; Hokari, R; Komoto, S; Kurihara, C; Maruta, K; Matsuo, H; Miura, S; Nagao, S; Narimatsu, K; Okada, Y; Sato, H; Shirakabe, K; Takajo, T; Tomita, K; Watanabe, C; Yasutake, Y; Yoshikawa, K, 2017
)
2.24
"The treatment of uric acid stones consists not only of hydration (urine volume above 2000 ml daily), but mainly of urine alkalinization to pH values between 6.2 and 6.8."( [Diagnosis and prevention of uric acid stones].
Bonny, O; Ferrari, P, 2004
)
0.94
"The treatment of uric acid stones should focus on alkalinization of the urine with citrate or bicarbonate salts."( Uric acid nephrolithiasis.
Bushinsky, DA; Liebman, SE; Taylor, JG, 2007
)
2.11
"Pretreatment with uric acid reduced 3-NT labelling in leukocytes in mesenteric tissues and in neutrophils obtained from peritoneal exudates."( Peroxynitrite mediates the failure of neutrophil migration in severe polymicrobial sepsis in mice.
Alves-Filho, JC; Celes, MR; Cunha, FQ; Dal-Secco, D; Dalto, VF; Ferreira, SH; Freitas, A; Rossi, MA; Spiller, F; Torres-Dueñas, D, 2007
)
0.66
"Treatment with uric acid, at doses of 50, 100 or 300 mg/kg body weight, by gavage, provided some measure of protection against all of these effects, and the protection was generally dose dependent."( A study of uric acid pretreatment for the protection of rat gastric mucosa against toxic damage.
Afal, M; Ahmed, MM; al-Bekairi, AM; Qureshi, S; Shah, AH, 1992
)
1.01
"Pretreatment with uric acid provided significant protection against cyclophosphamide-induced impairment of DNA, RNA and protein biosynthesis."( Uric acid as an inhibitor of biochemical changes induced by cyclophosphamide in mice.
al-Bekairi, AM; Chaudhry, MA; Qureshi, S; Shah, AH, 1991
)
2.05
"Pretreatment with uric acid was found to provide significant protection against cyclophosphamide-induced bone marrow depression and micronucleated polychromatic erythrocytes."( Uric acid as an inhibitor of cyclophosphamide-induced micronuclei in mice.
al-Bekairi, AM; Chaudhry, MA; Qureshi, S; Shah, AH, 1991
)
2.05

Toxicity

Treatment with febuxostat sufficiently lowered uric acid levels without severe adverse effects in stable kidney transplant recipients with PTHU.

ExcerptReferenceRelevance
" With respect to sorbitol and xylitol, lactic acidosis was not considered a serious side effect until now."( Possible side effects of glucose, fructose, sorbitol and xylitol in man.
Förster, H, 1976
)
0.26
"A long term study was carried out to determine the possible toxic effects of therapeutic doses of a suspension of benorilate on bone marrow, liver and kidneys in 33 patients with rheumatoid arthritis."( [Long-term toxicity of benorylate].
Reiter, W,
)
0.13
" Overall, adverse reactions characterized as probably drug-related or questinably drug-related were reported in 28% of patients treated with tienilic acid, 24% treated with hydrochlorothiazide, 25% of patients treated with probenecid and 33% treated with placebo."( Safety of tienilic acid.
Beg, MA; Ragland, R, 1979
)
0.26
" However, the observed findings would appear to be consistent with a toxic effect of iopanoate in the small vessels possibly resulting in ischemic tubular necrosis."( Nephrotoxicity of sodium iopanoate in hydrated and dehydrated dogs.
Burgener, FA; Fischer, HW,
)
0.13
" Adverse events were reported in 11 of the 38 patients in the ramipril group, in 22 of 83 patients treated with the combination for more than 50 weeks, and in 9 of 38 patients treated with the combination for 50 weeks or less."( Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study.
Bauer, B; Breitstadt, A; Cairns, V; Froer, KL; Heidbreder, D, 1991
)
0.28
" These data suggest that large doses of EC enzymes reduce steatorrhea and are safe in patients who have malabsorbtion with small doses."( Effectiveness and safety of small vs. large doses of enteric coated pancreatic enzymes in reducing steatorrhea in children with cystic fibrosis: a prospective randomized study.
Brady, MS; Eigen, H; Rickard, K; Yu, PL, 1991
)
0.28
" There was statistical evidence for greater adverse effects of aspirin/codeine on mood and mental alertness in comparison to ibuprofen/codeine and placebo."( Multiple-dose safety study of ibuprofen/codeine and aspirin/codeine combinations.
Friedman, H; Oster, H; Royer, G; Seckman, C; Stubbs, C, 1990
)
0.28
" Adverse events were recorded without judgment of causality."( Safety of nizatidine in clinical trials conducted in the USA and Europe.
Cloud, ML, 1987
)
0.27
" This increased potency and the consequent decreased dose requirement give bumetanide the potential for increased effectiveness and decreased incidence of adverse effects."( Cellular mechanism of action of loop diuretics: implications for drug effectiveness and adverse effects.
Feig, PU, 1986
)
0.27
" With the lower-dose compound, the metabolic side effect of hypokalemia was less of a problem and there was no evidence of glucose intolerance."( Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study.
Gens, JD; Green, DE; Mehrotra, KG; Mookherjee, S; Vardan, S; Willsey, GA,
)
0.13
" This study describes the observed adverse reactions in this group of patients not undergoing transplantation."( Side effects of systemic cyclosporine in patients not undergoing transplantation.
Chan, CC; Nussenblatt, RB; Palestine, AG, 1984
)
0.27
" Results suggest that very-low-calorie diets can be an effective and safe means of substantial weight reduction."( Safety and effectiveness of weight reduction using a very-low-calorie formulated food.
Budell, W; Clements, M; Kreitzman, SN; Krissman, P; Nichols, D; Pedersen, M, 1984
)
0.27
" How the adverse effects of and charges for this procedure compare with those of the standard marrow harvest is not known."( Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.
Anderlini, P; Champlin, R; Chan, KW; Körbling, M; Lichtiger, B; Miller, P; Norfleet, F; Przepiorka, D; Seong, D; Sundberg, J, 1996
)
0.29
" Adverse events and laboratory effects resolved within 7 days after apheresis."( Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.
Anderlini, P; Champlin, R; Chan, KW; Körbling, M; Lichtiger, B; Miller, P; Norfleet, F; Przepiorka, D; Seong, D; Sundberg, J, 1996
)
0.29
" Ethanol was toxic to HepG2 E9 cells, which express CYP2E1, but not to HepG2 MV5 cells, which do not express CYP2E1."( Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1.
Cederbaum, AI; Wu, D, 1996
)
0.29
" Addition of the intact MAS did not alter the developmental toxicity of 1-methyl- or 3-methylxanthine which were slightly more developmentally toxic on an equimolar basis than theophylline itself."( Evaluation of the developmental toxicity of theophylline, dimethyluric acid, and methylxanthine metabolites using Xenopus.
Bantle, JA; Fort, DJ; Hull, MA; Propst, T; Stover, EL, 1996
)
0.53
"Cisplatin caused differential toxic effects on blood glucose and plasma urea, uric acid and creatinine levels."( Rehabilitating role of glutathione ester on cisplatin induced nephrotoxicity.
Babu, E; Chandramohan, N; Ebrahim, AS; Sakthisekaran, D, 1999
)
0.53
" Cyclosporine microemulsion demonstrated efficacy with minimal adverse events (12% mild hypertension) when appropriately monitored and administered in low doses (3 mg/kg/day)."( [Efficacy, tolerability and safety of cyclosporine for microemulsion in the treatment of active rheumatoid arthritis. Open study].
Battagliotti, C; Díaz, EA; Garsd, A; Grosman, H; Gutfraind, E; Maccagno, A; Maldonado Cocco, J; Marcos, JC; Messina, DO; Onetti, CM; Otero, AB; Tate, G; Venarotti, HO, 2000
)
0.31
" Disappearance of cosmetic side-effects and improvement of cardiovascular risk factors, together with conservation of renal function, encourage us to use tacrolimus as an efficacious and safe immunosuppressive therapy."( Safety and efficacy of tacrolimus rescue therapy in 55 kidney transplant patients treated with cyclosporine.
Amenábar, JJ; Gaínza, FI; Gómez-Ullate, P; Lampreabe, I; Orbe, J; Urbizu, JM; Virto, J; Zárraga, S, 2003
)
0.32
" Although not uncommon, adverse events were mild and self-limited, and no deaths or serious adverse events were observed."( Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Becker, MA; Hunt, B; Joseph-Ridge, N; Khosravan, R; Kisicki, J; MacDonald, P; Mulford, D; Wu, J, 2004
)
0.32
" Incidences of treatment-related adverse events were similar in the febuxostat and placebo groups."( Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL, 2005
)
0.33
" Febuxostat therapy was safe and well tolerated."( Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL, 2005
)
0.33
" It can be concluded from the results that crude enzyme extract had minor toxic effects on various organ systems tested; more extensive investigation on the safe use of this extract is therefore necessary."( The toxicity of a crude enzyme extract from Gliomastix murorum in Swiss Albino mice.
Aritajat, S; Saenphet, K; Srikalayanukul, C, 2005
)
0.33
" Safety was monitored based on adverse events recorded during the treatment period and on the results of laboratory tests, including measurement of creatinine and uric acid levels."( Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study.
Brazier, M; Fardellone, P; Grados, F; Kamel, S; Maamer, M; Mathieu, M; Morel, A; Sebert, JL, 2005
)
0.52
" Treatment-related adverse events were reported in 21 (22."( Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study.
Brazier, M; Fardellone, P; Grados, F; Kamel, S; Maamer, M; Mathieu, M; Morel, A; Sebert, JL, 2005
)
0.33
" Application of these drugs in chemotherapy is limited because of their toxic effects."( Effects of melatonin in reducing the toxic effects of doxorubicin.
Ilhan, MN; Oz, E, 2006
)
0.33
" The majority of adverse events were mild-to-moderate in intensity."( Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT, 2006
)
0.33
" Safety was assessed by recording adverse events."( Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency.
Prior, C; Puig, JG; Torres, RJ, 2007
)
0.34
" There were no significant differences in the incidences of clinical and laboratory drug-related adverse events between any of the combination groups and the placebo group."( Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension.
Hirayama, Y; Matsuoka, H; Nonaka, K; Ogihara, T; Saruta, T; Suzuki, H; Takahashi, K; Toki, M, 2007
)
0.34
" Adverse drug reactions occurred in 1,081 of the 29,850 patients."( Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study.
Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2008
)
0.35
" We demonstrate that both DF and meloxicam are toxic to renal tubular epithelial (RTE) cells following 12 h of exposure, due to an increase in production of reactive oxygen species (ROS), which could be temporarily ameliorated by pre-incubation with uric acid (UA)."( Diclofenac toxicity in Gyps vulture is associated with decreased uric acid excretion and not renal portal vasoconstriction.
Naidoo, V; Swan, GE, 2009
)
0.77
"MMF monotherapy is a safe alternative in patients with posttransplant renal failure secondary to the use of CNIs."( Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
Alamo Martínez, JM; Barrera Pulido, L; Bernal Bellido, C; Bernardos Rodríguez, A; García González, I; Gómez Bravo, MA; Pareja Ciuró, F; Pascasio Acevedo, JM; Serrano Díez-Canedo, J; Suárez Artacho, G, 2008
)
0.35
" Thirteen subjects withdrew due to an adverse event."( Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009
)
0.35
" Overall adverse event rates (including cardiovascular adverse event rates), adjusted for 10-fold greater febuxostat than allopurinol exposure, did not differ significantly among treatment groups."( Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009
)
0.35
" Electrolyte abnormalities such as hypomagnesaemia and hypokalemia are commonly reported adverse effects, in addition to increased serum creatinine and uremia."( Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children.
Chayama, K; Fujieda, M; Hayashi, A; Matsunaga, A; Sekine, T; Tauchi, H, 2009
)
0.35
" Surveys of livestock carcasses in India indicate that toxic levels of residual ketoprofen are already present in vulture food supplies."( Toxicity of non-steroidal anti-inflammatory drugs to Gyps vultures: a new threat from ketoprofen.
Cromarty, D; Cuthbert, R; Diekmann, M; Duncan, N; Meharg, AA; Naidoo, V; Taggart, MA; Venter, L; Wolter, K, 2010
)
0.36
" Safety assessments included blinded adjudication of each cardiovascular (CV) adverse event (AE) and death."( The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF, 2010
)
0.36
" No serious adverse events were observed."( Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
Barclay, ML; Chapman, PT; Frampton, C; James, J; O'Donnell, JL; Stamp, LK; Zhang, M, 2011
)
0.37
" No serious adverse events occurred in any of the 3 groups."( Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study.
Chen, P; Chen, X; Huang, S; Li, Y; Lie, C; Liu, S; Miao, L; Wang, L; Wu, X; Xie, Y; Zhang, A, 2011
)
0.37
", adverse effects on electrolytes and uric acid, very few data exist on serum electrolyte levels in patients with trichlormethiazide treatment."( Adverse effect profile of trichlormethiazide: a retrospective observational study.
Asai, S; Nakayama, T; Nishida, Y; Takahashi, Y, 2011
)
0.64
"Our study showed adverse effects of decreased serum potassium and increased serum uric acid with trichlormethiazide treatment, and suggested that a lower dose of trichlormethiazide may minimize these adverse effects."( Adverse effect profile of trichlormethiazide: a retrospective observational study.
Asai, S; Nakayama, T; Nishida, Y; Takahashi, Y, 2011
)
0.59
" Allopurinol is efficacious and safe in most patients, but intolerance is estimated to occur in up to 10% of treated patients."( Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
Chohan, S, 2011
)
0.37
"Recent investigations have proved the crucial role of nutritional antioxidants to prevent the damage caused by toxic compounds."( Antioxidant-rich date palm fruit extract inhibits oxidative stress and nephrotoxicity induced by dimethoate in rat.
Achour, L; El Arem, A; Elfeki, A; Hammami, M; Louedi, M; Najjar, MF; Saafi-Ben Salah, EB; Saoudi, M; Zakhama, A, 2012
)
0.38
" CYA alone and the combination of MEL and CYA had adverse effects on the performance, but MEL alone had no effects on the performance."( Toxicity of melamine and cyanuric acid in broilers and residues in tissues.
Bai, SP; Ding, XM; Wang, L; Zhang, KY, 2012
)
0.67
" Rates of adverse events (AEs) were low."( Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012
)
0.38
"Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients."( Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011
)
0.37
" To investigate the potency of MSU crystals as a cancer vaccine carrier in vivo, this preclinical study examined whether intradermal injection of MSU crystals was safe for healthy adults."( Safety of intradermal injection of monosodium urate crystals as a vaccine carrier in volunteers.
Inai, K; Sakamaki, I; Tsutani, H, 2011
)
0.37
" Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects."( Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension.
Arimura, T; Fujisawa, K; Inoue, A; Kuwano, T; Matsunaga, E; Mitsutake, R; Miura, S; Morii, J; Nagata, I; Norimatsu, K; Saku, K; Shiga, Y; Shimizu, T; Shirotani, T; Uehara, Y, 2012
)
0.63
"0 mg/dL at the final visit, overall and by renal function status, percent change in sUA from baseline to final visit, flare rates, and rates of adverse events (AEs)."( The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Hunt, B; Jackson, RL; MacDonald, PA, 2012
)
0.38
" Allopurinol hypersensitivity syndrome (AHS) is a rare but potentially fatal adverse event."( Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Dalbeth, N; Dockerty, JL; Drake, J; Frampton, C; Jones, PB; Stamp, LK; Taylor, WJ, 2012
)
0.38
" There were no significant differences in adverse effects between groups, with the exception of more respiratory disorders in the amlodipine/benazepril group than in the valsartan/hydrochlorothiazide group (17 vs 5; P = 0 ."( Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012
)
0.38
" However, respiratory adverse events (particularly coughing) were more frequently reported in the amlodipine/benazepril group."( Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012
)
0.38
"The present work aimed to study the toxic effect of cadmium (Cd) on rabbits' blood indices, as well as the therapeutic effect of the antioxidant agents, vitamins C and B complex and bee honey on Cd intoxicated rabbits."( Toxicity of cadmium and protective effect of bee honey, vitamins C and B complex.
Abdelaziz, I; Ashour, AA; Elhabiby, MI, 2013
)
0.39
" Gout flares and IRs were the most frequently reported adverse events; these were least common in patients with a sustained urate-lowering response to treatment and those receiving biweekly treatment."( Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
Baraf, HS; Becker, MA; Dillon, A; Khanna, D; Ottery, FD; Sundy, JS; Vázquez-Mellado, J; Yood, RA, 2013
)
0.39
"These results suggest that n-3 fatty acids could ameliorate the toxic effects of DEN in part by means of its free radical scavenging activity and may be of therapeutic value in the protection of liver against toxic effects of DEN."( Protective effect of omega-3 fatty acids on diethylnitrosamine toxicity in rats.
Atakisi, E; Atakisi, O; Karapehlivan, M; Kart, A; Ozcan, A, 2013
)
0.39
" vasica extract offers a biologically safe alternative to detoxify aflatoxin and has huge potential to be used in the poultry industry to reduce aflatoxicosis."( Role of Adhatoda vasica (L.) Nees leaf extract in the prevention of aflatoxin-induced toxicity in Wistar rats.
Brinda, R; Malathi, D; Paranidharan, V; Uma, D; Velazhahan, R; Vijayanandraj, S, 2013
)
0.39
"A perspective adsorptive method to minimize systemic toxic effects of chemotherapy is enterosorption (ES)."( Enterosorption as a method to decrease the systemic toxicity of cisplatin.
Bardakhivskaya, KI; Ivanyuk, AA; Korotich, VG; Maslenniy, VN; Nikolaev, VG; Nikolaeva, VV; Sakhno, LA; Shevchuk, OO; Yurchenko, OV, 2013
)
0.39
"to analyze ES influence on anticancer activity and toxic reactions of cisplatin (CP) upon the use of carbon enterosorbent in 1 h after intravenous administration of cytostatic."( Enterosorption as a method to decrease the systemic toxicity of cisplatin.
Bardakhivskaya, KI; Ivanyuk, AA; Korotich, VG; Maslenniy, VN; Nikolaev, VG; Nikolaeva, VV; Sakhno, LA; Shevchuk, OO; Yurchenko, OV, 2013
)
0.39
" CP caused significant toxic injuries in kidneys, liver, and spleen tissues."( Enterosorption as a method to decrease the systemic toxicity of cisplatin.
Bardakhivskaya, KI; Ivanyuk, AA; Korotich, VG; Maslenniy, VN; Nikolaev, VG; Nikolaeva, VV; Sakhno, LA; Shevchuk, OO; Yurchenko, OV, 2013
)
0.39
"Active carbon enterosorbents which are administrated just 1 h after CP administration possesses detoxicating potential sufficient for significant elimination of toxic effect of the cytostatic at the background of complete preservation of its antitumor activity."( Enterosorption as a method to decrease the systemic toxicity of cisplatin.
Bardakhivskaya, KI; Ivanyuk, AA; Korotich, VG; Maslenniy, VN; Nikolaev, VG; Nikolaeva, VV; Sakhno, LA; Shevchuk, OO; Yurchenko, OV, 2013
)
0.39
"In this study, we reviewed and analyzed a large number of randomized controlled clinical trials to systematically assess the clinical efficacy and adverse reactions of Chinese herbal decoctions for treating gout."( Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout.
Chen, P; Cheng, D; Liu, L; Liu, X; Pettigrew, JC; Wu, Y; Yi, D; Zhang, Y; Zhou, L, 2014
)
0.4
"Through a systematic review of the clinical efficacy and safety of Chinese herbal decoctions and traditional Western medicine for the treatment of gout, we found that Chinese herbal decoction and traditional Western medicine led to similar clinical efficacy, but the Chinese herbal decoctions were superior to Western medicine in terms of controlling adverse drug reactions."( Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout.
Chen, P; Cheng, D; Liu, L; Liu, X; Pettigrew, JC; Wu, Y; Yi, D; Zhang, Y; Zhou, L, 2014
)
0.4
"The available scientific data indicate that the pathomechanism of Parkinson's disease (PD) involves the accumulation of endogenous and exogenous toxic substances."( Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013
)
0.39
" The explanation of these findings would be that the stimulation of MRP1- and MRP2-mediated transport of glutathione conjugates of toxic substances may have slight beneficial effects, while stimulation of MRP4-mediated efflux of brain urate, which has an important antioxidant potency, may worsen the effects of oxidative stress."( Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013
)
0.39
"0 mg/dL), estimated glomerular filtration rates in allografts, and adverse events were retrospectively analyzed in the FX, NFX, and NPTHU groups."( Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
Hara, T; Hayashida, Y; Inui, M; Kakehi, Y; Kohno, M; Moriwaki, K; Nishijima, Y; Nishiyama, A; Sofue, T; Ueda, N, 2014
)
0.4
" None of the patients in the FX group experienced any severe adverse effects, such as pancytopenia or attacks of gout, throughout the entire study period."( Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
Hara, T; Hayashida, Y; Inui, M; Kakehi, Y; Kohno, M; Moriwaki, K; Nishijima, Y; Nishiyama, A; Sofue, T; Ueda, N, 2014
)
0.4
"Treatment with febuxostat sufficiently lowered uric acid levels without severe adverse effects in stable kidney transplant recipients with PTHU."( Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
Hara, T; Hayashida, Y; Inui, M; Kakehi, Y; Kohno, M; Moriwaki, K; Nishijima, Y; Nishiyama, A; Sofue, T; Ueda, N, 2014
)
0.66
" 516 adverse events occurred in the uric acid group and 532 in the placebo group, of which 61 (12%) and 67 (13%), respectively, were serious adverse events (p=0·703)."( Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial.
Amaro, S; Arenillas, J; Cánovas, D; Carné, X; Castellanos, M; Chamorro, A; Deulofeu, R; Gállego, J; Gomis, M; Krupinski, J; Martí-Fábregas, J; Oleaga, L; Planas, AM; Román, LS; Segura, T; Torres, F, 2014
)
0.99
" However, a major challenge in treating patients with HU is the adverse effects caused by urate-lowering drugs used to treat CKD."( Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.
Hosoya, T; Kimura, K; Ohno, I; Shibagaki, Y, 2014
)
0.4
" The primary endpoint was safety, assessed by adverse events (AE) and laboratory values."( Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
Evans, RR; King-Davis, S; Kivitz, A; Schumacher, HR; Sundy, JS; Weinstein, SP; Wu, R, 2014
)
0.65
"rate of adverse events and death."( Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
Carmona, L; Castrejon, I; Loza, E; Pérez-Ruiz, F; Rosario, MP; Toledano, E, 2015
)
0.42
" Therefore, this study deduces that alpha-tocopherol administration may ameliorate the adverse effects of subacute exposure to MT on rat liver and kidney and this antioxidant can protect PON1 from oxidative stress induced by this organophosphorus pesticide."( Toxic effects of methamidophos on paraoxonase 1 activity and on rat kidney and liver and ameliorating effects of alpha-tocopherol.
Araoud, M; Douki, W; Houas, Z; Kenani, A; Khaled, L; Najjar, MF; Neffeti, F, 2016
)
0.43
"The objective of this study is to evaluate the efficacy of a new mycotoxin inactivator (AdiDetox™) in reducing the toxic effects of fumonisin B1 (FB1) in the diet of rats."( Efficacy of AdiDetox™ in reducing the toxicity of fumonisin B1 in rats.
Blandon, JC; Casas, J; Denli, M; Guynot, ME; Pérez, JF; Salado, S, 2015
)
0.42
" Therefore, it could be concluded that ceftriaxone and/or ascorbic acid administration able to minimize the toxic effects of DLM through their free radical-scavenging and potent antioxidant activity."( Synergistic protective effects of ceftriaxone and ascorbic acid against subacute deltamethrin-induced nephrotoxicity in rats.
Abdel-Daim, MM; El-Ghoneimy, A, 2015
)
0.42
"Heavy metals are known to be toxic to organisms."( Nephrotoxic effects of lead nitrate exposure in diabetic and nondiabetic rats: Involvement of oxidative stress and the protective role of sodium selenite.
Baş, H; Kalender, Y, 2016
)
0.43
"The individual toxic effects of aluminum and acrylamide are known but there is no data on their combined effects."( Co-exposure to aluminum and acrylamide disturbs expression of metallothionein, proinflammatory cytokines and induces genotoxicity: Biochemical and histopathological changes in the kidney of adult rats.
Boudawara, T; Ellouze Chaabouni, S; Fendri, N; Ghorbel, I; Jamoussi, K; Maktouf, S; Zeghal, N, 2016
)
0.43
" Coadministration of tolvaptan, a selective vasopressin V2 receptor antagonist, can ameliorate such adverse events by reducing the required dose of loop diuretics; however, the safety of tolvaptan in patients with reduced renal function is not known."( Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N, 2015
)
0.42
"In this short-term pilot study, coadministration of tolvaptan and furosemide appears to be safe in patients with heart failure and CKD."( Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N, 2015
)
0.42
" The incidence of adverse events was similar in the three treatment groups."( A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y, 2015
)
0.42
" Febuxostat, at a daily dose of 40 or 80 mg, was safe and well tolerated."( A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y, 2015
)
0.42
" Lesinurad was generally safe and well tolerated."( Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
Hingorani, V; Kerr, B; Manhard, K; Quart, B; Rowlings, C; Shen, Z; Storgard, C; Yeh, LT, 2015
)
0.65
" Treatment-emergent adverse events possibly related to allopurinol occurred in 15."( An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Baumgartner, S; Becker, MA; Choi, HK; Cravets, M; Dalbeth, N; Fitz-Patrick, D; Storgard, C, 2015
)
0.42
" Following an initial 2-week washout period, over the next 12 weeks we made five measurements of serum urate levels along with assessments of adverse events (AEs)."( Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH, 2016
)
0.43
" Incidences of overall adverse events (AEs) in the topiroxostat groups were comparable to those in the placebo group; however, the incidence of AEs in the 120-mg group was statistically lower than that in the placebo group."( Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
Hashimoto, H; Hosoya, T; Ohashi, T; Sakamoto, R; Sasaki, T, 2016
)
0.43
" Specific information about the dose, effect on serum urate, adverse effects and liver function tests after commencing benzbromarone was recorded."( The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
Cathro, A; Corkill, M; Dalbeth, N; Frampton, C; Gardner, D; Grainger, R; Haslett, J; Kain, T; Kumar, R; Kumar, S; Metcalfe, S; Porter, D; Stamp, LK; Stebbings, S; Taylor, G; White, D; Wyeth, J, 2016
)
0.43
" Benzbromarone-related adverse events included rash (n = 4), diarrhoea (n = 9), nausea (n = 6) and urate stones (n = 3)."( The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
Cathro, A; Corkill, M; Dalbeth, N; Frampton, C; Gardner, D; Grainger, R; Haslett, J; Kain, T; Kumar, R; Kumar, S; Metcalfe, S; Porter, D; Stamp, LK; Stebbings, S; Taylor, G; White, D; Wyeth, J, 2016
)
0.43
" Drug efficacy and safety, as outcomes, were measured by whether the target level of serum urate acid was achieved and whether any adverse events occurred, respectively."( Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
Gao, Y; Guo, Y; Li, D; Li, M; Li, S; Li, W; Sun, L; Wang, Y; Wei, F; Xu, W; Yang, H; Yang, X, 2016
)
0.43
" No significant difference in the incidence of adverse events was observed among all groups, including the allopurinol group."( Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Hosoya, T; Ohashi, T; Sasaki, T, 2017
)
0.46
" The serum uric acid (UA) concentrations of the patients in each group were recorded and compared from week 2 through week 24 after the treatments, and all adverse events were evaluated to determine the safety of the various treatment regimens."( A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J, 2017
)
0.84
" However, the total number of patients experiencing adverse events was significantly higher in the febuxostat 80-mg group."( A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J, 2017
)
0.46
"Chinese patients treated with the 40-mg dose of febuxostat experienced a treatment effect and total rate of adverse events similar to those produced by allopurinol or benzbromarone."( A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J, 2017
)
0.46
" The primary endpoints were reduction in SU and adverse events (AEs)."( A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Barclay, ML; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017
)
0.46
" The results of the safety study showed that no organ toxicity and no treatment-related adverse effects were observed in mice treated with high doses of MFEs."( Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study.
Chen, HM; Chen, MH; Chen, RJ; Chen, SJ; Chen, YL; Hsiao, CM; Wang, YJ; Wu, MD; Yech, YJ; Yuan, GF, 2017
)
0.46
" In summary, despite conventional wisdom, our research confirmed that NCs are not very safe and that NC particle sizes are closely related to the degree of NC toxicity."( In vitro toxicity assessment of nanocrystals in tissue-type cells and macrophage cells.
Chen, M; Li, Y; Li, Z; Mei, X; Wang, Z; Yang, Y; Yang, Z; Zhang, H; Zhou, J, 2018
)
0.48
" All adverse effects were recorded and categorized by severity."( One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan.
Ando, R; Iwaki, H; Miyaue, N; Nagai, M; Nishikawa, N; Nomoto, M; Tada, S; Tsujii, T; Yabe, H, 2017
)
0.46
"We did not observe any adverse events requiring termination or reduction of the study drug, although uric acid crystalluria was transiently observed in a single subject."( One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan.
Ando, R; Iwaki, H; Miyaue, N; Nagai, M; Nishikawa, N; Nomoto, M; Tada, S; Tsujii, T; Yabe, H, 2017
)
0.67
" No other adverse events were reported."( Efficacy and Safety of Febuxostat in Kidney Transplant Patients.
Baek, CH; Han, DJ; Kim, H; Park, SK; Yang, WS, 2018
)
0.48
"Febuxostat reduced serum uric acid levels effectively in kidney transplant patients without severe adverse events."( Efficacy and Safety of Febuxostat in Kidney Transplant Patients.
Baek, CH; Han, DJ; Kim, H; Park, SK; Yang, WS, 2018
)
0.78
" The effect of baseline kidney function on urate lowering and adverse effects was investigated."( The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Barclay, M; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017
)
0.46
" Adverse events were similar among groups."( The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Barclay, M; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017
)
0.46
"Allopurinol is effective at lowering urate even though and accepting that there were small numbers of participants with CrCL <30 ml/min, these data indicate that allopurinol dose escalation to target SU is safe in people with severe CKD."( The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Barclay, M; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017
)
0.46
" Rates of treatment-emergent adverse events were low and evenly distributed between treatment arms."( Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019
)
0.51
" To adjust for treatment duration, treatment-emergent adverse events (TEAEs) were expressed as exposure-adjusted incidence rates (patients with events per 100 person-years)."( Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
Baumgartner, S; Goldfarb, DS; Jalal, D; Pillinger, M; Saag, KG; Schechter, BM; Terkeltaub, R; Valiyil, R; White, WB, 2019
)
0.51
" Major adverse cardiovascular events were 3, 4 and 9 with XOI, LESU200+XOI and LESU400+XOI, respectively."( Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
Baumgartner, S; Goldfarb, DS; Jalal, D; Pillinger, M; Saag, KG; Schechter, BM; Terkeltaub, R; Valiyil, R; White, WB, 2019
)
0.51
"At the approved dose of 200 mg once-daily combined with an XOI, LESU did not increase renal, cardiovascular or other adverse events compared with XOI alone, except for sCr elevations."( Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
Baumgartner, S; Goldfarb, DS; Jalal, D; Pillinger, M; Saag, KG; Schechter, BM; Terkeltaub, R; Valiyil, R; White, WB, 2019
)
0.51
" Three of 39 subjects were excluded because of adverse events (AEs) after receiving an initial febuxostat treatment for 2 months."( Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
Chen, X; Gu, B; Li, C; Qian, K; Ren, Q; Shen, M; Su, D; Wang, X; Xu, W; Yang, L; Yuan, H; Zhang, J, 2018
)
0.72
" Liver and blood functions were monitored and other adverse events were recorded."( Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
Chen, P; Chen, X; Fu, Q; Gao, X; Li, J; Liu, L; Shen, X; Wang, C, 2019
)
0.51
"Older drugs for ULT like allopurinol are well studied and extensively described from typical adverse effects (mild skin rash) to unusual fatal reactions, while febuxostat seems to be overall well tolerated."( Safety and tolerability of available urate-lowering drugs: a critical review.
Cicero, AF; Fogacci, F; Strilchuk, L, 2019
)
0.51
" The difference in incidence of adverse events among patients with stage 1-3 CKD, those with stage 4-5 CKD, and those on dialysis was not significant."( Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Kim, JM; Kim, SH; Lee, SY; Son, CN, 2020
)
0.56
" The serum levels of uric acid (UA), creatinine, other biochemical parameters, estimated glomerular filtration rate (eGFR), and adverse events were measured at baseline as well as at 1, 3, and 6 months after the switch to febuxostat."( Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients.
Li, Y; Liu, M; Lu, Y; Meng, J; Zhang, X, 2019
)
0.83
" Long term usage and over-dosage of diclofenac is associated with adverse effects like drug-induced liver injury, gastrointestinal and renal toxicity."( Protective effect of the ethanolic and methanolic leaf extracts of Madhuca longifolia against diclofenac-induced toxicity in female Wistar albino rats.
Katturaja, R; Namachivayam, A; Nithyanandham, S; Parthasarathy, M; Prince, SE; Simon, JP, 2019
)
0.51
" The clinical efficacy, blood pressure, blood uric acid level, inflammatory factor level and adverse event rate were analyzed."( Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia.
Gao, H, 2019
)
0.77
" The incidence of adverse events was comparable among all groups."( Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 stu
Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020
)
0.56
" No serious adverse event was found."( Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 stu
Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020
)
0.56
" Regarding safety, the incidence of adverse events did not increase with dose escalation in the dotinurad groups."( Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020
)
0.56
" The hepato- and nephrotoxic potential of acetamiprid has not been clarified although it is known to be toxic to other several organ systems, including the nervous, respiratory and immune systems."( Toxic effects of subchronic oral acetamiprid exposure in rats.
Arican, YE; Binay, S; Boran, T; Kaptan, E; Karaca, BU; Okyar, A; Özhan, G,
)
0.13
" Hence, designing safe and self-anticoagulant hemoperfusion absorbents with robust toxin clearance remains a considerable challenge."( Construction of Kevlar nanofiber/graphene oxide composite beads as safe, self-anticoagulant, and highly efficient hemoperfusion adsorbents.
Cheng, C; He, C; Ma, L; Wu, X; Yang, Y; Yin, J; Yin, S; Zhang, J; Zhao, C; Zhao, W, 2020
)
0.56
"Febuxostat had the best efficacy and safety results among the tested agents, and topiroxostat and allopurinol appeared to have fewer adverse events."( Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
Lin, CJ; Lin, JY; Shi, Y; Sun, SS; Zhang, DH, 2020
)
0.56
"This study suggests that there is no particular concern about adverse drug reactions or the efficacy of topiroxostat for hyperuricemic patients with or without gout in a post-marketing setting in Japan."( Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
Hashimoto, T; Ichikawa, K; Ishikawa, T; Kanno, Y; Maeda, T; Nakagawa, T; Sato, Y, 2020
)
0.56
" Safety outcomes included total adverse events (AEs), serious AEs, withdrawals due to AEs, and AEs per organ system."( Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan, M; Gu, J; Li, X; Liu, J; Schlesinger, N; Wu, X; Zhao, B, 2021
)
0.62
" In the febuxostat group, 222 (7·2%) of 3063 patients died and 1720 (57·3%) of 3001 in the safety analysis set had at least one serious adverse event (with 23 events in 19 [0·6%] patients related to treatment)."( Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J, 2020
)
0.56
"Febuxostat is non-inferior to allopurinol therapy with respect to the primary cardiovascular endpoint, and its long-term use is not associated with an increased risk of death or serious adverse events compared with allopurinol."( Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J, 2020
)
0.56
" The aim is to evaluate efficacy and safety of SOF/LDV and SOF/DACLA plus ribavirin in treating HCV related child A liver cirrhosis and assess hyperuricaemia as a potential adverse effect to this regimen."( Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
Abbas, A; Elsayed, A; Hassan, H; Hassnine, A; M Abdelraheem, E, 2020
)
0.56
" Hyperuricaemia is considered a potential adverse effect to DAAS containing ribavirin and may lead to serious side effects such as renal impairment."( Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
Abbas, A; Elsayed, A; Hassan, H; Hassnine, A; M Abdelraheem, E, 2020
)
0.56
" The most commonly reported adverse events are dizziness, headache, fatigue, upper respiratory tract infection and urinary tract infection."( Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review.
Antonopoulos, AS; Katsi, V; Michalakeas, C; Soulaidopoulos, S; Tousoulis, D; Tsioufis, K; Vlachopoulos, C, 2021
)
0.62
" We transformed the bis-aryl ketone structure of BBR to generate novel monocyclic amide-linked phenol derivatives that should possess uric acid excretion activity without adverse properties associated with BBR."( Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity.
Ashizawa, N; Iwanaga, T; Kobashi, S; Matsumoto, K; Uda, J, 2021
)
1.04
" The three outcomes used to assess the safety of uric acid lowering medications were treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE)."( The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Chen, J; Deng, Q; Guo, J; Xie, Q; Xie, S; Yu, Y; Zhang, S; Zhong, L, 2021
)
0.88
" We found no statistically significant differences in their effects on treatment-related adverse events and MACE."( The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Chen, J; Deng, Q; Guo, J; Xie, Q; Xie, S; Yu, Y; Zhang, S; Zhong, L, 2021
)
0.62
"Renal adverse effects were associated to lead fumes exposure."( Evaluation of the Role of KIM-1 in Detecting Early Nephrotoxicity in Lead-Exposed Workers.
Ahmed, MH; Ayesh, NA; Fouad, MM; Hussein, AA; Kamal, MM, 2021
)
0.62
" Endpoints were defined as major adverse limb events (MALE; target vessel revascularization, amputation, or disease progression) and major adverse cardiovascular events (MACE; stroke, myocardial infarction, or all-cause death) during the entire follow-up period."( C-reactive Protein, Free Fatty Acid, and Uric Acid as Predictors of Adverse Events after Endovascular Revascularization of Arterial Femoropopliteal Occlusion Lesions.
Di, X; Han, W; Liu, C; Zhang, R; Zheng, Y, 2022
)
0.99
"Pre-procedure hsCRP and FFA levels could serve as predictors of adverse events after EVT in patients with arterial femoropopliteal occlusive disease."( C-reactive Protein, Free Fatty Acid, and Uric Acid as Predictors of Adverse Events after Endovascular Revascularization of Arterial Femoropopliteal Occlusion Lesions.
Di, X; Han, W; Liu, C; Zhang, R; Zheng, Y, 2022
)
0.99
" The frequency of adverse drug reactions in the dotinurad 2-mg group, and in the benzbromarone 50-mg group tended to be lower than in the febuxostat 40-mg group."( Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Lee, YH; Song, GG, 2022
)
0.72
" Therefore, administration of xanthenone along with tacrolimus could be a promising therapeutic strategy to reduce the adverse effects and increase the tolerability to tacrolimus immunosuppressive therapy."( Impact of the ACE2 activator xanthenone on tacrolimus nephrotoxicity: Modulation of uric acid/ERK/p38 MAPK and Nrf2/SOD3/GCLC signaling pathways.
Ali, FEM; Azouz, AA; Hersi, F; Hussein Elkelawy, AMM; Omar, HA, 2022
)
0.95
" The frequency of adverse events (AEs) in the placebo group was lower than that in the topiroxostat 40 mg, topiroxostat 60 mg, and topiroxostat 200 mg groups."( Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Lee, YH; Song, GG, 2022
)
0.72
"Uricosuric agents are the typical approach to the control of hyperuricemia; however, their use has been eclipsed by adverse reactions, and a safer uricosuric drug is badly needed."( Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study.
Chen, Y; Di, X; Fan, L; Jin, Y; Li, X; Liu, R; Wang, Y; Wang, Z; Zheng, L; Zhou, Y, 2022
)
0.72
" HP501 appeared to be safe and well tolerated in both groups."( Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study.
Chen, Y; Di, X; Fan, L; Jin, Y; Li, X; Liu, R; Wang, Y; Wang, Z; Zheng, L; Zhou, Y, 2022
)
0.72
" We suggest that these adverse effects are at least in part the result of suppressed activity of sirtuins, particularly Sirtuin1."( Sirtuin deficiency and the adverse effects of fructose and uric acid synthesis.
Garcia-Arroyo, FE; Johnson, RJ; Lanaspa, MA; Nakagawa, T; Rodriguez-Iturbe, B; Sánchez-Lozada, LG, 2022
)
0.96
" The control group received neither acetaminophen nor the extract while the last group received only a toxic dose of acetaminophen."( Protective Effect of the Hydroalcoholic Extract of Pelargonium Graveolens L. on Rats with Acetaminophen- Induced Nephrotoxicity.
Akbarpour, B; Asmarian, S; Gholyaf, M; Mohammadi, F, 2022
)
0.72
"The results showed that by strengthening cell protection mechanisms against oxidative stress, geranium extract reduces the toxic effects of acetaminophen on mice's kidney function and thus ameliorates the damage."( Protective Effect of the Hydroalcoholic Extract of Pelargonium Graveolens L. on Rats with Acetaminophen- Induced Nephrotoxicity.
Akbarpour, B; Asmarian, S; Gholyaf, M; Mohammadi, F, 2022
)
0.72
" The use of recommended first-line treatment agents for AGA may be limited by adverse events."( Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: protocol for a multi-center, randomized, double-blind, placebo-controlled trial.
Dong, X; Huang, JY; Li, XP; Liu, JP; Liu, Y; Shang, YX; Wang, XC; Wei, SF; Xie, ZM, 2022
)
0.72
" Other outcome measures will be joint mobility, joint redness, C-reactive protein, serum uric acid, and the use of rescue medicine as well as adverse effect."( Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: protocol for a multi-center, randomized, double-blind, placebo-controlled trial.
Dong, X; Huang, JY; Li, XP; Liu, JP; Liu, Y; Shang, YX; Wang, XC; Wei, SF; Xie, ZM, 2022
)
0.94
" The potential risk factors for the discontinuation events caused by sac/val-related adverse events (AEs) were explored."( Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China.
Chen, C; Fan, L; Li, J; Li, X; Lv, Q; Tian, D; Zuo, C, 2022
)
0.72
"Our findings confirm that gentamicin is safe at the dose of 5 mg/kg/day for one week intravenously in brucellosis patients."( Assessing the Risk of Nephrotoxicity Associated with Aminoglycosides in Brucellosis Patients: A Cross-sectional Study.
Ataei, S; Derakhshandeh, K; Ghodsipour, Z; Keramat, F; Kord, M; Majzoobi, MM; Mohammadi, M; Mohammadi, Y; Nili-Ahmadabadi, A, 2023
)
0.91
" Adverse events (AEs) resulting from febuxostat treatment were collected from medical records."( The safety and urate-lowering efficacy of febuxostat in patients undergoing peritoneal dialysis: a retrospective single-arm cohort study of 84 patients.
Bao, S; Bian, X; Dai, L; Huang, J; Ma, J; Yu, Q; Zhang, A, 2022
)
0.72
"Febuxostat may be safe and efficient in patients undergoing PD and may not impair RRF."( The safety and urate-lowering efficacy of febuxostat in patients undergoing peritoneal dialysis: a retrospective single-arm cohort study of 84 patients.
Bao, S; Bian, X; Dai, L; Huang, J; Ma, J; Yu, Q; Zhang, A, 2022
)
0.72
"This network meta-analysis demonstrated an important absolute benefit of dotinurad 4 mg once daily to achieve target serum uric acid and low risk of adverse events for drug treatment of gout or hyperuricemia patients."( Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis.
Chen, LR; Guo, Y; He, GH; Jiang, FF; Li, YJ; Qian, K; Wang, P; Yang, M; Yang, ZL; Yin, SJ, 2023
)
1.12
" The single ascending dose of Naoqingzhiming tablet (180-2160 mg) were well tolerated in all enrolled subjects, without serious adverse events and adverse events leading to withdrawal from the study."( Safety, tolerability and pharmacokinetics of a Class I natural medicine with therapeutic potential for vascular dementia: Naoqingzhiming tablet.
Cao, Y; Chen, M; Han, Y; Jiang, H; Jiang, X; Li, T; Lin, P; Liu, X; Sun, F; Tao, Y; Yan, F, 2022
)
0.72
"9%) of 49 placebo patients experienced ≥1 adverse event (AE), most commonly gout flare (64 [66."( A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
Botson, JK; Chamberlain, J; Grewal, S; La, D; LaMoreaux, B; LoCicero, K; Majjhoo, A; Obermeyer, K; Ong, S; Parikh, N; Peterson, J; Saag, K; Sainati, S; Tesser, JRP; Verma, S; Weinblatt, ME; Xin, Y, 2023
)
0.91
" We examined the toxic effects of BPS on gastric and renal functions, as well as the efficacy of allopurinol as a treatment."( Evaluation of the therapeutic role of allopurinol on bisphenol S gastric and renal toxicity in adult male albino rats: An in vivo study.
Fattah, AA; Hosny, SA; Khalifa, FN; Matter, LM; Moawad, AM; Ramadan, NM, 2022
)
0.72
" The present study further widens our insights into the adverse effects of TCS."( Adverse effects of triclosan on kidney in mice: Implication of lipid metabolism disorders.
Cai, Z; Cao, G; Chen, D; Chen, Y; Deng, C; Huang, W; Wang, T, 2023
)
0.91
" All of the above RCTs showed that probiotics did not increase the incidence of adverse events."( Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.
Chen, H; Deng, Y; He, Q; Li, J; Liu, H; Xiang, W; Yang, K; Zeng, L; Zhu, X, 2022
)
0.72
" DF toxic effects could be the consequences of mitochondrial dysfunction and free radical effects."( Hepatoprotective Effect of Coenzyme Q10 in Rats with Diclofenac Toxicity.
Abed Al-Kareem, Z; Ali Zghair, M; Aziz, ND, 2022
)
0.72
" According to the obtained results, MP was found to be quite effective in the protection of kidneys from the toxic effects of AK."( Prevention of nephrotoxicity induced by amikacin: The role of misoprostol, A prostaglandin E1 analogue.
Azırak, S, 2023
)
0.91
" Besides, the drug-related adverse events (AEs) were recorded."( Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Cao, B; Yang, N, 2022
)
0.72
" The incidence of adverse events was 50."( Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.
Lee, J; Min, J; Saag, KG; Shin, S; Terkeltaub, R, 2023
)
0.91
" Thereby, we used a biological model species-Japanese quail (Coturnix japonica) to examine the nephrotoxic effects of Pb exposure and possible toxic mechanism of Pb on birds."( Lead exposure induced developmental nephrotoxicity in Japanese quail (Coturnix japonica) via oxidative stress-based PI3K/AKT pathway inhibition and NF-κB pathway activation.
Jing, L; Zhang, G; Zhang, Y; Zhao, H, 2023
)
0.91
" We emulated a hypothetical trial comparing the rate of major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) among seven different strategies over 24 months."( Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach.
Desai, RJ; Glynn, RJ; Kim, SC; Liu, J; Solomon, DH; Yoshida, K, 2023
)
0.91
"0 for the analysis focusing on the first major adverse cardiovascular event during follow-up and on comparison to the strategy requiring continuation of urate-lowering therapy (but not necessarily titration)."( Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach.
Desai, RJ; Glynn, RJ; Kim, SC; Liu, J; Solomon, DH; Yoshida, K, 2023
)
0.91
"Our treatment strategy trial emulation did not find increased risk of major adverse cardiovascular events with intensive urate-lowering strategies."( Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach.
Desai, RJ; Glynn, RJ; Kim, SC; Liu, J; Solomon, DH; Yoshida, K, 2023
)
0.91
" However, its toxic effect on the heart limits its clinical application."( Glycine protects against doxorubicin-induced heart toxicity in mice.
El-Ablack, FZ; Saad, EA; Shosha, MI, 2023
)
0.91
" The primary objective was to assess the safety of rasburicase by the incidence of adverse events (AEs)."( Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin's Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study.
Chen, Y; Fang, J; Gao, J; He, Y; Liu, R; Shen, S; Sun, J; Tang, Y; Wang, T; Wu, X; Zhang, H; Zhang, J; Zhang, M; Zhu, X, 2023
)
0.91
"Out of 50 patients, 25 reported a total of 76 treatment-emergent adverse events (TEAEs), including eight TEAEs of grade ≥ 3 in 12 patients."( Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin's Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study.
Chen, Y; Fang, J; Gao, J; He, Y; Liu, R; Shen, S; Sun, J; Tang, Y; Wang, T; Wu, X; Zhang, H; Zhang, J; Zhang, M; Zhu, X, 2023
)
0.91
" However, these studies almost focused on the individual smoking pattern rather than the toxic ingredients of tobacco smoke."( Comprehensive evaluation of serum cotinine on human health: Novel evidence for the systemic toxicity of tobacco smoke in the US general population.
Hu, Y; Hua, L; Lei, T; Li, M; Yang, J; Zhu, Z, 2023
)
0.91
" The secondary outcome measures including the blood uric acid (BUA), 24-h urinary total protein (24-h UTP), blood urea nitrogen (BUN), interleukin (IL)-6, IL-8, tumor necrosis factor-alpha (TNF-α) and adverse effects."( The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness.
Hua, Q; Lin, Y; Liu, X; Luo, Y; Xia, A; Yang, Q; Zheng, K, 2023
)
1.16
"Tongfengding capsules plus conventional treatment is safe and beneficial for adults with gout compared with conventional treatment."( The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness.
Hua, Q; Lin, Y; Liu, X; Luo, Y; Xia, A; Yang, Q; Zheng, K, 2023
)
0.91
" The toxic effects of this medication in tissues have been associated with redox state imbalance, which can lead to salivary gland dysfunction."( Assessment of the toxic effects of levetiracetam on biochemical, functional, and redox parameters of salivary glands in male Wistar rats.
Antoniali, C; Chaves-Neto, AH; da Silva, LGL; de Freitas, RN; Dornelles, RCM; Fakhouri, WD; Ferreira, DSB; Fiais, GA; Kawaguchi, M; Nakamune, ACMS; Teixeira, GR; Veras, ASC, 2023
)
0.91
" Mild adverse events were reported in 48 (9%) patients and serious adverse events, including cerebral vascular accident and portal vein thrombosis were reported in two patients each."( Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study.
Ali, M; Ali, Z; Ismail, M; Khan, MTM; Rani, GF; Rehman, IU, 2023
)
0.91
" Some drugs are more toxic than others."( Comparative analysis of multiorgan toxicity induced by long term use of disease modifying anti-rheumatic drugs.
Iqbal, MA; Mumtaz, T; Tahir, A; Tariq, MA, 2023
)
0.91
" Adverse events were similar across all three groups."( Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study.
Cui, L; Dalbeth, N; Han, L; He, Y; Ji, A; Ji, X; Li, C; Li, X; Liu, Z; Sun, M; Sun, W; Wang, C; Wang, X; Wang, Z; Xue, X, 2023
)
0.91
"To determine the risk of adverse events associated with colchicine or non-steroidal anti-inflammatory drug (NSAID) prophylaxis when initiating allopurinol for gout."( Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink.
Bajpai, R; Clarson, LE; Forrester, H; Mallen, CD; Muller, S; Padmanabhan, N; Partington, RJ; Roddy, E; Whittle, R, 2023
)
0.91
" Weighted Cox proportional hazards models investigated associations between colchicine/NSAID and specified adverse events."( Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink.
Bajpai, R; Clarson, LE; Forrester, H; Mallen, CD; Muller, S; Padmanabhan, N; Partington, RJ; Roddy, E; Whittle, R, 2023
)
0.91
" Adverse event incidence rates were <200/10 000 patient-years except diarrhoea (784."( Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink.
Bajpai, R; Clarson, LE; Forrester, H; Mallen, CD; Muller, S; Padmanabhan, N; Partington, RJ; Roddy, E; Whittle, R, 2023
)
0.91
" The MGH Acupuncture Sensation Scale and adverse events related to acupuncture will be measured after each treatment."( Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol.
Chen, Z; Fang, MY; Huang, Y; Li, CN; Lin, FP; Liu, WH; Ma, Y; Tu, SH; Wang, B; Wang, Y; Xie, WX; Yu, LL; Zhang, RY; Zheng, CH, 2023
)
1.15

Pharmacokinetics

The aim of this study was to develop a population pharmacodynamic (PPD) model to describe uric acid (UA)-lowering effects in patients treated with febuxostat. The pharmacodynamic effect of oxipurinol was smaller in elderly than young subjects. A simple HPLC method was develop.

ExcerptReferenceRelevance
" After the patient recovered, a pharmacokinetic study demonstrated that normal methylxanthine metabolism was re-established."( Pharmacokinetics of theophylline and its metabolites during acute renal failure. A case report.
Coates, PE; Elias-Jones, AC; Leakey, TE; Smith, KJ, 1991
)
0.28
" 6-MP plasma concentrations in the patients were low (mean peak concentration 36."( Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine.
Ascher, NL; Canafax, DM; Chan, GL; Chen, S; Erdmann, GR; Gruber, SA; Stock, P, 1989
)
0.58
" Furthermore, the plasma oxipurinol half-life was increased from 27."( Sustained reductions in oxipurinol renal clearance during a restricted diet.
Berlinger, WG; Kitt, TM; Park, GD; Spector, R; Tsalikian, E, 1987
)
0.27
" There was no significant difference between the plasma levels of torasemide on Days 1, 10 and 21, nor between its elimination half-life on Days 1 and 21."( Diuretic activity, safety and pharmacokinetics of torasemide during chronic treatment in normal subjects.
Ambroes, Y; Dodion, L; Ronflette, I, 1986
)
0.27
" Its pharmacodynamic profile shows a diuretic efficacy is similar to that of frusemide (furosemide) at doses up to 40 mg, but the onset and duration of action are comparable to those of hydrochlorothiazide."( Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
Brogden, RN; Prichard, BN, 1985
)
0.27
" Tiazofurin levels were measured using a high-pressure liquid chromatography assay, and pharmacokinetic studies were performed in patients treated at each dose level."( Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Boldt, DH; Clark, GM; Hersh, MR; Kuhn, JG; Melink, TJ; Patton, TF; Siegler, R; Sternson, LA; Von Hoff, DD, 1985
)
0.27
"A slow-release formulation of 40 mg furosemide as capsules (Eutensin) was investigated for its pharmacokinetic and pharmacodynamic properties in comparison with conventional tablets containing 40 mg furosemide (Lasix) in a single-blind clinical pharmacological trial in 6 healthy subjects."( Pharmacodynamic and pharmacokinetic study of a slow-release formulation of furosemide in man.
Ebihara, A; Oka, T; Tawara, K, 1983
)
0.27
" Peak serum levels are seen at three hours, and the serum half-life is six hours."( Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic.
Vidt, DG,
)
0.13
" The pharmacokinetic parameters found differed only slightly from those reported in the literature, as there was faster absorption and a shorter half-life."( Pharmacokinetic and pharmacodynamic studies of tienilic acid in healthy volunteers.
Gribnau, FW; Kerremans, AL; Tan, Y; van Ginneken, CA, 1982
)
0.26
"The possibility of a pharmacokinetic interaction between two hypolipidemic drugs, colestipol, an ion exchange resin, and fenofibrate, a phenoxyacid derivative, was studied in 6 male volunteers."( Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers.
Desager, JP; Harvengt, C, 1980
)
0.26
" The acute pharmacodynamic actions of intravenous (i."( Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension.
Berman, RS; Bradstreet, DC; Jallard, N; Saenz, A; Sweet, CS; Weidler, DJ, 1994
)
0.29
"The purpose of this investigation was to determine the pharmacokinetic disposition of intravenous allopurinol and its metabolite oxypurinol in neonates with the hypoplastic left heart syndrome (HLHS) and to evaluate the subsequent degree of xanthine oxidase inhibition using serum uric acid as a marker."( The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome.
Clancy, RR; Davis, LE; Jacobs, ML; Krawczeniuk, MM; McGaurn, SP; Murphy, JD; Norwood, WI, 1994
)
0.47
" Pharmacokinetic parameters were determined for elimination half-life, clearance, volume of distribution, and mean residence time."( The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome.
Clancy, RR; Davis, LE; Jacobs, ML; Krawczeniuk, MM; McGaurn, SP; Murphy, JD; Norwood, WI, 1994
)
0.29
" to healthy male volunteers to evaluate its pharmacokinetic and pharmacodynamic properties."( Pharmacokinetic and pharmacodynamic properties of a novel xanthine oxidase inhibitor, BOF-4272, in healthy volunteers.
Nakashima, M; Uematsu, T, 1994
)
0.29
"In the present study we have investigated the use of caffeine, administered in the form of instant coffee, as a prodrug for 1MX to validate the use of the 1MU:1MX ratio following caffeine administration as a pharmacodynamic measure of oxypurinol effect on xanthine oxidase."( 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect.
Birkett, DJ; Day, RO; Lillywhite, KJ; Miners, JO; Valente, L, 1997
)
0.3
"In this study we aimed at evaluating the modifications in the pharmacokinetic profile of cyclosporin A (CyA) after conversion from standard formulation (CyA-ST) to a new formulation (CyA-NF, Sandimmun Neoral) in patients with rheumatoid arthritis (RA)."( Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients.
Battafarano, N; Fantini, F; Leoni, L; Marchesoni, A; Padula, A; Pasero, G; Ruiu, G; Taglione, E; Zeni, S, 1998
)
0.3
" Pharmacokinetic (PK) and pharmacodynamic (PD) data were simultaneously fitted using nonlinear mixed effects modeling (NONMEM) to the one-compartment model and indirect response model."( Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach.
Castañeda-Hernández, G; Flores-Acevedo, DM; Flores-Murrieta, FJ; Jusko, WJ; Ko, HC; López-Muñoz, FJ; Sale, ME, 1998
)
0.3
"25) as was the area under the oxipurinol plasma concentration-time curve, AUC (260+/-46 and 166+/-23 microgram ml-1 h, respectively), the pharmacodynamic effect of oxipurinol was smaller in elderly than young subjects (time-dependent decrease of plasma uric acid 83+/-30 microgram ml-1 h in elderly compared with 176+/-21 in young controls)."( Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Krivanek, P; Oberbauer, R; Turnheim, K, 1999
)
0.48
" The elimination half-life of BOF-4272 in the liver was 5-1-fold longer than that in the plasma."( Evaluation of the pharmacological actions and pharmacokinetics of BOF-4272, a xanthine oxidase inhibitor, in mouse liver.
Naito, S; Nishimura, M; Tamao, Y, 2000
)
0.31
" Hence, the pharmacokinetic parameters of theophylline, 1,3-DMU and 1-MU were compared after intravenous administration of aminophylline, 5 mg/kg as theophylline, to control Sprague-Dawley rats and NARs."( Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats.
Kim, EJ; Lee, MG; Suh, OK, 2003
)
0.32
"A total of 36 healthy volunteers (12, 9, 1, 9, 3, and 2 carriers of CYP2C9 genotypes *1/*1 , *1/*2 , *2/*2 , *1/*3 , *2/*3 , and *3/*3 , respectively) received a single oral dose of 10 mg torsemide for pharmacokinetic and pharmacodynamic analysis."( CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Brockmöller, J; Engelhardt, S; Kirchheiner, J; Meineke, I; Tuchen, F; Vormfelde, SV; Zirk, A, 2004
)
0.32
" Regression analyses indicated that febuxostat tmax and Cmax,u values were not affected by CLcr."( Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.
Joseph-Ridge, N; Khosravan, R; Mayer, MD; Mulford, DJ; Vernillet, L; Wu, JT,
)
0.13
"A simple HPLC method was developed and validated for the determination of uric acid (UA), xanthine (X) and hypoxanthine (HX) concentrations in human serum to support pharmacodynamic (PD) studies of a novel xanthine oxidase inhibitor during its clinical development."( Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies.
Cooper, N; Erdmann, C; Fiene, J; Khosravan, R; Lee, JW, 2006
)
0.9
" During the course of the study, blood and urine samples were collected to assess the pharmacokinetics of febuxostat and its metabolites, and its pharmacodynamic effects on uric acid, xanthine and hypoxanthine concentrations after both single and multiple dose administration."( Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT, 2006
)
0.53
" There appeared to be a linear pharmacokinetic and dose-response (percentage decrease in serum uric acid) relationship for febuxostat dosages within the 10-120 mg range."( Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT, 2006
)
0.55
" Pharmacokinetic and pharmacodynamic parameters were analysed using two-way ANOVA."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2008
)
0.35
" However, in 96-h KPLPS rats, the pharmacokinetic parameters of theophylline and 1,3-DMU returned fully or partially to those in control rats."( Time-dependent effects of Klebsiella pneumoniae endotoxin (KPLPS) on the pharmacokinetics of theophylline in rats: return of the parameters in 96-hour KPLPS rats to the control levels.
Jung, YS; Kim, YC; Lee, DY; Lee, JH; Lee, MG; Yang, KH, 2008
)
0.35
" Following multiple dosing with febuxostat, there were no statistically significant differences in the plasma or urinary pharmacokinetic or pharmacodynamic parameters between subjects aged 18 to 40 years and >or=65 years."( The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Joseph-Ridge, N; Khosravan, R; Kukulka, MJ; Vernillet, L; Wu, JT, 2008
)
0.35
" Here, we describe the following: (1) the design, synthesis, and structure-activity relationship of a series of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives by in vitro studies of XO inhibitory activity in bovine milk and in vivo studies of serum uric acid (UA) reductive activity in rats, (2) a drug interaction study by a cytochrome P450 3A4 (CYP3A4) assay, and (3) a pharmacokinetic (PK) study."( Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors.
Ashizawa, N; Inoue, T; Iwanaga, T; Matsumoto, K; Nagata, O; Nakamura, H; Sato, T, 2009
)
0.53
"To investigate the pharmacokinetic and pharmacodynamic interaction between probenecid and oxypurinol (the active metabolite of allopurinol) in patients with gout."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2011
)
0.37
" The long elimination half-life of mPEG-UHC in non-human primate (191."( Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
Chen, Z; Fan, K; Hu, C; Liu, R; Luo, H; Ma, X; Min, Z; Wei, D; Yang, L; Zhang, C, 2012
)
0.38
" D-ribose was absorbed rapidly with mean Tmax ranging between 18 and 30 minutes."( Evaluation of D-ribose pharmacokinetics, dose proportionality, food effect, and pharmacodynamics after oral solution administration in healthy male and female subjects.
Homer, K; Khankari, R; Neutel, J; Shah, A; Tempero, K; Thompson, J, 2014
)
0.4
" Synovial fluid and plasma gentamicin concentrations were measured for 14 days after implantation, and pharmacokinetic parameters modeled using statistical moment analyses."( Intra-articular pharmacokinetics of a gentamicin impregnated collagen sponge in the canine stifle: an experimental study.
Gibson, TW; Hayes, GM; Johnson, RJ; Moens, NM; Monteiro, B, 2014
)
0.4
" ABT-639 demonstrated acceptable safety and pharmacokinetic profiles in human."( Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.
An, G; Awni, W; Duan, WR; Dutta, S; Liu, W; Nothaft, W, 2015
)
0.68
"All pharmacokinetic parameters were comparable between the two formulations The observed mean Cmax, AUC(last), and AUC(∞) values for the reference formulation were 3,670 ng/mL, 12,086 ng x h/mL, and 12,880 ng x h/mL, respectively."( Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects.
Kim, KA; Park, JY, 2015
)
0.69
" A relative bioavailability study in healthy males (N=8) indicated a nearly identical pharmacokinetic profile following dosing of tablets or capsules."( Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
Hingorani, V; Kerr, B; Manhard, K; Quart, B; Rowlings, C; Shen, Z; Storgard, C; Yeh, LT, 2015
)
0.65
" The mean Cmax and AUClast values increased with increasing doses, and exposure to LC350189 was dose proportional."( Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.
Jang, IJ; Lee, H; Shin, D; Yoon, S; Yu, KS, 2015
)
0.42
" The pharmacokinetic parameters of UOMVLs and UOX were as follows, respectively: area under time-concentration curve from 0 to infinity time (AUC0-∞) (498."( [The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes].
Deng, X; He, D; Xiong, HR; Zhang, JQ; Zhou, YL, 2015
)
0.42
"UOMVLs can prolong tmax and t1/2 and improve the relative bioavailability."( [The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes].
Deng, X; He, D; Xiong, HR; Zhang, JQ; Zhou, YL, 2015
)
0.42
"The aim of this study was to develop a population pharmacodynamic (PPD) model to describe uric acid (UA)-lowering effects in patients treated with febuxostat based on electronic medical records in 2 independent hospitals (university and city hospitals)."( Population Pharmacodynamic Analysis of Uric Acid-Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals.
Fukae, M; Hirakawa, M; Hirota, T; Ieiri, I; Kakara, M; Moriki, K; Muraki, S; Shigematsu, S; Shimada, M; Takane, H; Yamashita, D, 2018
)
0.97
"AZD4831 was generally well tolerated, rapidly absorbed, had a long plasma half-life and lowered uric acid concentrations after single oral doses in healthy men."( Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Ericsson, H; Fuhr, R; Gan, LM; Heijer, M; Kjaer, M; Lagerström-Fermér, M; Lindstedt, EL; Michaëlsson, E; Nelander, K; Whatling, C, 2019
)
0.98
" The in vitro release of MPs compared with free myricitrin was measured in different dissolution media while the pharmacokinetic study was also conducted in rats."( Preparation, characterization, pharmacokinetics and anti-hyperuricemia activity studies of myricitrin-loaded proliposomes.
Adu-Frimpong, M; Ji, H; Man, N; Toreniyazov, E; Wang, Q; Wei, C; Wei, Q; Weng, W; Xu, X; Yu, J; Zhang, K, 2019
)
0.51
" This study sought to clarify the pharmacokinetic (PK) profile of dotinurad."( Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.
Fushimi, M; Ito, A; Iwanaga, T; Kobashi, S; Miyata, K; Ohashi, T; Omura, K; Sasaki, T; Uda, J, 2020
)
0.56
"Q141K had a longer half-life (34."( Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.
Brackman, DJ; Garcia-Cremades, M; Giacomini, KM; Savic, RM; Sirota, M; Vora, B; Zou, L, 2021
)
0.62
" Blood samples were collected for pharmacokinetic and pharmacodynamic analysis."( Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of SHR4640, a Selective Urate Transporter 1 Inhibitor, in Healthy Chinese Male Volunteers.
Bai, N; Cai, Y; Liang, B; Lin, H; Wang, J; Wang, R; Zhuo, J, 2023
)
0.91
" The primary aim of the present study was to study the pharmacokinetic drug‒drug interactions (DDIs) of HP501, febuxostat, and colchicine in hyperuricemic patients."( A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia.
Chen, H; Chen, L; Ding, R; Hu, X; Jiang, F; Li, X; Li, Y; Liu, K; Peng, Q; Wu, J; Xiong, T; Zhou, Y, 2023
)
0.91
" Coadministration of HP501 and febuxostat did not significantly change the pharmacokinetic profiles of either drug."( A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia.
Chen, H; Chen, L; Ding, R; Hu, X; Jiang, F; Li, X; Li, Y; Liu, K; Peng, Q; Wu, J; Xiong, T; Zhou, Y, 2023
)
0.91
"The concomitant use of HP501, febuxostat, and colchicine did not produce clinically meaningful DDIs in terms of their pharmacokinetic properties."( A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia.
Chen, H; Chen, L; Ding, R; Hu, X; Jiang, F; Li, X; Li, Y; Liu, K; Peng, Q; Wu, J; Xiong, T; Zhou, Y, 2023
)
0.91

Compound-Compound Interactions

Verinurad combined with febuxostat decreased sUA dose-dependently. Chinese herbal medicine combined with allopurinol could obviously reduce the uric acid level in blood.

ExcerptReferenceRelevance
" They received in random order: placebo; tienilic acid 250 mg/day; propranolol 80 mg twice daily; and tienilic acid 250 mg/day combined with propranolol 80 mg twice daily."( Biochemical and haematological changes induced by tienilic acid combined with propranolol in essential hypertension.
Bulpitt, CJ; Havard, CW; Pearson, RM, 1979
)
0.26
" It can be concluded that ramipril alone and in combination with HCTZ is an effective and safe drug for the long-term treatment of essential hypertension."( Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study.
Bauer, B; Breitstadt, A; Cairns, V; Froer, KL; Heidbreder, D, 1991
)
0.28
" The increase in lifespan (ILS) of mice treated with 5'-DFUR was augmented by the combination with guanosine or inosine in a dose-dependent fashion, and the maximum ILS was about 160% with the combination, while that in the case of 5'-DFUR alone was only 48% in the P388 leukemia system."( Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.
Iigo, M; Ishitsuka, H; Miwa, M; Nitta, K, 1987
)
0.27
"The antihypertensive and biochemical effects of 25 mg hydrochlorothiazide alone or 50 mg hydrochlorothiazide alone or in combination with triamterene (either 37."( Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene.
Eisalo, A; Gordin, A; Kohvakka, A; Salo, H, 1986
)
0.27
"Seven patients with glycogen disease type I have been treated with nocturnal intragastric feeding combined with frequent daytime feeding."( Glycogen storage disease type I. Results of treatment with frequent daytime feeding, combined with nocturnal intragastric feeding and with administration of an alpha-glucosidase inhibitor.
Gröbe, H; Ullrich, K, 1983
)
0.27
"Disposition of uric acid upon administration of ofloxacin (O) alone and in combination with other anti-tuberculosis drugs, rifampicin (R), isoniazid (H) and pyrazinamide (Z) was studied."( Disposition of uric acid upon administration of ofloxacin alone and in combination with other anti-tuberculosis drugs.
Gurumurthy, P; Kumar, AK, 2004
)
1.03
"To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout."( Effect of fenofibrate in combination with urate lowering agents in patients with gout.
Lee, CH; Lee, J; Lee, YH, 2006
)
0.33
" The treatment group were treated with electroacupuncture combined with point-injection, and the control group with western medicine."( [Observation on therapeutic effect of electroacupuncture combined with acupoint-injection on acute gouty arthritis].
Xu, Y; Zhang, HX; Zhang, TF; Zou, R, 2007
)
0.34
"Electroacupuncture combined with point-injection is an effective method for treatment of acute gouty arthritis, and it can decrease blood uric acid content."( [Observation on therapeutic effect of electroacupuncture combined with acupoint-injection on acute gouty arthritis].
Xu, Y; Zhang, HX; Zhang, TF; Zou, R, 2007
)
0.54
" The treatment group was treated by jiawei simiaosan and combined with the external application of Sihuangshuimi."( [A clinical research of Jiawei simiaosan oral administration combined with the external application of Sihuangshuimi in the treatment of acute gouty arthritis].
Chen, SQ; Chen, ZX; Sun, BG; Ye, XY; Yin, LR; Zhou, HM, 2007
)
0.34
"The effect of using sihuangshuimi combined with Jiawei simiaosan to cure acute gouty arthritis is not only to improve joint function and cut down UA level obviously, but also to decline the body temperature and decrease swelling to relieve pain."( [A clinical research of Jiawei simiaosan oral administration combined with the external application of Sihuangshuimi in the treatment of acute gouty arthritis].
Chen, SQ; Chen, ZX; Sun, BG; Ye, XY; Yin, LR; Zhou, HM, 2007
)
0.34
"To study the effect of retention enema of Chinese herbal medicine combined with allopurinol in treating hyperuricaemia (HUE)."( Clinical study on treatment of hyperuricaemia by retention enema of Chinese herbal medicine combined with allopurinol.
Akebaier, W; Chen, Q; Ma, L, 2009
)
0.35
"Seventy-eight patients with HUE were assigned to two: groups, the 40 patients in the treated group were treated with retention enema of Chinese herbal medicine combined with oral intake of allopurinol, and the 38 patients in the control group were treated with allopurinol alone."( Clinical study on treatment of hyperuricaemia by retention enema of Chinese herbal medicine combined with allopurinol.
Akebaier, W; Chen, Q; Ma, L, 2009
)
0.35
"Retention enema with: Chinese herbal medicine combined with allopurinol could obviously reduce the uric acid level in blood, improve patients' renal function and lipid metabolism, and alleviate the clinical symptoms in patients with HUE."( Clinical study on treatment of hyperuricaemia by retention enema of Chinese herbal medicine combined with allopurinol.
Akebaier, W; Chen, Q; Ma, L, 2009
)
0.57
" The effects of casein or soya protein combined with palm or safflower-seed oil on various serum parameters and renal histology were investigated on hyperuricaemic rats."( Relative efficacy of casein or soya protein combined with palm or safflower-seed oil on hyperuricaemia in rats.
Chiou, HY; Lai, SH; Lo, HC; Wang, YH; Yang, Y, 2010
)
0.36
"Few have tried to prove the effectiveness of mizoribine combined with losartan for adult IgA nephropathy patients in a randomized controlled trial."( Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study.
Chen, P; Chen, X; Huang, S; Li, Y; Lie, C; Liu, S; Miao, L; Wang, L; Wu, X; Xie, Y; Zhang, A, 2011
)
0.37
"A multicenter, randomized, controlled, 12-month study was performed to evaluated the efficacy and safety of mizoribine combined with losartan for adult IgA nephropathy."( Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study.
Chen, P; Chen, X; Huang, S; Li, Y; Lie, C; Liu, S; Miao, L; Wang, L; Wu, X; Xie, Y; Zhang, A, 2011
)
0.37
" Moreover, more information can be provided on the evaluation of toxicity of phorate using metabonomics combined with clinical chemistry."( Metabonomics evaluation of urine from rats administered with phorate under long-term and low-level exposure by ultra-performance liquid chromatography-mass spectrometry.
Guo, L; Hou, Y; Sun, C; Sun, X; Xu, W; Zeng, Y; Zhao, X, 2014
)
0.4
" Thus, application of ursodeoxycholic acid, rosuvastatin and allopurinol in these study patients with NAFLD dosages in combination with hyperuricemia improves the clinical symptoms and normalization of biochemical parameters and normalizes the spectrum of biliary acids."( [CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA].
Barabanchyk, OV; Kozak, NP; Svintsits'kyĭ, AS, 2014
)
0.4
"This study was aimed to investigate the therapeutic potential of coenzyme Q10 and its combination with metformin on streptozotocin (STZ)-nicotinamide-induced diabetic nephropathy (DN)."( Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats.
Balaraman, R; Maheshwari, RA; Sen, AK; Seth, AK,
)
0.13
"To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout."( Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
Adler, S; Baumgartner, S; Bhakta, N; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Kopicko, J; Perez-Ruiz, F; Storgard, C; Terkeltaub, R, 2017
)
0.77
"Treatment with lesinurad in combination with febuxostat demonstrated superior lowering of serum UA levels as compared with febuxostat alone, with clinically relevant added effects on tophi and an acceptable safety profile with lesinurad 200 mg in patients with tophaceous gout warranting additional therapy."( Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
Adler, S; Baumgartner, S; Bhakta, N; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Kopicko, J; Perez-Ruiz, F; Storgard, C; Terkeltaub, R, 2017
)
0.77
" The presence of positive correlations between the levels of TC, HDL-C, LDL-C, AC, UA and TG indicates its direct role in the pathogenesis of hypertension, and the combination with CTD complicates the underlined pathology."( Indscators of blood lipid profile, acute phase reactions and uric acid in patients with arterial hypertension combined with connective tissue dysplasia.
Odnorih, LO; Rak, NO; Virna, MM; Zaremba, OV; Zaremba, YH; Zaremba-Fedchyshyn, OV,
)
0.37
"The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout and hyperuricemia."( The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
Baumgartner, S; Kerr, B; Manhard, K; Quart, B; Shen, Z; Yeh, LT, 2018
)
0.95
" The aim of this Phase 2a, randomized, open-label study was to investigate the multiple-dose pharmacodynamics, pharmacokinetics and safety of oral verinurad combined with febuxostat vs febuxostat alone and verinurad alone."( Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018
)
0.48
"Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricaemia (n = 35) and serum urate (sUA) ⩾8 mg/dl were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2."( Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018
)
0.48
"Verinurad combined with febuxostat decreased sUA dose-dependently while maintaining uric acid excretion similar to baseline."( Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018
)
0.71
"This study aimed to introduce this surgical technique laparoscopic sleeve gastrectomy combined with single-anastomosis duodenal-jejunal bypass (LDJB-LSG), and to confirm this new surgical technique was safe in the treatment of type 2 diabetes mellitus (T2DM) of patients with body mass index (BMI) higher than 27."( Laparoscopic sleeve gastrectomy combined with single-anastomosis duodenal-jejunal bypass in the treatment of type 2 diabetes mellitus of patients with body mass index higher than 27.5 kg/m2 but lower than 32.5 kg/m2.
Fang, DH; Li, YX; Liu, TX, 2018
)
0.48
" We conducted a meta-analysis to explore the benefits of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) combined with calcium channel blockers (CCBs) on metabolic, renal, and cardiovascular outcomes in hypertensive patients."( The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.
Eiam-Ong, S; Pitakpaiboonkul, P; Pongpanich, P; Praditpornsilpa, K; Susantitaphong, P; Takkavatakarn, K, 2018
)
0.48
"gov (until April 7, 2016) to identify randomized controlled trials (RCTs) comparing the benefits of ACEIs/ARBs combined with CCBs versus other dual or triple combinations on clinical outcomes in hypertensive patients."( The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.
Eiam-Ong, S; Pitakpaiboonkul, P; Pongpanich, P; Praditpornsilpa, K; Susantitaphong, P; Takkavatakarn, K, 2018
)
0.48
"We aimed to assess the relative efficacy and safety of once-daily administration of lesinurad in combination with xanthine oxidase inhibitor (XOI) in hyperuricemic patients with gout."( Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
.
Lee, YH; Song, GG, 2019
)
0.51
"To evaluate the differences between traditional Chinese medicine combined with western medicine and western medicine alone for the treatment of secondary tuberculosis and its impact on the evaluation of clinical efficacy and safety of patients in randomized controlled trials."( Traditional Chinese medicine combined with western medicine for the treatment of secondary pulmonary tuberculosis: A PRISMA-compliant meta-analysis.
Li, X; Liu, Q; Shi, C; Sun, N; Zhang, B; Zhang, R, 2020
)
0.56
" The following indicators in the treatment group (traditional Chinese medicine decoction combined with western medicine chemotherapy) improved in comparison with those in the control group:focus absorption rate (RR:1."( Traditional Chinese medicine combined with western medicine for the treatment of secondary pulmonary tuberculosis: A PRISMA-compliant meta-analysis.
Li, X; Liu, Q; Shi, C; Sun, N; Zhang, B; Zhang, R, 2020
)
0.56
" In order to determine which combination was better as the next-step therapy for standard-dose combination of ARBs and CCBs, a combination with high-dose CCBs or a triple combination with diuretics, the authors conducted a prospective, randomized, open-label trial to determine which of the following combination is better as the next-step treatment: a combination with high-dose CCBs or a triple combination with diuretics."( Assessment of suitable antihypertensive therapies: Combination with high-dose amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide (ASAHI-AI study).
Hasebe, N; Koyama, S; Maruyama, J; Morimoto, H; Nakagawa, N; Nakamura, Y; Ogawa, Y; Ohta, T; Saijo, Y; Sato, N; Takeuchi, T; Uekita, K, 2020
)
0.56
"To examine the efficacy and safety of pegloticase in combination with methotrexate (MTX) in patients with uncontrolled gout in an exploratory, open-label clinical trial (ClinicalTrials."( Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR).
Bennett, R; Botson, JK; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Tesser, JRP; Weinblatt, ME, 2021
)
0.62
" Azilsartan medoxomil in combination with the older diuretic chlorthalidone (CLD) in fixed-doses of AZM/CLD 40/12."( Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review.
Antonopoulos, AS; Katsi, V; Michalakeas, C; Soulaidopoulos, S; Tousoulis, D; Tsioufis, K; Vlachopoulos, C, 2021
)
0.62
"The purpose of this study was to investigate the application value of serum 25(OH)D3, uric acid, triglyceride (TG), and homeostasis model assessment of insulin resistance (HOMA-IR) in male patients with hyperuricemia combined with hypogonadism."( The application value of serum 25(OH)D3, uric acid, triglyceride, and homeostasis model assessment of insulin resistance in male patients with hyperuricemia combined with hypogonadism.
Chen, W; Wang, J; Yun, C; Zhang, Q, 2021
)
1.11
"Anthropometric, clinical biochemical data, and serum samples were collected from patients with MetS, MetS combined with HUA (MetS & HUA) and healthy controls."( NMR spectroscopy based metabolomics confirms the aggravation of metabolic disorder in metabolic syndrome combined with hyperuricemia.
Bian, C; Pan, H; Rong, S; Yang, Y; Zhang, H; Zhang, Y, 2021
)
0.62
"To assess the efficacy of febuxostat combined with hydration on contrast-induced nephropathy (CIN) in coronary heart disease patients with hyperuricemia undergoing percutaneous coronary intervention (PCI)."( Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
He, Z; Li, M; Ma, G; Teng, W; Xia, Z; Zhai, X, 2022
)
0.72
"Our study demonstrated that prophylactic treatment with febuxostat combined with hydration can reduce the incidence of CIN in patients with coronary heart disease and hyperuricemia after PCI."( Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
He, Z; Li, M; Ma, G; Teng, W; Xia, Z; Zhai, X, 2022
)
0.72
"To elucidate the effect of acupuncture-moxibustion combined with rehabilitation training (RHT) on the curative effect, cognitive function (CF), and activities of daily living (ADL) of patients with cerebral infarction (CI)."( Acupuncture-Moxibustion Combined with Rehabilitation Training Is Conducive to Improving the Curative Effect, Cognitive Function, and Daily Activities of Patients with Cerebral Infarction.
Ding, M; Gui, X; Huang, L; Tao, J; Zeng, P; Zhang, D; Zhang, L, 2022
)
0.72
" Among them, 80 patients who were treated with acupuncture-moxibustion combined with RHT were included in the research group, and 70 patients who received acupuncture-moxibustion alone were included in the control group."( Acupuncture-Moxibustion Combined with Rehabilitation Training Is Conducive to Improving the Curative Effect, Cognitive Function, and Daily Activities of Patients with Cerebral Infarction.
Ding, M; Gui, X; Huang, L; Tao, J; Zeng, P; Zhang, D; Zhang, L, 2022
)
0.72
"Acupuncture-moxibustion combined with RHT can inhibit serum UA, hs-CRP, and Cys-C levels of patients with CI while improving the curative effect, CF, and ADL, which is worthy of clinical promotion."( Acupuncture-Moxibustion Combined with Rehabilitation Training Is Conducive to Improving the Curative Effect, Cognitive Function, and Daily Activities of Patients with Cerebral Infarction.
Ding, M; Gui, X; Huang, L; Tao, J; Zeng, P; Zhang, D; Zhang, L, 2022
)
0.72
"This study was to investigate the correlation between glycated haemoglobin (HbA1c) level, cardiac function, and prognosis in patients with diabetes mellitus combined with myocardial infarction."( Correlation between Glycated Haemoglobin Level, Cardiac Function, and Prognosis in Patients with Diabetes Mellitus Combined with Myocardial Infarction.
An, H; Fang, D; Li, W; Sun, M; Zeng, G; Zheng, Q, 2022
)
0.72
"HbA1c level in patients with diabetes mellitus combined with myocardial infarction is closely related to the degree of cardiac function damage."( Correlation between Glycated Haemoglobin Level, Cardiac Function, and Prognosis in Patients with Diabetes Mellitus Combined with Myocardial Infarction.
An, H; Fang, D; Li, W; Sun, M; Zeng, G; Zheng, Q, 2022
)
0.72
" aristatus is related to the regulation of gut microbiota by 16S rDNA gene sequencing combined with widely targeted metabolomics."( Study on the mechanism of Orthosiphon aristatus (Blume) Miq. in the treatment of hyperuricemia by microbiome combined with metabonomics.
Bian, M; Niu, H; Zhang, X; Zhou, Z; Zhu, C, 2023
)
0.91
" aristatus on the gut microbiota and its metabolites, we utilized 16S rDNA gene sequencing combined with widely targeted metabolomics."( Study on the mechanism of Orthosiphon aristatus (Blume) Miq. in the treatment of hyperuricemia by microbiome combined with metabonomics.
Bian, M; Niu, H; Zhang, X; Zhou, Z; Zhu, C, 2023
)
0.91
"To investigate the clinical value of hemoglobin to serum creatinine ratio (Hb/SCr) combined with blood uric acid (SUA) in predicting in-hospital mortality after emergency percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI)."( [Predictive value of hemoglobin to serum creatinine ratio combined with serum uric acid for in-hospital mortality after emergency percutaneous coronary intervention in patients with acute myocardial infarction].
Bao, F; Yang, C; Zhou, G, 2023
)
1.35
" Hb/SCr ratio combined with SUA has a higher predictive value for in-hospital death after emergency PCI in AMI patients than single index, which is helpful for early identification of high-risk patients."( [Predictive value of hemoglobin to serum creatinine ratio combined with serum uric acid for in-hospital mortality after emergency percutaneous coronary intervention in patients with acute myocardial infarction].
Bao, F; Yang, C; Zhou, G, 2023
)
1.14
" The positive rate of LAAT detected by ECG combined with CTA was closest to the gold standard TEE, but the difference was not statistically significant (p>0."( Predictive value of echocardiography combined with CT angiography for left atrial appendage thrombosis in patients with non-valvular atrial fibrillation.
Xing, LM; Zhong, J, 2023
)
0.91
"ECG combined with CTA has a high diagnostic value for LAAT formation in NVAF patients, with a high degree of confidence and reduced patient intolerance."( Predictive value of echocardiography combined with CT angiography for left atrial appendage thrombosis in patients with non-valvular atrial fibrillation.
Xing, LM; Zhong, J, 2023
)
0.91

Bioavailability

UHLN/UHLNM had significantly increased bioavailability (∼533% and ∼331% compared to Uase) and demonstrated greatly improved efficacy. UNAs increased the bioavailability and uric acid-lowering efficacy of uricase, while the immunogenicity and hemolysis rate of uriase were decreased.

ExcerptReferenceRelevance
" The bioavailability of breast milk Mo seems to be higher than formula Mo according to the Mo levels and to their statistical link with uric acid excretion which could be proposed as a functional index of Mo status."( Molybdenum in the premature infant.
Bougle, D; Bureau, F; Duhamel, JF; Foucault, D; Voirin, J, 1991
)
0.48
" The addition of SITS, DIDS, or furosemide to the luminal perfusion solution resulted in a decreased rate of absorption of water and 2-14C-urate."( Effect of anion exchange inhibitors and para-aminohippurate on the transport of urate in the rat proximal tubule.
Bennett, S; Kahn, AM; Sansom, SC; Weinman, EJ, 1983
)
0.27
" These results suggest ATP dependence of transport of iodothyronines into the liver in vivo and show that, in the rat liver and in humans, uptake of T4 may be regulated by intracellular energy stores; in this way the tissue uptake process may affect intracellular metabolism and bioavailability of thyroid hormone."( T4 uptake into the perfused rat liver and liver T4 uptake in humans are inhibited by fructose.
Bernard, BF; De Jong, M; Docter, R; Hennemann, G; Krenning, EP; van der Heijden, JT; van Toor, H, 1994
)
0.29
" The bioavailability of the compound is relatively independent of food intake and bile flow."( Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year.
Budde, K; Färber, L; Haller, P; Kohnen, R; Luft, FC; Maibücher, A; Neumayer, HH; Schuster, A; Vollmar, J; Waiser, J, 1996
)
0.29
"Oxipurinol is well absorbed and sufficiently effective in hyperuricemic patients when administered as a rapid release preparation of oxipurinol sodium."( Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol.
de Vries, JX; Ernst, B; Frei, M; Kolb, S; Kosmowski, J; Priebe, U; Schroder, HE; Slotty, C; Voss, A; Walter-Sack, I; Weber, A; Wegscheider, K, 1996
)
1.74
" The results showed that the bioavailability of CyA-NF was greater than that of CyA-ST (AUC tau, bss: 3335 +/- 1300 vs 2667 +/- 1155 ng."( Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients.
Battafarano, N; Fantini, F; Leoni, L; Marchesoni, A; Padula, A; Pasero, G; Ruiu, G; Taglione, E; Zeni, S, 1998
)
0.3
"Due to the large variations in the absorption and bioavailability of conventional cyclosporine A (CyA), 1:1 (mg:mg) conversion to its microemulsion formulation (Neoral) has been advocated in transplant recipients."( The impact of (1:1) cyclosporine A conversion to its microemulsion formulation on the kidney function of patients with cardiac allografts.
Bastani, B; Khajehdehi, P; Yip, D, 1999
)
0.3
" However, flavonoids are poorly absorbed by humans, and the increase in plasma antioxidant capacity observed after consumption of flavonoid-rich foods often greatly exceeds the increase in plasma flavonoids."( The increase in human plasma antioxidant capacity after apple consumption is due to the metabolic effect of fructose on urate, not apple-derived antioxidant flavonoids.
Frei, B; Lotito, SB, 2004
)
0.32
" Therefore, the objectives of this study were to assess the bioavailability of vitamin C from pulsed electric fields-treated orange juice in comparison with freshly squeezed orange juice and its impact on 8-epiPGF(2alpha) concentrations (biomarker of lipid peroxidation) in a healthy human population."( Pulsed electric fields-processed orange juice consumption increases plasma vitamin C and decreases F2-isoprostanes in healthy humans.
Cano, MP; de Ancos, B; Elez-Martínez, P; Granado, F; Martín, A; Martín-Belloso, O; Olmedilla, B; Plaza, L; Sánchez-Moreno, C, 2004
)
0.32
" These results suggested that Y-700 is a new effective inhibitor of XO in rats and humans with high oral bioavailability being predominantly eliminated via the liver unlikely to allopurinol."( Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man.
Fukunari, A; Iwane, J; Kamezawa, M; Mori, H; Osajima, T; Yamada, I, 2004
)
0.32
"The bioavailability of vitamin C from pulsed electric fields (PEF)-treated vegetable soup in comparison with freshly made (FM) vegetable soup-gazpacho-and its impact on 8-epiPGF(2alpha) and uric acid concentrations in a human population were assessed."( Intake of Mediterranean vegetable soup treated by pulsed electric fields affects plasma vitamin C and antioxidant biomarkers in humans.
De Ancos, B; Elez-Martínez, P; Granado, F; Martín, A; Martín-Belloso, O; Olmedilla, B; Pilar Cano, M; Plaza, L; Sánchez-Moreno, C, 2005
)
0.52
" A human intervention study was performed to evaluate the bioavailability and antioxidant capacity of (-)-epigallocatechin-3-gallate (EGCG) administered as a single large dose in the form of either purified EGCG or as green tea extract (Polyphenon E)."( Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals.
Carpenter, CL; Hara, Y; Heber, D; Henning, SM; Lee, NH; Liu, Y; Minutti, RR; Niu, Y; Thames, GD; Wang, H, 2005
)
0.33
" Daily PRAL was calculated considering the mineral and protein composition of foods, the mean intestinal absorption rate for each nutrient and the metabolism of sulfur-containing amino acids."( Effect of potential renal acid load of foods on urinary citrate excretion in calcium renal stone formers.
Lizzano, R; Marchesotti, F; Trinchieri, A; Zanetti, G, 2006
)
0.33
" These results supported our hypothesis that HSCAS tightly-bind and immobilized ZEN resulted in reduction of toxin bioavailability in animal's gastrointestinal tract."( Preventive role of phyllosilicate clay on the Immunological and Biochemical toxicity of zearalenone in Balb/c mice.
Abbès, S; Abdel-Wahhab, MA; Bacha, H; Houas, Z; Othman, O; Ouanes, Z; Oueslati, R; Salah-Abbès, JB, 2006
)
0.33
" However, the concomitant production of superoxide and other reactive oxygen species (ROS) during I/R may diminish the bioavailability of NO and hence compromise the beneficial effects."( Prevention of postischemic myocardial reperfusion injury by the combined treatment of NCX-4016 and Tempol.
Colantuono, G; Khan, M; Kumbala, D; Kuppusamy, P; Kutala, VK; Mandal, R; Potaraju, V, 2006
)
0.33
" This notion, however, has been challenged recently by studies on the bioavailability of flavonoids, which indicate that they reach only very low concentrations in human plasma after the consumption of flavonoid-rich foods."( Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?
Frei, B; Lotito, SB, 2006
)
0.33
" We suggest that potassium depletion and hyperuricemia in rats exacerbates endothelial dysfunction and lowers the bioavailability of nitric oxide, which blocks insulin activity and causes insulin resistance during thiazide usage."( Thiazide diuretics exacerbate fructose-induced metabolic syndrome.
Johnson, RJ; Mu, W; Nakagawa, T; Reungjui, S; Roncal, CA; Sirivongs, D; Srinivas, TR, 2007
)
0.34
" Bioavailability of thiopurines may be competitively inhibited by dietary purines."( Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease.
Ansari, A; Aslam, Z; De Sica, A; Duley, J; Fairbanks, L; Gilshenan, K; Marinaki, A; Sanderson, J; Smith, M, 2008
)
0.35
" Nonlinear mixed effect modeling identified dose volume as a significant predictor of relative oral bioavailability in a negative nonlinear relationship for acai pulp and juice."( Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers.
Derendorf, H; Jilma-Stohlawetz, P; Meibohm, B; Mertens-Talcott, SU; Pacheco-Palencia, LA; Rios, J; Talcott, ST, 2008
)
0.35
"In conclusion, uric acid decreased NO bioavailability and enhanced superoxide generation in A23187-stimulated bovine aortic endothelial cells."( The effect of uric acid on homocysteine-induced endothelial dysfunction in bovine aortic endothelial cells.
Kubala, L; Lojek, A; Papezikova, I; Pekarova, M, 2009
)
1.07
" The aim of this study was to explore this hypothesis by measuring changes in UA concentration and systemic NO bioavailability as well as endothelial function in response to acute ingestion of a glucose-fructose beverage."( Assessment of endothelial function and blood metabolite status following acute ingestion of a fructose-containing beverage.
Bidwell, AJ; Doyle, RP; Fairchild, TJ; Holmstrup, ME, 2010
)
0.36
"05) difference in endothelial function or systemic NO bioavailability was observed."( Assessment of endothelial function and blood metabolite status following acute ingestion of a fructose-containing beverage.
Bidwell, AJ; Doyle, RP; Fairchild, TJ; Holmstrup, ME, 2010
)
0.36
" Decreased nitric oxide bioavailability may be the main reason."( Association between endothelial dysfunction and hyperuricaemia.
Ho, WJ; Hsu, TS; Kuo, CT; Tsai, WP; Tsay, PK; Wang, CL; Yu, KH, 2010
)
0.36
" On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2."( Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia.
Fukushima, K; Kokuhu, T; Okamoto, M; Sugioka, N; Takada, K; Takai, M; Yasuda, K; Yoshida, K; Yoshimura, N, 2010
)
0.7
" Occasional reports on beneficial results of ATP administration in human and animal studies have suggested the bioavailability of oral ATP supplements."( Oral bioavailability of ATP after prolonged administration.
Arts, IC; Bast, A; Bekers, O; Coolen, EJ; Dagnelie, PC; Vervaet, C, 2011
)
0.37
" Fructose area under the curve and maximum concentration, dose-normalized glucose area under the curve and maximum concentration, relative bioavailability of glucose, changes in postprandial concentrations of serum uric acid, and systolic blood pressure maximum levels were higher when HFCS-sweetened beverages were consumed as compared with sucrose-sweetened beverages."( Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects.
Cheng, J; Frye, RF; Johnson, JA; Johnson, RJ; Le, MT; McFann, KK; Rivard, CJ; Segal, MS, 2012
)
0.56
" These findings suggest that furocoumarins may interfere in metabolism, excretion and bioavailability of endogenous and exogenous compounds to impair liver and kidney functions mediated by affecting hepatic CYP450 and renal organic ion transport system."( Furocoumarins affect hepatic cytochrome P450 and renal organic ion transporters in mice.
Kong, LD; Lou, YJ; Shi, YW; Wang, MX; Wang, X; Xu, HX, 2012
)
0.38
" Moreover, the acceptable bioavailability of mPEG-UHC after subcutaneous administration in monkeys (94."( Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
Chen, Z; Fan, K; Hu, C; Liu, R; Luo, H; Ma, X; Min, Z; Wei, D; Yang, L; Zhang, C, 2012
)
0.38
" The present study aimed to establish the physiological effects of acute ingestion of a F&V purée-based drink (FVPD) on vasodilation, antioxidant status, phytochemical bioavailability and other CVD risk factors."( Effects of acute consumption of a fruit and vegetable purée-based drink on vasodilation and oxidative status.
George, TW; Gordon, MH; Lovegrove, JA; Niwat, C; Waroonphan, S, 2013
)
0.39
"Endothelial dysfunction characterized by decreased nitric oxide (NO) bioavailability is the first stage of coronary artery disease."( Uric acid modulates vascular endothelial function through the down regulation of nitric oxide production.
Baldus, S; Klinke, A; Kolářová, H; Kubala, L; Lau, D; Lojek, A; Papežíková, I; Pekarová, M, 2013
)
1.83
"Reduced nitric oxide bioavailability contributes to increased cardiovascular disease risk in patients with chronic kidney disease (CKD)."( Impaired L-arginine uptake but not arginase contributes to endothelial dysfunction in rats with chronic kidney disease.
Edwards, DG; Kuczmarski, JM; Lennon-Edwards, S; Martens, CR, 2014
)
0.4
" We then suggest a bioequivalence test based on the estimated bioavailability parameters in the proposed mixed-effects model."( New approach to assess bioequivalence parameters using generalized gamma mixed-effect model (model-based asymptotic bioequivalence test).
Chen, YI; Huang, CS, 2014
)
0.4
"09 w/kg specific absorption rate (SAR) value were used for 15 and 30 min."( Evaluation of selected biochemical parameters in the saliva of young males using mobile phones.
Abu Khadra, KM; Abu Samak, M; Aljaberi, A; Khalil, AM, 2015
)
0.42
" Since disturbed NO bioavailability is a major pathway whereby high uric may cause renal damage, we tested the interaction between the major endogenous inhibitor of NO synthase, asymmetric-dimethylargine (ADMA), and the rs734553 polymorphism for CKD progression in the same cohort."( Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression.
Leonardis, D; Mallamaci, F; Pisano, A; Sanguedolce, MC; Spoto, B; Testa, A; Tripepi, G; Zoccali, C, 2015
)
0.65
" Hydrophobic substitution such as isopropyl at 1-position of the indole moiety without any substitution at 2-position has an essential role for enhancing bioavailability and therefore for high in vivo efficacy."( Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors.
Choi, SP; Jung, CK; Jung, SH; Kim, GT; Kim, TH; Lee, JY; Song, JU, 2015
)
0.42
" A relative bioavailability study in healthy males (N=8) indicated a nearly identical pharmacokinetic profile following dosing of tablets or capsules."( Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
Hingorani, V; Kerr, B; Manhard, K; Quart, B; Rowlings, C; Shen, Z; Storgard, C; Yeh, LT, 2015
)
0.65
"The ATP-binding cassette transporter G2/breast cancer resistance protein (ABCG2/BCRP) is an efflux protein involved in the bioavailability and milk secretion of endogenous and exogenous compounds, actively affecting milk composition."( Effect of bovine ABCG2 polymorphism Y581S SNP on secretion into milk of enterolactone, riboflavin and uric acid.
Álvarez, AI; Espín, JC; García-Villalba, R; González-Lobato, L; Merino, G; Miguel, V; Otero, JA; Prieto, JG, 2016
)
0.65
" The relative bioavailability of UOMVLs was (1 750."( [The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes].
Deng, X; He, D; Xiong, HR; Zhang, JQ; Zhou, YL, 2015
)
0.42
" UNAs increased the bioavailability and uric acid-lowering efficacy of uricase, while the immunogenicity and hemolysis rate of uricase were decreased."( Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia.
Deng, X; He, D; Sun, Q; Xiong, H; Zhang, J; Zhou, Q; Zhou, Y, 2016
)
0.7
" According to ADME (absorption, distribution, metabolism, and excretion) simulation in silico, flazin had good oral bioavailability in vivo."( Effect of Soy Sauce on Serum Uric Acid Levels in Hyperuricemic Rats and Identification of Flazin as a Potent Xanthine Oxidase Inhibitor.
Li, H; Lin, L; Su, G; Wang, Y; Zhao, M, 2016
)
0.73
" Minimal data exist regarding the bioavailability and insulinotropic effects of non-animal-derived protein sources."( Mycoprotein represents a bioavailable and insulinotropic non-animal-derived dietary protein source: a dose-response study.
Bowtell, JL; Dunlop, MV; Finnigan, TJA; Kilroe, SP; Salmon, DL; Wall, BT, 2017
)
0.46
"Nanocrystals (NCs), a type of innovative material particle, are a potential drug delivery platform that aims to improve the bioavailability of hydrophobic drugs."( In vitro toxicity assessment of nanocrystals in tissue-type cells and macrophage cells.
Chen, M; Li, Y; Li, Z; Mei, X; Wang, Z; Yang, Y; Yang, Z; Zhang, H; Zhou, J, 2018
)
0.48
" The cellular mechanisms that lead to those outcomes require an increase in intracellular concentrations of uric acid inducing oxidative stress that then activates the synthesis and secretion of proinflammatory factors and vasoconstrictive substances, and diminishes the bioavailability of nitric oxide produced by eNOS."( The Pathophysiology of Uric Acid on Renal Diseases.
Sánchez-Lozada, LG, 2018
)
1
"The objectives of this study were to determine the absolute bioavailability of lesinurad and to characterized its disposition in humans."( Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans.
Gillen, M; Hall, J; Kerr, BM; Lee, CA; Shah, V; Shen, Z; Tieu, K; Wilson, DM; Yang, C, 2019
)
0.78
" In the process of purine metabolism, reactive oxygen species, including superoxide, are generated concomitantly with uric acid production, which may deteriorate endothelial function through the reaction of superoxide with nitric oxide (NO), leading to decreased NO bioavailability and increased production of peroxynitrite, a reactive oxidant."( Hyperuricemia and endothelial function: From molecular background to clinical perspectives.
Higashi, Y; Hisatome, I; Kihara, Y; Maruhashi, T, 2018
)
0.69
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Notably, compared with the free myricitrin, the cumulative release in vitro and in vivo oral bioavailability of MPs were markedly increased."( Preparation, characterization, pharmacokinetics and anti-hyperuricemia activity studies of myricitrin-loaded proliposomes.
Adu-Frimpong, M; Ji, H; Man, N; Toreniyazov, E; Wang, Q; Wei, C; Wei, Q; Weng, W; Xu, X; Yu, J; Zhang, K, 2019
)
0.51
" In this study, we used glucosyl hesperidin (GH), which has greater bioavailability than hesperidin, to clarify comprehensive mechanisms underlying the hypouricemic effects of hesperidin in vivo."( Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin.
Harada-Shiba, M; Hirata, H; Ogura, M; Ota-Kontani, A; Tsuchiya, Y, 2020
)
0.56
"Despite convincing experimental evidence, epidemiological studies on the effects of serum uric acid (SUA) on bone health are still conflicting since factors influencing SUA bioavailability have not been adequately considered."( Changes in Adipose Tissue Distribution and Association between Uric Acid and Bone Health during Menopause Transition.
Bianchi, N; Bonaccorsi, G; Cervellati, C; Gemmati, D; Giganti, M; Greco, P; Guglielmi, G; Rossini, M; Tisato, V; Trentini, A, 2019
)
0.97
" The following indicators in the treatment group (traditional Chinese medicine decoction combined with western medicine chemotherapy) improved in comparison with those in the control group:focus absorption rate (RR:1."( Traditional Chinese medicine combined with western medicine for the treatment of secondary pulmonary tuberculosis: A PRISMA-compliant meta-analysis.
Li, X; Liu, Q; Shi, C; Sun, N; Zhang, B; Zhang, R, 2020
)
0.56
" UHLN/UHLNM had significantly increased bioavailability (∼533% and ∼331% compared to Uase) and demonstrated greatly improved efficacy, whereby the time required for UHLN/UHLNM to lower the plasma uric acid concentration to a normal level was much shorter than that for free Uase."( Biomimetic polysaccharide-cloaked lipidic nanovesicles/microassemblies for improving the enzymatic activity and prolonging the action time for hyperuricemia treatment.
Abagyan, R; He, D; Li, K; Li, Y; Shi, D; Wang, T; Xie, J; Yang, L; Zhang, J; Zhang, Y; Zhong, C, 2020
)
0.75
" The bromatological composition showed that coarse particles increased the bioavailability and content of crude, digestible, and soluble protein for the diet and hemolymph protein of larvae alike."( Big particles, best nutrition? Absorption and excretion of protein by
Aceituno-Medina, M; García-Fajardo, LV; Hernández, E; Rincón-Betancurt, O, 2021
)
0.62
"Ginsenoside Rb1 (GsRb1) is the best constituent of ginseng and although it shows clinical efficacy as an antineoplastic, antioxidative and antirheumatic agent, its oral bioavailability is poor due to its limited solubility."( Anti-inflammatory and anti-gouty-arthritic effect of free Ginsenoside Rb1 and nano Ginsenoside Rb1 against MSU induced gouty arthritis in experimental animals.
Liu, Y; Ye, Q; Zhou, W; Zhu, H, 2020
)
0.56
" However, BBR exhibits low bioavailability due to its extensive metabolism and limited absorption."( Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway.
Chen, J; Huang, Z; Jiang, L; Li, Y; Lin, G; Lin, Z; Liu, Y; Mai, L; Su, Z; Xie, J; Xu, L; Yu, Q, 2021
)
0.62
" Accumulated studies have proposed mechanisms of renal damage and atherosclerosis in hyperuricemia, including inflammasome activation, decreased nitric oxide bioavailability and oxidative stress induced by uric acid, urate crystals and xanthine oxidoreductase (XOR)-mediated reactive oxygen species."( Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.
Maeda, N; Nishizawa, H; Shimomura, I, 2022
)
0.91
" Geniposide (GEN) is a typical natural iridoid glucoside compound with a series of biological activities, but the poor bioavailability of GEN limits its clinical application."( A geniposide-phospholipid complex ameliorates posthyperuricemia chronic kidney disease induced by inflammatory reactions and oxidative stress.
Chen, JS; Guo, X; Liao, ZX; Liu, C; Liu, JS; Sun, JY; Wang, MM; Wang, MX; Zhang, J; Zhang, MQ, 2022
)
0.72
" The bioavailability of Spartinin F2 was 63."( Discovery of derivatives from Spartina alterniflora-sourced moiety as xanthine oxidase inhibitors to lower uric acid.
Jiao, QC; Liu, J; Qin, P; Wang, B; Yang, YS; Zhou, KM, 2022
)
0.93
"Results indicated significant increases in body weight, BMI, Lee index, food consumption, systolic and diastolic pressure and decrease in serum nitric oxide bioavailability in the 8-hr sedentary rats."( Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers.
Akomolafe, RO; Alabi, QK, 2022
)
0.72
"A comprehensive analysis of the mechanism of the anti-gout effect of theaflavins is presented through a literature review and network pharmacology prediction, and strategies for increasing the bioavailability of theaflavins are summarized."( Mechanisms of theaflavins against gout and strategies for improving the bioavailability.
Chen, J; Gong, S; Hu, J; Li, X; Ma, L; Yu, H; Zheng, Y; Zheng, Z, 2023
)
0.91
"This review presents the mechanisms of anti-gout action of theaflavins and strategies for improving the bioavailability of theaflavins, as well as providing research strategies for anti-gout treatment measures and the development of novel anti-gout drugs."( Mechanisms of theaflavins against gout and strategies for improving the bioavailability.
Chen, J; Gong, S; Hu, J; Li, X; Ma, L; Yu, H; Zheng, Y; Zheng, Z, 2023
)
0.91
" In this review, we discuss recent advances and novel insights into the effects exerted by HUA conditions in ED and related underlying mechanisms focusing on impaired UA metabolism, reduction in the synthesis and bioavailability of nitric oxide, endothelial cell injury, the endothelial-to-mesenchymal transition, insulin resistance, procoagulant activity, and acquisition of an inflammatory phenotype."( Hyperuricemia: A key contributor to endothelial dysfunction in cardiovascular diseases.
He, Y; Huang, S; Lan, X; Lei, W; Luo, H; Wei, X; Zhang, M; Zheng, J, 2023
)
0.91
"These mechanisms directly or indirectly affect the bioavailability of endogenous nitric oxide (NO)."( [Effect of High-Concentration Uric Acid on Nitric Oxide].
Bai, X; Guan, BS; Hou, ZL; Jiang, H; Lan, RY; Li, WL; Pei, SY; Qin, SY; Qiu, HB; Qu, MH; Qu, RJ; Wang, JT; Yin, XL; Zeng, J, 2023
)
1.2

Dosage Studied

Study found a dose-response relationship between uric acid levels and kidney function. The dosage of allopurinol to accomplish full control of gout and to lower serum uric acid varies with theseverity of the disease.

ExcerptRelevanceReference
" During the first week clofezone was given at a daily dosage of 1200 mg and thereafter 600 mg."( [Experiences in the management of rheumatoid diseases using different clofezone doses].
Celik, CM,
)
0.13
" Benorilate was given in a daily dosage varying from 6-8-12 g (as a suspension containing 40% benorilate)."( [Long-term toxicity of benorylate].
Reiter, W,
)
0.13
" Blood pressure was significantly reduced with both medications, although most patients required an increase in dosage from 250 to 500 mg ticrynafen daily."( Clinical study of ticrynafen. A new diuretic, antihypertensive, and uricosuric agent.
Freis, ED; Kyle, MC; Nemati, M, 1977
)
0.26
" On the 5th and 6th day after beginning the treatment the dosage of 25 mg of Benzbromarone renders a morning value of 5,3 +/- 1,0 and an evening value of 5,0 +/- 0,9 mg/100 ml."( [Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone].
Berg, G; Matzkies, F; Minzlaff, R, 1977
)
0.26
" Further studies are necessary to determine optimal dosage regimes and long term safety."( A double-blind comparison of the effects of hydrochlorothiazide and tienylic acid (a diuretic with uricosuric properties) in hypertension.
Gillies, AH; Morgan, TO, 1978
)
0.26
" The ideal uricase inhibitor for induction of hyperuricemia would be one which is irreversible, noncompetitive, and relatively nontoxic, so that its activity would be independent of high levels of uric acid, and effective inhibition could be attained at low dosage levels."( Use of the uricase-inhibited rat as an animal model in toxicology.
Nera, EA; Stavric, B, 1978
)
0.45
" It is concluded that the arthralgia was often self-limiting, that aspirin had a small beneficial effect, that allopurinol, in the dosage studied, may have had a slightly deleterious effect, but that it would be worth studying larger dosages of allopurinol because the dosage studied did not affect the serum uric acid concentration."( Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration.
Allan, WG; Fox, W; Girling, DJ; Horsfall, PA; Nunn, AJ; Plummer, J, 1979
)
0.43
"001), but a major determinant of the magnitude of the decrease was the dosage change of the timolol."( Serum potassium and uric acid changes during treatment with timolol alone and in combination with a diuretic.
Mikkelsen, E; Pedersen, OL, 1979
)
0.58
" When warranted, dosage was increased to a maximum of 500 mg of tienilic acid and 100 mg of hydrochlorothiazide daily."( Long-term usage of tienilic acid in essential hypertension.
Beg, MA; Noble, RE, 1979
)
0.26
" Differences between oral and parenteral administration are shown and finally dosage guidelines for parenteral administration are established on the basis of the different metabolic effects depending on the administered dose."( [Biochemistry and metabolism of sugar substitutes].
Bässler, KH, 1977
)
0.26
" Nevertheless, in view of the potential seriousness of volume depletion, dosage should probably begin at 20 rather than 40 mg daily."( Adverse reactions to frusemide in hospital inpatients.
Gray, J; Henry, DA; Lawson, DH; Lowe, J, 1979
)
0.26
" A reduction in the dosage of the 5-fluorocytosine resulted in a marked decrease in the excretion of urinary gravel which was shown to be a coprecipitate of 5-fluorocytosine and uric acid."( Crystalluria during flucytosine therapy.
Chinwah, PM; Cobcroft, R; Williams, KM, 1979
)
0.45
" The mean resting blood pressures were 168/108 mmHg, 151/98 mmHg and 150/96 mmHg at pre-trial, after the twice-daily dosage period and after the once-daily dosage period, respectively."( A fixed combination of metoprolol and hydrochlorothiazide for hypertension: a multi-centre study.
Goodfellow, RM, 1979
)
0.26
"Furosemide (20 mg) was administered intravenously to 7 healthy volunteers, before and after 4 days of oral administration of aspirin in uricosuric dosage (1 g daily)."( Effect of combined administration of furosemide and aspirin on urinary urate excretion in man.
Komninos, Z; Mayopoulou-Symvoulidou, D; Mountokalakis, T; Rallis, D, 1979
)
0.26
" The dosage of the single components is this combined therapy is significantly lower than the doses usually used for clofibrate or mesoinositol-hexanicotinate."( [Clinical study with a new antihyperlipemic combination].
Pistautz, H, 1977
)
0.26
" In a dosage of 100 and 300 mg/day benzbromaron proved to be a much more potent uricosuricum."( [The uricosuric effect of benzbromaron and probenecid under fasting conditions (author's transl)].
Kleinschmidt, A; Schräpler, P; Schulz, E, 1978
)
0.26
" Extrapolation of the observed log dose-response curves provides one possible explanation for the relative potency (bumetanide: frusemide) of 20:1 reported when the drugs are used at high dosage in patients with renal failure."( Bumetanide and frusemide: a comparison of dose-response curves in healthy men.
Hettiarachchi, J; McInnes, GT; Ramsay, LE; Scott, P; Shelton, J, 1978
)
0.26
" -- The potassium loss is variable according to dosage (maximum at 500 mg), renal function (low when reduced)."( [Thienylic acid, a new drug with saluretic and uricosuric activity. Preliminary data].
Borghetti, A; Borghi, L; Guariglia, A; Minari, M; Novarini, A; Peracchi, R, 1978
)
0.26
"At the high dosage of 600 mg daily, the uric-acid reducing effect of allopurinol depends on the initial level of uric-acid concentration in the same manner as at the usual dosage of 300 mg daily, but is more marked at the entire hyperuricaemic concentration range of 65--71 mumol/l (11--12 mg/l)."( [Uric-acid reduction with high allopurinol dosages (author's transl)].
Loewer, H; Mertz, DP, 1979
)
0.26
"The relationship between the dosage of pancreatic extract and the excretion of uric acid was investigated in 29 patients with cystic fibrosis and exocrine pancreatic insufficiency."( Therapeutic approach to pancreatic extract-induced hyperuricosuria in cystic fibrosis.
Kennedy, J; Linshaw, MA; Nouisa-Arvanitakis, S; Stapleton, FB, 1977
)
0.48
" In these three children, reducing pancreatic extract dosage by 85 percent lowered their purine intake by 307, 225, and 148 mg, respectively; urinary uric acid excretion decreased by 245, 239, and 158 mg."( Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis.
Kennedy, J; Linshaw, MA; Nousia-Arvanitakis, S; Stapleton, FB, 1976
)
0.45
" A reduction in dosage from 50 mg daily to 50 mg three times a week produced no significant changes in the diastolic or mean blood pressures though the systolic blood pressure was moderately increased."( Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate.
Bengtsson, C; Johnsson, G; Sannerstedt, R; Werkö, L, 1975
)
0.25
" Each group obtained in respect to the part of carbohydrates a different infusion solution (5% glucose, 5% fructose, 5% xylitol, 5% xylitol-glucose-fructose, 5% sorbitol) with an always constant part of electrolytes, the dosage of which was 60 ml/kg body weight on the day of operation and 40 ml/kg body weight during the first 3 postoperative days being continuously distributed over 24 hours."( [Metabolic behavior and utilization of parenterally administered carbohydrates in the postoperative phase].
Ahnefeld, FW; Dölp, R; Grab, E; Knoche, E, 1975
)
0.25
" The new method was compared with six other manual and mechanized methods for the dosage of uric acid, and the results were analyzed statistically."( [A mechanized enzymic method for the determination of uric acid (author's transl)].
Hunziker, P; Keller, H, 1975
)
0.72
"The effect of vitamin A deprivation at different stages, and of dosing with different levels of the vitamin of some parameters of protein catabolism was examined in chicks."( Influence of vitamin A on formation and excretion of end products of nitrogen catabolism in chicks.
Ascarelli, I; Bruckental, I, 1975
)
0.25
" The precise dosage of trace elements like zinc or magnesium is unknown."( [Recommendations for the use of carbohydrates in the infusion therapy].
Berg, G, 1975
)
0.25
" Cyclosporine was administered orally for at least 2 years at an initial dosage of 5 mg/kg body weight per day."( Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis.
Aupetit, B; Baumelou, A; Benhmida, M; Deray, G; Jacobs, C; Le Hoang, P; Maksud, P, 1992
)
0.28
"The excretions of urinary sodium, potassium, magnesium, urate, and water after dosing with diuretics or the angiotensin-converting enzyme inhibitor perindopril are reported, as well as the results of other recent studies."( Effects of angiotensin-converting enzyme inhibitors on urinary excretions: interactions with diuretics.
Leary, WP; Reyes, AJ; Van der Byl, K, 1992
)
0.28
" At the same time serum BUN and CPK were elevated significantly with a dose-response relationship."( Effect of scorpion Leiurus quinquestriatus (H&E) venom on the clinical chemistry parameters of the rat.
Abdel-Rahman, MS; Omran, MA, 1992
)
0.28
" During treatment, the investigator was permitted to adjust the dosage of ramipril and HCTZ according to BP response and tolerance."( Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study.
Bauer, B; Breitstadt, A; Cairns, V; Froer, KL; Heidbreder, D, 1991
)
0.28
" This could be completely blocked by combination dosing with allopurinol, an inhibitor of xanthine oxidase."( Hyperuricemia induced by the uricosuric drug probenecid in rats.
Shinosaki, T; Yonetani, Y, 1991
)
0.28
" Dosing with theophylline was used to produce 1MX as an intermediate metabolite in six healthy volunteers."( 1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.
Birkett, DJ; Day, RO; Miners, JO, 1991
)
0.28
" We conclude that the cyclosporine blood level was a better discriminant than cyclosporine dosage in the analysis of renal dysfunction and hypertension in these patients."( Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders.
Brown, MD; Ellis, CN; Goldfarb, MT; Gupta, AK; Rocher, LL; Schmaltz, SP; Voorhees, JJ, 1991
)
0.28
"After a brief review of the history of allopurinol therapy the mechanism of action, interactions with other drugs, side-effects, indications and contra-indications of Milurit (100 mg allopurinol per tab, EGIS Pharmaceuticals, Budapest) in adults and children, and the dosage of the drug have been discussed."( Milurit's place in therapy.
Gömör, B; Szebenyi, B, 1990
)
0.28
" Preclinical studies suggested that the antitumor effects of this drug were schedule dependent, since repeated dosing increased killing of tumor cells when compared to intermittent injections."( Phase I clinical and pharmacological study of merbarone.
Baltzer, L; Dimaggio, JJ; Haines, I; Lee, SJ; Lowenthal, DA; Muindi, J; Stevens, YW; Walsh, TD; Warrell, RP; Yaldaei, S, 1990
)
0.28
" The slopes of the dose-response regression lines were similar for the three drugs."( Mechanism of action of colchicine. VI: Effect of colchicine on generation of leukotriene B4 by human polymorphonuclear leukocytes.
Bhuta, S; Chang, YH; Ouyang, Y; Wang, W,
)
0.13
" Dosage of each quinolone was 200 mg twice daily for four days, starting three days prior to the theophylline infusion."( Drug-drug interactions affecting fluoroquinolones.
Guelen, PJ; Janssen, TJ; Vree, TB; Wijnands, GJ, 1989
)
0.28
" It was apparent that many patients were taking unnecessarily high daily doses of allopurinol and that renal status was not always considered when deciding dosage regimens of allopurinol."( Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
Birkett, DJ; Day, RO; Hayes, J; Miners, JO; Naidoo, D; Savdie, E; Whitehead, A, 1988
)
0.27
", twice daily for 11 days in a sustained release dosage form."( Enoxacin--a potent inhibitor of theophylline metabolism.
Beckmann, J; Elsässer, W; Gundert-Remy, U; Hertrampf, R, 1987
)
0.27
" The complement activation measured by the dosage of the C3a Desarg fraction existed in all the patients, reaching an average 6 times the initial level compared to 40 times for Cuprophan."( Evaluation and tolerance of a new polycarbonate membrane in elderly patients. Preliminary results.
Alibeu, C; Forêt, M; Hachache, T; Kuentz, F; Meftahi, H, 1986
)
0.27
" The time-course and dose-response of associated inflammation and sensory abnormalities are described."( Ankle joint urate arthritis (AJUA) in rats: an alternative animal model of arthritis to that produced by Freund's adjuvant.
Coderre, TJ; Wall, PD, 1987
)
0.27
" Plasma oxipurinol concentrations correlated directly with both allopurinol dosage and with renal glomerular function as reflected by the plasma creatinine concentration."( Plasma oxipurinol concentrations during allopurinol therapy.
Cross, M; Emmerson, BT; Gordon, RB; Thomson, DB, 1987
)
0.27
" Monitoring of plasma oxipurinol levels (ideally less than 100 mumol/l) by high-pressure liquid chromatography is helpful for adjusting dosage in renal failure."( Allopurinol in renal failure and the tumour lysis syndrome.
Cameron, JS; Davies, PM; Morris, GS; Simmonds, HA, 1986
)
0.27
"The purpose of this study was to determine the effects on blood pressure and selected biochemical measures of reducing the dosage of chlorthalidone from 100 mg to 50 mg."( Beneficial effects from systematic dosage reduction of the diuretic, chlorthalidone: a randomized study within a clinical trial.
Allen, R; Bailey-Hoffman, G; Case, J; Childs, J; Grimm, RH; Hulley, SB; Kousch, D; McDonald, M; McGill, E; Neaton, JD, 1985
)
0.27
" M at a lower dosage than F has demonstrated an effective diuretic response irrespective the degree of renal impairment."( Step-dose of muzolimine at different stages of chronic renal failure: comparison with furosemide.
Bazzato, G; Coli, U; Fracasso, A; Landini, S; Morachiello, P; Righetto, F; Scanferla, F, 1985
)
0.27
" Each patient was allocated, according to his/her baseline values of serum uric acid or serum creatinine to four different sulphinpyrazone incremental dosage schedules."( Sulphinpyrazone dose schedule in hyperuricemic patients with cardiovascular diseases: tolerability assessment.
Bertoli, L; Borghi, C; Busnardo, I; Zagnoni, P, 1985
)
0.5
" The combination of furosemide and triamterene brought about a 'softer' diuresis, no hypokalaemia and the advantage of dosage as only one tablet, thus eliminating the need for taking two separate drugs."( Comparison of the efficacy of furosemide with two furosemide-triamterene combinations in the treatment of cardiac insufficiency.
Ojasalo, T; Saarimaa, H, 1985
)
0.27
" If diastolic pressure was normalized (less than 95 mmHg), this dosage was continued for a further 6 weeks; patients whose blood pressure remained high after the initial 6 weeks received 1 capsule twice daily for a further 6 weeks."( The effects of piretanide capsules on blood pressure during ergometric and isometric work loads in patients with mild to moderate essential hypertension.
Maass, L; Meywald, W; Rangoonwala, B; Verho, M, 1985
)
0.27
" Almost half of the patients taking aspirin were unable to tolerate the drug in adequate dosage for six months."( Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin.
Balme, HW; Berry, H; Hart, FD; Huskisson, EC; Scott, J; Wojtulewski, JA, 1974
)
0.25
"In a woman with hereditary fructose intolerance and intact parathyroid function, the experimental administration of fructose at different dosage schedules invariably induced the dose-dependent, complex dysfunction of the proximal renal tubule now recognized as characteristic."( Modulation of experimental renal dysfunction of hereditary fructose intolerance by circulating parathyroid hormone.
McSherry, E; Morris, RC; Sebastian, A, 1971
)
0.25
" The importance of dosage schedule for remission maintenance chemotherapy is stressed."( The management of acute leukemia.
Freireich, EJ, 1967
)
0.25
" (3) Zotepine decreased serum uric acid level parallel with its dosage (r=0."( [Effects of zotepine, a psychotropic agent, on the serum uric acid level of inpatients at a psychiatric hospital].
Kaiya, H; Kondo, T; Sanpei, F; Takeda, N; Takeuchi, K; Yoshida, H, 1982
)
0.8
" It is therefore concluded that the relationship between the serum chlorthalidone level and the fall in serum potassium level is in keeping with the flat dose-response curves for the thiazide and phthalimide diuretics."( The effects of two combinations of a beta-blocker and a diuretic on diuresis in normal subjects.
Schoeman, HS; Sommers, DK; van Wyk, M, 1984
)
0.27
" The aim of the present study was to extend these observations, by examining the dose-response and to compare the uricosuric effect of azapropazone with that of probenecid."( The uricosuric action of azapropazone: dose-response and comparison with probenecid.
Higgens, CS; Scott, JT, 1984
)
0.27
" In these patients it is of importance to modify the drug dosage or to abandon the prophylaxis when it interferes with the metabolic changes of renal function impairment."( [Prevention of calculus recurrence in impaired kidney function].
Hautmann, R, 1984
)
0.27
" This increase was independent of dosage of ethambutol."( Hyperuricaemia induced by ethambutol.
Agarwal, MC; Bihari, K; Narang, RK; Raina, AK; Sharma, SN; Singh, SN, 1983
)
0.27
" Prompted by these observations, the dosage of chlorthalidone (monotherapy) was decreased in a stepwise fashion and then discontinued after the diastolic BP had been maintained below 85 mm Hg for 6 months in 67 patients with mild systemic hypertension (diastolic BP 92 to 104 mm Hg)."( Step-down treatment of mild systemic hypertension.
Finnerty, FA, 1984
)
0.27
" The dose-response curves for three different inhibitors were identical for the OH- and Cl- gradient-stimulated modes of urate uptake."( Urate transport via anion exchange in dog renal microvillus membrane vesicles.
Aronson, PS; Kahn, AM, 1983
)
0.27
" Each dose was given for 14 days and diflunisal apparent oral clearance and serum urate was measured on the last day of each dosing regimen."( Diflunisal disposition and hypouricemic response in osteoarthritis.
Bertouch, J; Brooks, PM; Harrington, BJ; Meffin, PJ; Veenendaal, JR, 1983
)
0.27
" Hyperuricosuria increased with the age of the patient and when the administered dosage of pancreatic enzyme exceeded 10,000 lipase units/kg body weight."( Hyperuricosuria in cystic fibrosis patients treated with pancreatic enzyme supplements. A study of 16 patients in Israel.
Ben-Zaray, S; Blau, H; Goldfarb, D; Katznelson, D; Sack, J, 1980
)
0.26
" The contamination level per dosage unit ranged from 2 to 10 mg urate equivalents, which, after purine absorption and metabolism, must be excreted by the kidneys."( Studies on the cause of hyperuricosuria in cystic fibrosis patients.
Niessen, KH; Wolf, A, 1982
)
0.26
" In type IIa etofylline clofibrate shows a good effect on total cholesterol and on the cholesterol fractions, both with regard to the collective treated and to the low dosage of 750 mg/d etofylline clofibrate compared to the usual dosage of 1500 mg clofibrate."( [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Hausmann, L; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980
)
0.26
" From the results obtained in this study, magnesium oxide in this dosage cannot be recommended for use in treatment of patients with urolithiasis."( Urine composition in patients with urolithiasis during treatment with magnesium oxide.
Ahlstrand, C; Larsson, L; Tiselius, HG, 1980
)
0.26
"Although nephrotoxicity is common following exposure to lead, the dose-response relationship in adults with occupational exposure is not well understood because information is lacking on early nephrotoxic effects."( Occupational exposure to lead: effects on renal function.
Hammond, PB; Hanenson, IB; Hong, CD; Lerner, S; Pesce, AJ; Pollak, VE, 1980
)
0.26
" Muscle relaxants do not cause measurable muscle relaxation following usual oral dosage regimens."( Effects of exercise performance on drugs used in musculoskeletal disorders.
Day, RO, 1981
)
0.26
"Differences in plasma theophylline clearance (ClT) and metabolism between smoking and nonsmoking normal subjects were examined by analysis of plasma and urinary theophylline concentrations and of urinary metabolite concentrations under steady-state oral dosing conditions."( Cigarette smoking and theophylline clearance and metabolism.
Birkett, DJ; Grygiel, JJ, 1981
)
0.26
" After 2 week's medication, a decline in blood pressure was noted in all dosage groups and this was maximal by 4 weeks."( Chlorthalidone in mild hypertension - dose response relationship.
Humphries, IS; Mayhew, SR; Russell, JG, 1981
)
0.26
"We dosed eight normal volunteers with single doses of probenecid alone and with aspirin or ibuprofen."( Effect of ibuprofen or aspirin on probenecid-induced uricosuria.
Brooks, CD; Ulrich, JE, 1980
)
0.26
" A twice-daily regimen was considerably more effective than a single morning dosage in reduction of plasma urate, though both regimens were equally effective in antihypertensive potency."( Controlled inpatient study of tienilic acid in treatment of gout and hypertension.
Reardon, JA; Scott, JT, 1980
)
0.26
" Although there were no statistically significant differences among the 100-, 200-, and 300-mg treatment groups, there was a trend toward a dose-response relationship for most plasma glucose variables that were measured."( Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Beisswenger, P; Coniff, RF; Kleinfield, R; McGill, JB; Robbins, D; Seaton, TB; Shapiro, JA, 1995
)
0.29
" A dose-response relationship to losartan was observed in this patient population."( Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.
Goldberg, AI; Pratt, JH; Soffer, BA; Sweet, CS; Wiens, B; Wright, JT, 1995
)
0.29
" Female turkeys, 8 weeks of age, were dually cannulated via the right jugular for intermittent (10 min every 2 hr) infusion of tGH at a low dosage (4."( Responses to exogenous pulsatile turkey growth hormone by growing 8-week-old female turkeys.
Bacon, WL; Long, DW; Vasilatos-Younken, R, 1995
)
0.29
" Urate-oxidase was given parenterally in a dosage of 1000 units per day, seven days a month."( Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases.
Borget, C; Bourgeois, P; Dorent, R; Koeger, AC; Roche, B; Rozenberg, S; Wrona, N, 1995
)
0.29
" Because of potential toxicity, colchicine should not be used to treat acute gout, but should be used in low dosage (0."( Prevention and management of gout.
Hochberg, MC; Star, VL, 1993
)
0.29
"To perform and evaluate an educational intervention program aimed at improving the dosage prescribing of allopurinol by general practitioners and based on the application of academic detailing."( Educational program to improve the dosage prescribing of allopurinol.
Peterson, GM; Sugden, JE, 1995
)
0.29
" Allopurinol dosage was 150 mg daily for children weighing < 20 kg and 300 mg daily for other patients."( Allopurinol as add-on therapy in refractory epilepsy: a double-blind placebo-controlled randomized study.
Bianchi, A; Canger, R; Cornaggia, C; D'Alessandro, P; DeMarco, P; Gianelli, M; Pisani, F; Verzé, L; Zagnoni, PG; Zolo, P,
)
0.13
" The present study was undertaken to confirm this finding, to determine its dose-response relationship and to identify the underlying mechanism of action."( Dose-dependent uricosuric effect of ambroxol.
Cornelissen, PJ; Jonkman, JH; Oosterhuis, B; Sollie, FA; Storm, G; Su, CA, 1993
)
0.29
"A total of 1,002 workers aged 36 to 72 years who were engaged in atomic industry and exposed to external gamma-irradiation and incorporated plutonium 239 in a wide dosage range."( [Uric acid in blood serum and incidence of hyperuricemia in irradiated people. Connection with radioactive and nonradioactive factors].
Tel'nov, VI; Zhuntova, GV,
)
1.04
" The dosage of losartan was 50 mg/day."( Effects of losartan on renal function in patients with essential hypertension.
Berra, N; Fauvel, JP; Laville, M; Madonna, O; Pozet, N; Velon, S; Zech, P, 1996
)
0.29
" In renal insufficiency, the drug must be used cautiously and in reduced dosage because increased serum concentration of oxipurinol, active metabolite of allopurinol, may induce severe side effect."( [Metabolic disorder of purine nucleotide in patients with renal disease].
Hosoya, T; Ichida, K; Ohno, I; Sakai, O, 1996
)
0.29
"To examine the dose-response relationship between coronary heart disease (CHD) risk factors and vigorous exercise above the recommended minimum levels to assess whether further benefits accrue."( Relationship of distance run per week to coronary heart disease risk factors in 8283 male runners. The National Runners' Health Study.
Williams, PT, 1997
)
0.3
" In the group composed of patients with normal kidney function (CCr > or = 80 ml/min), increase in the dosage of allopurinol was associated with a linear increase in the serum concentration of oxipurinol."( [A study of serum oxipurinol concentration and renal function in patients administered allopurinol].
Saji, M, 1996
)
0.29
"The relationship between the plasma oxypurinol (the active metabolite of allopurinol) concentration at the midpoint of each caffeine dosage interval and the decrement in the urinary 1MX to 1MU ratio fitted well by a sigmoid Emax model."( 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect.
Birkett, DJ; Day, RO; Lillywhite, KJ; Miners, JO; Valente, L, 1997
)
0.3
"A blinded, randomized, controlled single crossover design study was performed to determine the efficacy of meloxicam, using 2 dosage groups."( Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs.
Budsberg, SC; Cross, AR; Keefe, TJ, 1997
)
0.3
" The two dosage groups were well matched and had no difference in lipoprotein responses."( Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.
Bateman, ME; Byrnes, P; Firth, JC; Marais, AD; Martens, C; Mountney, J, 1997
)
0.3
"To study the effect of a safe dosage of allopurinol on ischemia-reperfusion damage following aortic surgery, 24 patients undergoing either elective or acute aortic reconstruction, were randomized to receive allopurinol or placebo, yielding four groups: elective/placebo (EP), elective/allopurinol (EA), acute/placebo (AP) and acute/allopurinol (AA)."( Allopurinol dosage and effect on ischemia-reperfusion damage in elective and acute aortic surgery.
Berger, HM; Camps, J; Dulfer, FT; Hermans, J; Kievit, J; Smeets, HJ; Van Bockel, JH; van Milligen de Wit, AW,
)
0.13
"A dosage of 300 mg/d of allopurinol was not effective in reducing pain or improving activities of daily living in chronic pancreatitis."( Does allopurinol reduce pain of chronic pancreatitis?
Banks, PA; Ferrante, M; Hughes, M; Noordhoek, EC; Ramagopal, V; Slivka, A, 1997
)
0.3
"The acute toxicity of 2,4-dichlorophenoxyacetic acid (2,4-D), a herbicide, was studied in chicks dosed with 100, 300, 500, or 600 mg 2,4-D/kg BW, by the oral route."( Acute 2,4-dichlorophenoxyacetic acid intoxication in broiler chicks.
Dagli, ML; Morgulis, MS; Oliveira, GH; Palermo-Neto, J, 1998
)
0.3
" Groups of six rats received either vehicle or analgesic drug and antinociception was evaluated by evaluating the dose-response curves over time."( Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid.
Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998
)
0.51
" To show biological effects of drinking, the dose-response relationships between alcohol use and serum indices were analyzed in 5919 Japanese men aged 40-59 years."( Dose-response relationships between drinking and serum tests in Japanese men aged 40-59 years.
Kawai, M; Matsuda, Y; Nagaya, T; Takahashi, H; Yoshida, H, 1999
)
0.3
" Losartan has been worldwide marketed as the first orally active AT1 receptor antagonist with once-daily dosing for treatment of hypertension."( [Pharmacological properties and its significance in clinical practice].
Ikemoto, F; Nishikibe, M, 1999
)
0.3
" When the analysis was performed in terms of the extra amounts of uric acid produced during the infusion of adenosine, where the initial bursts are also taken into account, different dose-response curves were found for each experimental protocol."( Regional heterogeneities in the production of uric acid from adenosine in the bivascularly perfused rat liver.
Bracht, A; Constantin, J; Fernandes, TR; Ishii-Iwamoto, EL; Suzuki-Kemmelmeier, F, 1999
)
0.8
"The purpose of this study was to assess the safety and antihypertensive dose-response effects of irbesartan and hydrochlorothiazide (HCTZ) in patients with mild-to-moderate hypertension."( Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.
Guthrie, R; Kassler-Taub, K; Kochar, M; Reeves, RA; Triscari, J, 1999
)
0.3
"Losartan decreased serum uric acid and increased uric acid excretion without increasing urinary dihydrogen urate, the primary risk factor for acute urate nephropathy, during 21 days of dosing in hypertensive patients with thiazide-induced hyperuricemia."( Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.
Carides, AD; Coe, FL; Nakagawa, Y; Parks, JH; Shahinfar, S; Simpson, RL; Thiyagarajan, B; Umans, JG, 1999
)
0.61
" Four of these individuals were additionally dosed with 200 mg allopurinol intravenously."( Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Krivanek, P; Oberbauer, R; Turnheim, K, 1999
)
0.3
" The paradoxical effect observed with probenecid was not seen in the E3040 dose-response curve for the uric acid excretion rate."( Mechanism of the uricosuric action of E3040, a drug used to treat inflammatory bowel disease II: study using DBA/2N mice.
Furitsu, H; Iga, T; Kotaki, H; Sawada, Y; Yamada, H, 1999
)
0.52
"Mini-dose aspirin, even at a dosage of 75 mg/day, caused significant changes in renal function and UA handling within 1 week in a group of elderly inpatients, mainly in those with preexisting hypoalbuminemia."( The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients.
Caspi, D; Graff, E; Habot, B; Lubart, E; Segal, R; Yaron, M, 2000
)
0.56
"The two basic aims of this study were to add to the limited literature concerning Inosine as an ergogenic aid, and to determine the effects of Inosine supplementation over a period of 5 and 10 days, at a dosage of 10,000 mg."( Inosine supplementation has no effect on aerobic or anaerobic cycling performance.
Dalton, B; McNaughton, L; Tarr, J, 1999
)
0.3
" The effect of acute (72 h) and subacute (30 days) treatment of the drug with different dosage on liver and kidney functions and hematological parameters were studied."( Toxic studies on biochemical parameters carried out in rats with Serankottai nei, a siddha drug-milk extract of Semecarpus anacardium nut.
Muthulakshmi, V; Sachdanandam, P; Vijayalakshmi, T, 2000
)
0.31
" In addition, TEI-6720 and allopurinol showed similar dose-response curves for the decrease in uric acid or allantoin concentration, and the associated increase in xanthine concentration, indicating that TEI-6720 and allopurinol have similar pharmacological characteristics although the dosage required differs."( A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
Horiuchi, H; Kaneko, H; Kasahara, Y; Kobayashi, M; Komoriya, K; Kondo, S; Nishimura, S; Ota, M, 1999
)
0.52
" In Experiment 1, vitamin D3 was supplemented at a dosage of either 2,064 IU/kg (low level) or 4,128 IU/kg (high level) in drinking water provided ad libitum only from Days 1 through 5 after hatch."( The effect of vitamin D3 on resistance to stress-related infection in an experimental model of turkey osteomyelitis complex.
Balog, JM; Huff, GR; Huff, WE; Rath, NC, 2000
)
0.31
" These results show that creatine supplementation in the dosage used in this study had no influence on muscle metabolic response or TBV."( Effect of creatine supplementation on muscle metabolic response to a maximal treadmill exercise test in Standardbred horses.
Essén-Gustavsson, B; Persson, SG; Schuback, K, 2000
)
0.31
" Allopurinol dosing guidelines and a therapeutic range for plasma oxypurinol levels have been published."( The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Gow, P; Raill, B; Sharples, K; Stamp, L, 2000
)
0.31
"We aimed to determine the appropriateness of allopurinol dosing according to current guidelines and to assess the relationship between plasma creatinine, oxypurinol and urate."( The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Gow, P; Raill, B; Sharples, K; Stamp, L, 2000
)
0.31
"There is poor adherence to the current recommended dosing guidelines for allopurinol."( The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Gow, P; Raill, B; Sharples, K; Stamp, L, 2000
)
0.31
" After drug-induced hepatitis, a caffeine test might be used to check the total recovery or to choose an adapted dosage of medicines."( Caffeine metabolism differences in acute hepatitis of viral and drug origin.
Bechtel, PR; Bechtel, YC; Brientini, MP; David-Laroche, M; Lelouët, H; Miguet, JP; Paintaud, G,
)
0.13
" Groups of 6 rats received either vehicle or the enantiomer in turn and antinociception was determined by evaluating the dose-response curves over time."( Analysis of antinociceptive effects of flurbiprofen enantiomers in a rat model of arthritic pain.
Cabré, F; Díaz, MI; Domínguez, AM; García, ML; Hernández, GP; López-Muñoz, FJ; Mauleón, D; Ventura, R, 2000
)
0.31
" Therefore, we examined the time dependence of toxicity (chronotoxicity) and of antitumor effects (chronotherapy) of celecoxib to determine optimal time of day for dosing with respect to light-dark cycles."( Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.
Blumenthal, RD; Burton, J; Flefleh, C; Goldenberg, DM; Lew, W; Waskewich, C, 2001
)
0.31
"This study was conducted in 19 patients with mild or moderate essential hypertension randomised open trial to evaluate the influence of potassium losartan dosed 50 mg per day on blood pressure, metabolic processes and left ventricular heart function."( [Estimation of blood pressure, selected biochemical parameters and indices of left ventricular heart function in patients with mild or moderate essential hypertension treated with potassium losartan].
Badowski, R; Cieślik, P; Haczkiewicz, P; Hefczyc, J; Hrycek, A; Scieszka, J, 2001
)
0.31
" Oral dosing of placebo, carprofen, or deracoxib was done 30 minutes before intraarticular injection of urate crystal suspension for induction of synovitis."( Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs.
Buonomo, FC; Millis, DL; Moyers, T; Weigel, JP, 2002
)
0.31
" In contrast, supplemental T(3) decreased IVL in euthyroid birds, regardless of the dosing interval, but had no effect on ME activity."( Methimazole and thyroid hormone replacement in broilers.
McMurtry, JP; Rosebrough, RW, 2003
)
0.32
" This study aimed to determine iron-induced oxidative damage provoked by a single clinical dosage of ferrous sulfate and to elucidate the antioxidant defense mechanisms in the human small intestine in vivo."( New method to study oxidative damage and antioxidants in the human small bowel: effects of iron application.
Bast, A; Brummer, RJ; Haenen, GR; Saris, WH; Troost, FJ, 2003
)
0.32
" Salicylate therapy in common dosage may therefore falsely elevate or depress serum uric acid levels."( The effects of oral salicylate on serum uric acid levels.
FORD, DK; PRICE, GE, 1963
)
0.73
" The daily dosage of triamterene ranged from 50 to 250 mg."( TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE.
FRIEDMAN, R; SCHUCHER, R; WENER, J, 1965
)
0.24
" Satisfactory compliance was defined as taking compliance or correct dosing > 80%, while unsatisfactory compliance was defined as taking compliance or correct dosing < or = 80%."( The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study.
de Klerk, E; Landewé, R; van der Linden, S; van der Tempel, H; van der Heijde, D, 2003
)
0.32
" To evaluate the biochemical responses of children with Down Syndrome to a nutritional regimen supplemented with aminoacids, vitamins and polyunsaturated fatty acids, we submitted 86 subjects divided in two groups (0-6 and 6-12 years) to the dosage of plasma levels of aminoacids, antioxidant enzymes activities and reactive oxygen species, before and after 12 months of such nutritional supplementation and in relation to normal controls."( Aminoacid profile and oxidative status in children affected by Down syndrome before and after supplementary nutritional treatment.
Bono, A; Ciaccio, M; Corsello, G; Giuffrè, M; Macaione, V; Piccione, M; Vocca, L, 2003
)
0.32
" These CUA/Ccr relations demonstrated a gene dosage effect that corresponds with the difference in serum urate levels."( Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion.
Endou, H; Enomoto, A; Hikita, M; Hisatome, I; Hosoya, T; Hosoyamada, M; Ichida, K, 2004
)
0.32
" Hence, a reduction in CsA dosage in kidney transplant recipients (KTR) may improve long-term outcomes."( Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction.
Cardarelli, F; Cosimi, AB; Delmonico, FL; Farrell, ML; Pascual, M; Saidman, SL; Shih, V; Tolkoff-Rubin, N; Winkelmayer, WC; Wong, W, 2004
)
0.32
" In the dose-response study, the maximum increase in plasma vitamin C occurred 4 hours postdose."( Pulsed electric fields-processed orange juice consumption increases plasma vitamin C and decreases F2-isoprostanes in healthy humans.
Cano, MP; de Ancos, B; Elez-Martínez, P; Granado, F; Martín, A; Martín-Belloso, O; Olmedilla, B; Plaza, L; Sánchez-Moreno, C, 2004
)
0.32
" A single oral dosing of Y-700 (5, 20 or 80 mg) to volunteers caused a dose-dependent reduction of serum uric acid levels indicating close relationship to plasma concentrations of the compound."( Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man.
Fukunari, A; Iwane, J; Kamezawa, M; Mori, H; Osajima, T; Yamada, I, 2004
)
0.54
" Gout flares occurred with similar frequency in the placebo (37%) and 40-mg febuxostat (35%) groups and with increased frequency in the higher dosage febuxostat groups (43% taking 80 mg; 55% taking 120 mg)."( Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL, 2005
)
0.33
" The protocol consisted in the collection of 2, 24-hour urine samples, for dosing Ca, P, uric acid, Na, K, Mg, Ox and Ci, glycemia and serum levels of Ca, P, Uric acid, Na, K, Cl, Mg, U and Cr, urinary pH and urinary acidification test."( Metabolic assessment in patients with urinary lithiasis.
Amaro, CR; Amaro, JL; Goldberg, J; Padovani, CR,
)
0.35
" A dose-response relationship was found for most parameters."( Evidence for predictive validity of blood assays to evaluate individual radiosensitivity.
Göhde, W; Greve, B; Hacker-Klom, U; Kienast, J; Pascher, E; Severin, E; Silling, G; Wedemeyer, N; Willich, N, 2006
)
0.33
" Each ingredient was present at a dosage sufficiently low to avoid any accompanying unwanted pharmacological effects."( The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy.
Bose, SK; Grunwald, GK; McCord, JM; Myhill, P; Nelson, SK, 2006
)
0.33
"Deionized water orally dosed, ad libitum dosage were tested on rats for 90 days period."( [The estimation of the influence of deionized water on the basic electrolytes level in blood and urine of tested animals].
Drobnik, M; Latour, T, 2005
)
0.33
" Quality control samples were prepared in control serum from individuals not dosed with the xanthine oxidase inhibitor."( Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies.
Cooper, N; Erdmann, C; Fiene, J; Khosravan, R; Lee, JW, 2006
)
0.67
" We investigated whether such dosing provides adequate control of hyperuricemia."( Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth, N; Gow, P; Kumar, S; Stamp, L, 2006
)
0.33
"9% were taking recommended doses, based on published allopurinol dosing guidelines."( Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth, N; Gow, P; Kumar, S; Stamp, L, 2006
)
0.33
"Adherence to published allopurinol dosing guidelines led to suboptimal control of hyperuricemia in this population of patients with gout."( Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth, N; Gow, P; Kumar, S; Stamp, L, 2006
)
0.33
"88 mg/dL) for all doses and was dose linear for the 10-120 mg/day dosage range."( Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT, 2006
)
0.33
" There appeared to be a linear pharmacokinetic and dose-response (percentage decrease in serum uric acid) relationship for febuxostat dosages within the 10-120 mg range."( Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT, 2006
)
0.55
" The lowest CsA dosage and shortest exposure time effect as well as unlimited renal monitoring are required in order to provide the best long-term renal outcome."( Renal outcome after ciclosporin-induced nephrotoxicity.
Bagnis, CI; Bodaghi, B; Deray, G; du Montcel, ST; Jaudon, MC; Le Hoang, P; Mallet, A; Tostivint, I, 2007
)
0.34
" This study aimed to establish its mechanism of action and to construct a dose-response curve for the effect of allopurinol."( High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
Belch, JJ; Carr, E; Davies, J; George, J; Struthers, A, 2006
)
0.54
"For the first time, we have shown that a steep dose-response relationship exists between allopurinol and its effect on endothelial function."( High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
Belch, JJ; Carr, E; Davies, J; George, J; Struthers, A, 2006
)
0.54
" This dosage of aciclovir did not change the activity of 7-ethoxyresorufin O-dealkylation, which is represented as CYP1A2 activity."( Lack of effect of aciclovir on metabolism of theophylline and expression of hepatic cytochrome P450 1A2 in rats.
Hasegawa, T; Kato, M; Kimura, M; Nadai, M; Tsunekawa, Y; Ueyama, J; Yasui, K; Yoshizumi, H; Zhao, YL, 2007
)
0.34
" Aim of our study was to assess the effect of low dosage of recombinant urate oxidase on hyperuricemia in renal failure patients that already receiving allopurinol."( Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
Cianci, R; De Angelis, S; De Lorenzo, A; Di Renzo, L; Giarrizzo, GF; Giordano, F; Naticchia, A; Noce, A; Splendiani, G; Tozzo, C,
)
0.13
" Venous blood samples were collected predose (at 0 hours) and 1, 2, 3, 4, 6, 8, 10 and 12 hours after dosage for determination of oxypurinol and/or probenecid concentrations."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2008
)
0.35
" The therapeutic benefits of MZB pulse therapy were assessed based on a comparison of the incidence of relapse (times/year) and the required daily dosage of prednisolone (PSL) before and after therapy."( Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome.
Fujieda, M; Hayashi, A; Ishihara, M; Morita, T; Ohta, T; Sakano, T; Utsunomiya, Y; Wakiguchi, H, 2008
)
0.35
"05), and the required daily dosage of PSL after therapy was lower than that before therapy (0."( Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome.
Fujieda, M; Hayashi, A; Ishihara, M; Morita, T; Ohta, T; Sakano, T; Utsunomiya, Y; Wakiguchi, H, 2008
)
0.35
"Our results show that MZB pulse therapy is effective in decreasing the frequency of relapse and reducing the required PSL dosage in older pediatric patients with FR-SDNS."( Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome.
Fujieda, M; Hayashi, A; Ishihara, M; Morita, T; Ohta, T; Sakano, T; Utsunomiya, Y; Wakiguchi, H, 2008
)
0.35
" The dosing regimens to maintain uric acid levels below the therapeutic target of 6 mg/dL were then predicted by the model."( Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Alton, M; Huang, W; Marco, MD; Maroli, AN; Waltrip, RW; Wright, D; Yue, CS, 2008
)
0.63
" Although lower dosage is now widely accepted, I131 may still be the source of salivary damage over the long-term and subsequent harmful effects on both the oral cavity and the gastrointestinal tract, into which the saliva is swallowed."( Sialochemical and oxidative analyses in radioactive I131-treated patients with thyroid carcinoma.
Durleshter, L; Ish-Shalom, S; Nagler, RM; Segal, E, 2008
)
0.35
" An inverse dose-response association was observed through vitamin C intake of 400-500 mg/day, and then reached a plateau."( Vitamin C intake and serum uric acid concentration in men.
Ascherio, A; Choi, HK; Curhan, G; Forman, JP; Gao, X, 2008
)
0.64
" Following multiple dosing with febuxostat, there were no statistically significant differences in the plasma or urinary pharmacokinetic or pharmacodynamic parameters between subjects aged 18 to 40 years and >or=65 years."( The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Joseph-Ridge, N; Khosravan, R; Kukulka, MJ; Vernillet, L; Wu, JT, 2008
)
0.35
" Healthy volunteers (12) were dosed at 7 mL/kg of body weight after a washout phase and overnight fast, and plasma was repeatedly sampled over 12 h and urine over 24 h after consumption."( Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers.
Derendorf, H; Jilma-Stohlawetz, P; Meibohm, B; Mertens-Talcott, SU; Pacheco-Palencia, LA; Rios, J; Talcott, ST, 2008
)
0.35
"Forty-one patients were randomized to undergo 12-14 weeks of treatment with pegloticase at 1 of 4 dosage levels: 4 mg every 2 weeks, 8 mg every 2 weeks, 8 mg every 4 weeks, or 12 mg every 4 weeks."( Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Baraf, HS; Barkhuizen, A; Becker, MA; Horowitz, Z; Huang, W; Maroli, AN; Moreland, LW; Sundy, JS; Waltrip, RW, 2008
)
0.35
"The mean plasma urate level was reduced to ( Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Baraf, HS; Barkhuizen, A; Becker, MA; Horowitz, Z; Huang, W; Maroli, AN; Moreland, LW; Sundy, JS; Waltrip, RW, 2008
)
0.35
"Our study is the first to demonstrate a dose-response association between SUA and cancer incidence in men, simultaneously reporting on the usefulness of a novel methodological framework in epidemiologic research."( Use of penalized splines in extended Cox-type additive hazard regression to flexibly estimate the effect of time-varying serum uric acid on risk of cancer incidence: a prospective, population-based study in 78,850 men.
Brant, LJ; Concin, H; Diem, G; Hilbe, W; Kaltenbach, L; Klenk, J; Kneib, T; Lang, S; Oberaigner, W; Pfeiffer, KP; Ruttmann, E; Strasak, AM; Ulmer, H, 2009
)
0.56
"Any sampling interval at least 4 h after caffeine dosing is suitable for NAT2 and XO activity assessments."( Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
Fuhr, U; Jetter, A; Kinzig, M; Rodamer, M; Sörgel, F; Tomalik-Scharte, D, 2009
)
0.35
" Between Weeks 4 and 24, dosing could be adjusted to febuxostat 40 or 120 mg."( Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009
)
0.35
" The drug dosing was calculated based on the patients' ideal body weight (IBW) or adjusted body weight (aBW) for those who were more than 30% above their IBW."( Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Campara, M; Haaf, CM; Shord, SS, 2009
)
0.35
"009) and daily levodopa dosage (R(p)=-0."( Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration.
Andreadou, E; Boufidou, F; Gournaras, F; Nikolaou, C; Rentzos, M; Tsoutsou, A; Vassilopoulos, D; Zissimopoulos, V; Zournas, C, 2009
)
0.83
" Doses were administered by oral gavage or through feeding tissues from cattle dosed with ketoprofen at 6 mg kg(-1) cattle body weight, before slaughter."( Toxicity of non-steroidal anti-inflammatory drugs to Gyps vultures: a new threat from ketoprofen.
Cromarty, D; Cuthbert, R; Diekmann, M; Duncan, N; Meharg, AA; Naidoo, V; Taggart, MA; Venter, L; Wolter, K, 2010
)
0.36
" Clinical trials found that 40 mg/d of febuxostat was noninferior to conventionally dosed allopurinol (300 mg/d) in the percentage of subjects achieving the primary end point of serum urate <6."( Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst, ME; Fravel, MA, 2009
)
0.35
"96 million (96%) direct cost savings for the 48 patients in this study when compared to the cost of manufacturer's dosing recommendation."( Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Crank, CW; Knoebel, RW; Lo, M, 2011
)
0.37
"We found a clear dose-response relation between serum uric acid and risk of early GFR loss in patients with type 1 diabetes."( High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.
Aschengrau, A; Doria, A; Eckfeldt, JH; Ficociello, LH; Galecki, AT; Krolewski, AS; Maselli, NJ; Niewczas, MA; Rosolowsky, ET; Stanton, RC; Warram, JH; Weinberg, JM, 2010
)
0.94
"The objectives of this study were to establish dose-response and blood concentration-response relationships for robenacoxib, a novel nonsteroidal anti-inflammatory drug with selectivity for inhibition of the cyclooxygenase (COX)-2 isoenzyme, in a canine model of synovitis."( Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog.
Jung, M; King, JN; Lees, P; Schmid, VB; Seewald, W; Spreng, DE, 2010
)
0.36
" In addition, there was a dose-response relationship between SU and NAFLD in subjects with and without gout."( Gout and risk of non-alcoholic fatty liver disease.
Chang, HC; Chen, HW; Chiu, CT; Hwang, JS; Ko, YS; Kuo, CF; Luo, SF; See, LC; Tseng, WY; Yu, KH, 2010
)
0.36
" There was a strong dose-response relationship between the quartiles of uric acid and the presence of SBI in women (p=0."( High levels of serum uric acid are associated with silent brain infarction.
Heo, SH; Lee, SH, 2010
)
0.91
" All treatments at the same dosage (100 mmol/kg) were administered to the abdominal cavity of PO-induced hyperuricemic mice, and serum uric acid level was measured at 3 h after administration."( Phytochemicals from Acacia confusa heartwood extracts reduce serum uric acid levels in oxonate-induced mice: their potential use as xanthine oxidase inhibitors.
Chang, ST; Chen, CS; Hsu, CA; Huang, CC; Tung, YT; Yang, SC, 2010
)
0.8
" Repeat dosing is indicated for uric acid levels >4 mg/dL determined ≥12 hours following the initial dose."( Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Shanholtz, CB; Thompson, JL; Vines, AN, 2010
)
0.64
" Subsequent TLS monitoring over 7 days after initial dosing was recorded."( Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Shanholtz, CB; Thompson, JL; Vines, AN, 2010
)
0.36
"0001) with 2 patients requiring repeat dosing before day 3 (n = 34)."( Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Shanholtz, CB; Thompson, JL; Vines, AN, 2010
)
0.36
" The effect of chronic aspirin and HCTZ dosing taken together upon the efficacy of chronic allopurinol therapy in patients with hyperuricaemia needs to be investigated."( Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.
Day, RO; Graham, GG; Ng, DY; Stocker, SL; Williams, KM, 2011
)
0.37
" A dose-response relationship between serum uric acid and early decline in renal function has recently been demonstrated in patients with type-1 diabetes."( Serum uric acid as a new player in the development of diabetic nephropathy.
Hovind, P; Johnson, RJ; Parving, HH; Rossing, P, 2011
)
1.11
" Data were analyzed using the dosage of allopurinol (mg/day) greater than the recommended dosage, as defined by the Hande criteria."( Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
Barclay, ML; Chapman, PT; Frampton, C; James, J; O'Donnell, JL; Stamp, LK; Zhang, M, 2011
)
0.37
" All doses except the 250 mg daily dose were divided and dosing was twice daily."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2011
)
0.37
" The most frequently used maximal dosage of allopurinol was 100 mg/day at each stage."( Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey.
Fukuhara, S; Nakata, T; Nakaya, I; Namikoshi, T; Onishi, Y; Shibagaki, Y; Tsuruta, Y, 2011
)
0.37
" There was a positive, dose-response relationship between alcohol intake and the risk of incident hyperuricaemia."( Alcohol intake and the risk of hyperuricaemia: a 6-year prospective study in Japanese men.
Ishizaki, M; Kido, T; Miura, K; Morikawa, Y; Nakagawa, H; Nakamura, K; Naruse, Y; Sakurai, M; Suwazono, Y; Yoshita, K, 2012
)
0.38
"Soy protein with isoflavones or isoflavones alone at the provided dosage showed no significantly beneficial effects on measured cardiovascular risk factors in postmenopausal Chinese women with early hyperglycaemia."( The effects of isoflavones combined with soy protein on lipid profiles, C-reactive protein and cardiovascular risk among postmenopausal Chinese women.
Chen, YM; Ho, SC; Ho, YP; Liu, ZM, 2012
)
0.38
"A multicenter study with randomized, placebo-controlled, double-blind, parallel, intergroup comparison was carried out to evaluate the dose-response relationship, efficacy, and safety of febuxostat in 202 patients with hyperuricemia (including patients with gout) in Japan."( Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011
)
0.37
" A statistically significant dose-response relationship was found."( Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011
)
0.37
"In a 52-week, multicenter, open-label trial, febuxostat was initially administered at 10 mg/d; then, the dosage was increased in a stepwise fashion to 40 mg/d."( Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011
)
0.37
" There was no marked difference between the 2 dosage groups in terms of the incidence of adverse events."( Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011
)
0.37
" The total number of participants was 556, the median dosage of vitamin C was 500 mg/day, trial size ranged from 8-184 participants, and the median study duration was 30 days."( Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials.
Gelber, AC; Juraschek, SP; Miller, ER, 2011
)
0.62
" Allopurinol is the most commonly used ULT, but there is no consensus on dosing in renal impairment."( The challenges of gout management in the elderly.
Jordan, S; Stamp, LK, 2011
)
0.37
"To study the prevalence of chronic kidney disease (CKD) and its impact on allopurinol dosing and uric acid control among patients with gout."( Chronic kidney disease in gout in a managed care setting.
Dabbous, O; Fuldeore, MJ; Krishnan, E; Pandya, BJ; Riedel, AA; Zarotsky, V, 2011
)
0.59
" Patients in the XCR group took XCR, one dosage daily, twice per day."( [Assessment on the clinical efficacy and safety of xiezhuo chubi recipe in treating hyperuricemia].
Sun, WF; Xu, W; Zhang, XX, 2011
)
0.37
"15 mg/kg) administered as single dose followed by as needed dosing (maximum five doses) versus daily dosing for 5 days in adult patients at risk for TLS."( A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Bueso-Ramos, CE; Cortes, JE; Fanale, MA; Fayad, LE; Fowler, N; Hagemeister, FB; Kwak, LW; McLaughlin, PW; Orlowski, RZ; Pro, B; Rodriguez, A; Romaguera, JE; Samaniego, F; Sarlis, NJ; Shah, J; Vadhan-Raj, S; Wang, M; Younes, A; Zhou, X, 2012
)
0.38
"Owing to the low effective dosage of indapamide (1."( Effects of short and long-term indapamide treatments on urinary calcium excretion in patients with calcium oxalate dihydrate urinary stone disease: a pilot study.
Alonso, D; Grases, F; Pieras, E; Pizá, P; Prieto, RM, 2012
)
0.38
" Dosing guidelines based on creatinine clearance have been proposed based on the recognition that dosages of ≥300 mg/day may be associated with AHS, particularly in patients with renal impairment."( Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Dalbeth, N; Dockerty, JL; Drake, J; Frampton, C; Jones, PB; Stamp, LK; Taylor, WJ, 2012
)
0.38
" We performed a meta-analysis to characterize the dose-response relationships for 3 commonly prescribed thiazide diuretics, hydrochlorothiazide, chlorthalidone, and bendroflumethiazide, on BP, serum potassium, and urate."( Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate.
Chaturvedi, N; Hardy, R; Hughes, AD; Peterzan, MA, 2012
)
0.38
" The aim of our study is to appreciate the clinical usefulness of the dosage serum homocysteine and malondialdehyde, as an oxidative stress marker, in the pregnancies complicated with risk of abortion or preterm birth."( The influence of homocysteine and oxidative stress on pregnancy outcome.
Antal, L; Bodog, A; Bodog, F; Micle, O; Muresan, M, 2012
)
0.38
"Potassium oxonate-induced hyperuricemic mice were dosed by gavage with eight stilbenes."( Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice.
Hong, Y; Kong, LD; Li, Z; Liu, L; Liu, YL; Shi, YW; Wang, CP; Wang, X, 2012
)
0.38
"Effects of the dosing matrix and timing on the onset of renal crystal formation were evaluated in male and non-pregnant female rats (Fisher 344) exposed to both melamine (MEL) and cyanuric acid (CYA) for 28 days."( Timing and route of exposure affects crystal formation in melamine and cyanuric exposed male and female rats: gavage vs. feeding.
Bandele, O; Black, T; Crosby, T; Evans, E; Ferguson, M; Gamboa da Costa, G; Keltner, Z; Loukotková, L; Nemser, SM; Olejnik, N; Reimschuessel, R; Scott, M; Sprando, RL; Stine, CB; Tkachenko, A; Woodling, K, 2012
)
0.57
"ULT prescription and dosing are key modifiable factors associated with achieving SU target."( Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth, N; Horne, A; House, ME; McQueen, FM; Petrie, KJ; Taylor, WJ, 2012
)
0.38
" A dose-response trend of serum urate to reduce PD risk was also observed involving 11 795 participants (RR=0."( Serum urate and the risk of Parkinson's disease: results from a meta-analysis.
Ding, M; Guo, Y; Lin, C; Luo, W; Shen, C, 2013
)
0.39
" As the dosage was increased (40, 80, 120 mg/d), the proportion of patients who achieved target sUA in the febuxostat-treated group increased gradually (50."( Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W, 2013
)
0.39
"Mizoribine (MZR) was approved in 1984 in Japan for the suppression of rejection in renal transplantation with an approved administration dosage of 1-3 mg/kg/day."( Randomized comparative trial of mizoribine versus mycophenolate mofetil in combination with tacrolimus for living donor renal transplantation.
Akiyama, T; Amada, N; Takahara, S; Takahashi, K; Tanabe, K; Toma, H; Uchida, K, 2013
)
0.39
"To evaluate single fixed dosing versus weight-based dosing strategies for rasburicase to determine the minimum dose required to mitigate hyperuricemia in the treatment or prevention of tumor lysis syndrome."( Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
Augustin, KM; Boehmer, L; Butler, SK; Lathon, SC; McBride, A; Westervelt, P, 2013
)
0.39
"5-mg, and weight-based dosing groups."( Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
Augustin, KM; Boehmer, L; Butler, SK; Lathon, SC; McBride, A; Westervelt, P, 2013
)
0.39
"The efficacy of all single fixed doses and weight-based dosing strategies evaluated in this study appear to be comparable in normalizing plasma uric acid levels within 24 hours of rasburicase administration."( Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
Augustin, KM; Boehmer, L; Butler, SK; Lathon, SC; McBride, A; Westervelt, P, 2013
)
0.59
" This meta-analysis study evaluated the efficacy and cost savings of a single-dose rasburicase (SDR) regimen compared with the Food and Drug Administration-approved daily dosing of rasburicase (DDR) for 5 days or the traditional treatment with allopurinol in adult cancer patients with hyperuricaemia or at high risk for TLS."( Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Bhutada, NS; Dong, K; Feng, X; Inciardi, J; Pence, S; Pham, D, 2013
)
0.39
" Dose-response relationship was assessed by restricted cubic spline model and multivariate random-effect meta-regression."( Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies.
Jia, Z; Kang, S; Wu, Y; Zhang, X, 2013
)
0.87
" Inappropriate dosing of medications in the setting of renal disease and lack of prophylaxis when initiating urate-lowering therapy (ULT) accounted for much of the lack of compliance with treatment recommendations."( Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire.
Firneno, C; Harrold, LR; Mazor, KM; Negron, A; Ogarek, J; Yood, RA, 2013
)
0.39
"A modest dosage of vitamin C (500 mg/day) for 8 weeks had no clinically significant urate-lowering effects in patients with gout, despite the fact that plasma ascorbate levels increased."( Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial.
Chapman, PT; Drake, JM; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2013
)
0.39
" We herein conducted a dose-response analysis of TRT in 160 patients with female to male GID."( Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder.
Araki, M; Ariyoshi, Y; Ishii, K; Kumon, H; Kurahashi, H; Mahmood, S; Nagai, A; Nasu, Y; Sugimoto, M; Watanabe, M, 2013
)
0.65
" On 48% of occasions, the time of allopurinol dosing was recorded, while just 79 (19%) blood samples were collected 6-9 hours postdosing, the time window used to establish the therapeutic range for oxypurinol."( An audit of a therapeutic drug monitoring service for allopurinol therapy.
Day, RO; Graham, GG; Jones, G; Kannangara, DR; Ramasamy, SN; Ray, JE; Williams, KM, 2013
)
0.39
" However, inadequate dosing and patient nonadherence or intolerance to therapy often lead to treatment failure."( CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Bakris, GL; Doghramji, PP; Keenan, RT; Silber, SH, 2014
)
0.4
" The dosage of the study drugs should be one 10-mg tablet/day at weeks 1 to 4 after study initiation, increased to one 20-mg tablet/day at weeks 5 to 8, and elevated to one 40-mg tablet/day at week 9 and then maintained until week 108."( The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Hayakawa, H; Hosoya, T; Iimuro, S; Imai, N; Inaba, M; Itoh, S; Kimura, K; Kuwabara, M; Makino, H; Matsuo, S; Ohno, I; Shibagaki, Y; Tomino, Y; Uchida, S; Yamamoto, T, 2014
)
0.4
"Mean eGFR in both pegloticase dosing cohorts remained constant over the randomized treatment phase and long-term open-label extension study."( Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials.
Irish, W; Ottery, FD; Wolfson, M; Yood, RA, 2014
)
0.4
"Following the intraperitoneal administration of silymarin (with MRP1, 2, 4 and 5 inhibitory effects), naringenin (with MRP1, 2 and 4 stimulatory effects), sulfinpyrazone (with MRP1, 4 and 5 inhibitory and MRP2 stimulatory effects) and allopurinol (with MRP4 stimulatory effect in doses of 100 mg/kg, 100 mg/kg, 100 mg/kg and 60 mg/kg, respectively, for one week before and after the administration of MPTP in C57B/6 mice in acute dosing regimen the striatal concentrations of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid has been measured using high-performance liquid chromatography."( Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013
)
0.39
" Dose-response relationship was assessed by restricted cubic spline model and multivariate random effect meta-regression."( Dose-response relationship of serum uric acid levels with risk of stroke mortality.
Hu, D; Huang, J; Qu, Y; Wang, Y; Zhang, D, 2014
)
0.68
"Different dose-response relationships of SUA levels with risk of stroke mortality might exist for men and for women."( Dose-response relationship of serum uric acid levels with risk of stroke mortality.
Hu, D; Huang, J; Qu, Y; Wang, Y; Zhang, D, 2014
)
0.68
" Metabolic study consisted of two 24-h urine collections separated by a period of 3 months for dosing Ca, P, uric acid, Na, K, Mg, oxalate, and citrate."( An update on metabolic assessment in patients with urinary lithiasis.
Amaro, CR; Amaro, JL; Damasio, PC; Goldberg, J; Leitão, VA; Padovani, CR; Turney, B, 2015
)
0.63
" Green tea extract also significantly elevated serum antioxidant capacity with a positive dosage effect."( Effects of green tea extract on serum uric acid and urate clearance in healthy individuals.
Jatuworapruk, K; Kasitanon, N; Louthrenoo, W; Ounjaijean, S; Srichairatanakool, S; Wangkaew, S, 2014
)
0.67
"Urinary 1-hydroxyphenanthrene is associated with a dose-response increase in serum uric acid levels in coke oven workers, and exposure to phenanthrene in PAHs may be a risk factor for hyperuricemia."( [Association between urinary polycyclic aromatic hydrocarbon metabolites and elevated serum uric acid levels in coke oven workers].
Deng, Q; Deng, S; Guo, H; Hu, D; Li, J; Wu, T; Zhu, X, 2014
)
0.85
"This systematic review aims to summarise published evidence that assessed the management of gout in regard to the following: prescription of urate lowering therapy (ULT), monitoring of serum urate levels (sUA) and allopurinol dosing in patients with renal impairment, lifestyle advice and acute management of gout."( Management of gout in general practice--a systematic review.
Jeyaruban, A; Larkins, S; Soden, M, 2015
)
0.42
" There were dose-response relationships between arsenic exposure and PUA levels."( Elevated levels of plasma uric acid and its relation to hypertension in arsenic-endemic human individuals in Bangladesh.
Aktar, S; Alam, S; Ali, N; Arefin, A; Aziz, A; Himeno, S; Hossain, K; Hossain, MI; Hossain, S; Huda, N; Islam, K; Karim, MR; Mamun, AA; Miyataka, H; Mohanto, NC; Rahman, M; Salam, KA; Saud, ZA, 2014
)
0.7
"9991) between the mean uric acid concentration in blood and the mean uric acid excretion rate in urine in the range of 11 to 30 h after single dosing was found."( Pharmacodynamic analysis of intravenous recombinant urate oxidase using an indirect pharmacological response model in healthy subjects.
Cai, NF; Cheng, ZN; Guo, X; Liu, Z; Luo, X; Zheng, LY; Zi, Y, 2014
)
0.71
"We recruited 52 newly diagnosed, drug-naïve PD patients, and performed serum UA dosage and [(123) I]FP-CIT-SPECT."( Uric acid relates to dopamine transporter availability in Parkinson's disease.
Amboni, M; Barone, P; Erro, R; Longo, K; Moccia, M; Palladino, R; Pappatà, S; Pellecchia, MT; Picillo, M; Vitale, C, 2015
)
1.86
" The high and low dosage of chicory inulin also decreased serum UA levels on days 7, 14, and 28."( Effects of chicory inulin on serum metabolites of uric acid, lipids, glucose, and abdominal fat deposition in quails induced by purine-rich diets.
Jin, R; Lin, Z; Liu, X; Zhang, B; Zhu, W, 2014
)
0.66
" Dosing levels of SUA could be appropriate in the global management of patients with psoriasis, particularly in those who are obese and with serum triglycerides upper the normal range."( Hyperuricemia in patients with chronic plaque psoriasis.
Gisondi, P, 2014
)
0.4
"-Some of the reasons identified for poor adherence to anti-gout medications include the risk of flare of acute gout with the initiation of urate-lowering therapy (ULT), poor response to ULT and persistence of attacks of acute gout, suboptimal dosing of allopurinol therapy and intolerance of allopurinol."( Adherence and persistence to urate-lowering therapies in the Irish setting.
Bennett, K; McGowan, B; Silke, C; Whelan, B, 2016
)
0.43
"26 for a 1 mg/dl increase), and the risk is consistent in subgroup analyses and have a dose-response relationship."( Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies.
Chen, J; Huang, H; Li, J; Li, Y; Qin, T; Wang, J; Wang, L, 2014
)
0.4
"Hyperuricemia may modestly increase the risk of hypertension incidence, consistent with a dose-response relationship."( Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies.
Chen, J; Huang, H; Li, J; Li, Y; Qin, T; Wang, J; Wang, L, 2014
)
0.4
" Potentially modifiable factors associated with treatment adherence and obtaining the SUA goal in the multivariable analysis included concomitant diuretic use, prescriber specialty, and allopurinol dosing practices."( Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
Cheetham, TC; Coburn, BW; Curtis, JR; Mikuls, TR; Rashid, N; Saag, KG; Wu, YL, 2015
)
0.42
" Studies have identified the safe and effective dosing strategies for 'old' drugs such as allopurinol and colchicine."( Advances in pharmacotherapy for the treatment of gout.
Dalbeth, N; Robinson, PC, 2015
)
0.42
" Compared to women with normal fasting glucose (NFG), we found a dose-response relationship of the risk of prediabetes with age and body mass index (BMI) and total cholesterol, triglyceride, glutamic-pyruvic transaminase (GPT), and uric acid in serum."( Clinical risk factors of prediabetes in Taiwanese women without substance uses (tobacco, alcohol, or areca nut).
Cheng, CM; Chiu, KF; Huang, CT; Hung, CC; Lee, CY; Lin, HH; Lin, PC; Lin, WY; Wu, MT; Wu, WC, 2015
)
0.6
" There was a significant positive dose-response association between serum uric acid levels and the rate of elevated serum ALT (P for trend <0."( The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort.
Ben-Assuli, O; Chodick, G; Goldstein, A; Magid, A; Rabinowich, L; Shalev, V; Shibolet, O; Zelber-Sagi, S, 2015
)
0.91
" d-1 ) to prepare the hyperuricemia model, and divided into normal, model, Allopurinol, LE high dosage, middle dosage and low dose (200, 100, 50 mg ."( [Regulatory effect of leonurus extracts on hyperuricemia in rats].
An, YT; Li, J; Wang, T; Wu, ZZ; Yan, M, 2014
)
0.4
"We determined the dose-response effects of consuming beverages sweetened with high-fructose corn syrup (HFCS) at zero, low, medium, and high proportions of energy requirements (Ereq) on circulating lipid/lipoprotein risk factors for CVD and uric acid in adults [age: 18-40 y; body mass index (in kg/m(2)): 18-35]."( A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Bremer, AA; Chen, GX; Havel, PJ; Keim, NL; Lam, HD; Lee, V; Medici, V; Nunez, MV; Stanhope, KL, 2015
)
0.6
"5%, or 25% Ereq from HFCS produced significant linear dose-response increases of lipid/lipoprotein risk factors for CVD and uric acid: postprandial triglyceride (0%: 0 ± 4; 10%: 22 ± 8; 17."( A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Bremer, AA; Chen, GX; Havel, PJ; Keim, NL; Lam, HD; Lee, V; Medici, V; Nunez, MV; Stanhope, KL, 2015
)
0.62
" A relative bioavailability study in healthy males (N=8) indicated a nearly identical pharmacokinetic profile following dosing of tablets or capsules."( Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
Hingorani, V; Kerr, B; Manhard, K; Quart, B; Rowlings, C; Shen, Z; Storgard, C; Yeh, LT, 2015
)
0.65
" Suboptimal dosing is a key contributor to poor clinical outcomes, but few data are available on the safety and efficacy of dose-titrated allopurinol, particularly at doses > 300 mg/d."( An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Baumgartner, S; Becker, MA; Choi, HK; Cravets, M; Dalbeth, N; Fitz-Patrick, D; Storgard, C, 2015
)
0.42
"2% of patients; dosing duration was 115."( An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Baumgartner, S; Becker, MA; Choi, HK; Cravets, M; Dalbeth, N; Fitz-Patrick, D; Storgard, C, 2015
)
0.42
"Monitoring blood uric acid (UA) is important in all patients on urate-lowering therapy so that the selection of the effective drugs and dosage adjustments could be made until the target level is reached."( Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy.
Huang, Y; Zhao, J, 2015
)
1.17
" A random-effects model was used to evaluate dose-response relationships."( Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies.
Li, X; Sun, L; Yang, Z; Yu, C; Yuan, H; Zhang, Z; Zhao, C; Zhu, X, 2015
)
0.9
"This meta-analysis suggests that higher SUA levels led to an increased risk of MS regardless of the study characteristics, and were consistent with a linear dose-response relationship."( Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies.
Li, X; Sun, L; Yang, Z; Yu, C; Yuan, H; Zhang, Z; Zhao, C; Zhu, X, 2015
)
0.9
"5% of patients were followed-up > 1 month for second evaluation of uric acid and most of them not receiving dosage up-titration even though not achieving the target."( Outcome of Treatment in Gouty Arthritis Patients: A Retrospective Study.
Hanvivadhanakul, P; Wongdet, R, 2015
)
0.65
" In addition, the four major bioactive phytochemicals at the same dosage (100 mmol/kg) were administered to the abdominal cavity of potassium oxonate (PO)-induced hyperuricemic mice, and the serum uric acid level was measured after 3 h of administration."( Antioxidative phytochemicals from Rhododendron oldhamii Maxim. leaf extracts reduce serum uric acid levels in potassium oxonate-induced hyperuricemic mice.
Chiu, CC; Chuang, HL; Ho, ST; Huang, CC; Lin, CY; Lin, LC; Liu, YL; Tung, YT; Wu, JH, 2015
)
0.83
"Long-term flexible dosing with colestilan reduces serum phosphorus and demonstrates an acceptable safety and tolerability profile."( Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia.
Dimkovic, N; Locatelli, F; Spasovski, G; Wanner, C, 2016
)
0.43
" It remains to be seen whether allopurinol has a dose-response relationship with cardiovascular events at higher doses."( Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study.
Hallas, J; Lindegaard, HM; Pottegård, A; Søltoft Larsen, K, 2016
)
0.43
" Primary outcomes were fasting clinical safety markers (heart rate, blood pressure, lipid profiles, hematologic blood counts, biomarkers of liver/kidney/immune function) and energy, focus, concentration, anxiety, motivation to exercise, and POMS measured prior to daily dosing to ascertain potential tachyphylactic responses and habituation effects."( Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use.
Hayward, S; Mullins, J; Mumford, P; Roberts, M; Taylor, L; Urbina, S; Wilborn, C, 2016
)
0.43
" The dosage of the drug varied from 6 to 18 g per day and was selected individually, depending on the purpose of the appointment of Blemaren®."( [EXPERIENCE OF USE OF BLEMAREN® IN THE TREATMENT OF PATIENTS IN URIC ACID AND CALCIUM OXALATE UROLITHIASIS].
Konstantinova, OV; Yanenko, EK,
)
0.37
" When compared with the same dosage of benzbromarone, UR-1102 showed a better pharmacokinetic profile, increased the fractional excretion of urinary uric acid, and reduced plasma uric acid more effectively."( Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
Ahn, SO; Horiba, N; Kawabe, Y; Kim, BH; Kim, KH; Kiyokawa, J; Lee, KJ; Nakagawa, T; Ohtomo, S; Tanaka, J; Yamane, M, 2016
)
0.63
" Although dosing was otherwise well tolerated, two subjects experienced serious adverse events of acute kidney injury."( Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649.
Dua, P; Gurrell, R; Kirby, S; Loudon, PT; Sudworth, M, 2016
)
0.43
" We aimed to explore the dose-response relation between FPG level and serum UA concentration by conducted this epidemiological research in a large health check-up population in China."( An Invert U-Shaped Curve: Relationship Between Fasting Plasma Glucose and Serum Uric Acid Concentration in a Large Health Check-Up Population in China.
Guo, R; Li, H; Liu, M; Wen, Y; Zha, X; Zhu, Y, 2016
)
0.66
"67) and also revealed a dose-response relationship in this subgroup."( Association of cognitive function and serum uric acid: Are cardiovascular diseases a mediator among women?
Brenner, H; Mons, U; Perna, L; Schöttker, B, 2016
)
0.7
" In conclusion, the model was found useful for predicting therapeutic effect of rasburicase and individually determining rational dosage regimen of rasburicase."( Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model.
Homma, M; Kanehira, N; Kimura, K; Minohara, H; Takayanagi, R; Yamada, Y, 2016
)
0.43
" With dosing of ULT, 45."( A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia.
Riordan, J; Terrill, M, 2017
)
0.46
"There is poor adherence to recommended practice for dosing of colchicine in acute gout."( A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia.
Riordan, J; Terrill, M, 2017
)
0.46
" In post-AMI rats, XO activity and UA concentrations were increased, while SalA dosing palliated this increase."( Mechanism-based pharmacokinetic-pharmacodynamic modeling of salvianolic acid A effects on plasma xanthine oxidase activity and uric acid levels in acute myocardial infarction rats.
He, H; Li, X; Liu, X; Liu, Y; Wang, H; Wang, S; Zhang, W, 2017
)
0.66
" Allopurinol is recommended as first-line ULT and its dosage should be adjusted according to renal function."( 2016 updated EULAR evidence-based recommendations for the management of gout.
Bardin, T; Barskova, V; Becce, F; Castañeda-Sanabria, J; Coyfish, M; Doherty, M; Guillo, S; Jansen, TL; Janssens, H; Lioté, F; Mallen, C; Nuki, G; Pascual, E; Perez-Ruiz, F; Pimentao, J; Punzi, L; Pywell, T; Richette, P; So, A; Tausche, AK; Tubach, F; Uhlig, T; Zavada, J; Zhang, W, 2017
)
0.46
" Both biochemical and morphological studies clearly revealed that chrysin protects against cell injury induced by ammonia intoxication in a dose-response manner with respect to endogenous antioxidants and hypoammonemic effects."( Chrysin, a flavonoid attenuates histological changes of hyperammonemic rats: A dose dependent study.
Ramakrishnan, A; Renuka, M; Vijayakumar, N, 2016
)
0.43
" For dose-response analysis, a linear relationship (8 studies; Pfor non-linearity=0."( Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis.
Huang, F; Li, B; Lin, Z; Luo, Q; Xia, X; Yu, X, 2016
)
0.92
" There was a significantly positive dose-response association between SUA levels and the prevalence of elevated ALT."( Association between Serum Uric Acid and Elevated Alanine Aminotransferase in the General Population.
Chen, S; Guo, X; Li, Z; Sun, G; Sun, Y; Yang, H; Yu, S, 2016
)
0.73
"These findings confirm that higher sUA levels are associated with an increased risk of gout flares in a dose-response manner over 2 years."( Serum uric acid levels and the risk of flares among gout patients in a US managed care setting.
Buysman, EK; Korrer, S; Shiozawa, A, 2017
)
0.94
"These findings suggested that higher SUA levels were independently associated with a dose-response increased risk of CHD incidence."( Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji Cohort.
Angileri, F; Chen, X; Fang, Q; He, MA; Lai, X; Légaré, S; Li, X; Min, X; Wu, T; Xu, C; Yang, H; Yang, L; Yuan, J; Zhang, C; Zhang, X, 2016
)
0.7
" In terms of the effectiveness of topiroxostat in lowering serum urate levels, the dose-response relationship has been evaluated; however, it remains to be verified."( Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Hosoya, T; Ohashi, T; Sasaki, T, 2017
)
0.46
" Expert opinion: The initial dosage of allopurinol should be low, particularly in patients with renal impairment."( Allopurinol: insights from studies of dose-response relationships.
Carland, JE; Day, RO; Graham, GG; Kannangara, DR; Stocker, SL; Williams, KM, 2017
)
0.46
" Studies are needed in gout patients with chronic kidney disease and/or cardiovascular disease, so that escalation of dosing /combination of anti-inflammatory drugs needed to suppress gouty inflammation as well as escalation of dosing/combination of urate lowering drugs needed to achieve target serum urate level will lead to better understanding of gout treatment safety issues."( The safety of treatment options available for gout.
Schlesinger, N, 2017
)
0.46
" This study examined the changes in risk of CAD in gout patients taking allopurinol and/or benzbromarone, and analyzed the dose-response relationship of both drugs with CAD incidence."( Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
Chiang, SJ; Daimon, M; Ho, Y; Lin, HC; Uang, YS; Wang, CH; Wang, LH, 2017
)
0.46
" However, after adjustment for covariates in dose-response analyses, treatment with over 270 defined daily doses (DDDs) of allopurinol, and over 360 DDDs of benzbromarone, was associated with a significantly reduced risk of CAD."( Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
Chiang, SJ; Daimon, M; Ho, Y; Lin, HC; Uang, YS; Wang, CH; Wang, LH, 2017
)
0.46
"We found that the use of allopurinol and benzbromarone, whether alone or in combination, had a linear dose-response relationship between the numbers of defined daily doses and the risk of CAD, especially in higher DDDs."( Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
Chiang, SJ; Daimon, M; Ho, Y; Lin, HC; Uang, YS; Wang, CH; Wang, LH, 2017
)
0.46
"2%) 19 patients received the recommended starting dosage of 100mg/day."( GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations.
Delva, C; Ea, HK; Goossens, J; Guggenbuhl, P; Lambert, C; Lancrenon, S; Lanz, S; Lioté, F; Sahbane, S; Saraux, A, 2017
)
0.46
"2% were aware of first-line pharmacological management options; 28% answered the correct dosing regimen for colchicine."( A survey on the beliefs and knowledge of gout management in new medical graduates - New South Wales, Australia.
Riordan, J; Terrill, M, 2018
)
0.48
" Genetic data may inform assessment of disease prognosis in individuals with hyperuricaemia or established gout, personalised lifestyle advice, selection and dosing of urate-lowering therapy, and prevention of serious medication adverse effects."( The genetics of gout: towards personalised medicine?
Dalbeth, N; Merriman, TR; Stamp, LK, 2017
)
0.46
" Rather than prompting abandonment of antioxidant strategies, these failures have raised the bar for justifying drug and dosing selections and for improving study designs to test for disease modification by antioxidants."( Targeting urate to reduce oxidative stress in Parkinson disease.
Ascherio, A; Crotty, GF; Schwarzschild, MA, 2017
)
0.46
" Furthermore, there was a dose-response association between the number of CVD risk factors clustering and hyperuricemia."( Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population.
Cheng, Q; Cheng, XQ; Guo, XZ; Liu, L; Liu, Q; Qiu, L; Wu, J; Wu, W; Xu, CL; Xu, T; Ye, YC; Zeng, XJ; Zhu, GJ, 2017
)
0.46
" Two studies indicated dose-response relationship for sUA, achieving sUA target and gout attacks."( Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.
Astrup, A; Bartels, EM; Bliddal, H; Carmona, L; Christensen, R; Gudbergsen, H; Henriksen, M; Knop, FK; Kristensen, LE; Nielsen, SM; Perez-Ruiz, F; Singh, JA; Taylor, WJ; Wæhrens, EE, 2017
)
0.46
"Simulation results showed a surge in urinary uric acid occurring when dosing is restarted following missed doses."( Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E, 2018
)
0.99
"This large scale study finds plasma uric acid levels are lower in current, but not remitted, MDD and/or anxiety disorders, according to a dose-response gradient."( Uric acid in major depressive and anxiety disorders.
Black, CN; Bot, M; Penninx, BWJH; Scheffer, PG; Snieder, H, 2018
)
2.2
" We investigated the impact of mycoprotein ingestion, in a dose-response manner, on acute postprandial hyperaminoacidaemia and hyperinsulinaemia."( Mycoprotein represents a bioavailable and insulinotropic non-animal-derived dietary protein source: a dose-response study.
Bowtell, JL; Dunlop, MV; Finnigan, TJA; Kilroe, SP; Salmon, DL; Wall, BT, 2017
)
0.46
"Indication-based, low-dose rasburicase displayed significantly more value when compared to weight-based dosing as shown by achieving cost savings without compromising clinical efficacy."( The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Blackman, A; Boutin, A; Forcello, N; O'Sullivan, DM, 2019
)
0.51
"This research aims to evaluate the predictive performance of a published allopurinol dosing tool."( The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.
Barclay, ML; Dalbeth, N; Drake, J; Horne, A; Merriman, TR; Phipps-Green, AJ; Stamp, LK; Tan, P; Wright, DFB, 2018
)
0.48
"The dosing tool produced acceptable maintenance dose predictions for patients not taking diuretics."( The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.
Barclay, ML; Dalbeth, N; Drake, J; Horne, A; Merriman, TR; Phipps-Green, AJ; Stamp, LK; Tan, P; Wright, DFB, 2018
)
0.48
" Multiple regression analyses resulted in a significant positive association with lumbar spine BMD across SUA quintiles in a dose-response manner after adjusting for various confounding factors (p = 0."( Higher serum uric acid is associated with higher lumbar spine bone mineral density in male health-screening examinees: a cross-sectional study.
Ahn, JK; Hwang, J; Hwang, JH; Ryu, S, 2019
)
0.88
" Topiroxostat (stepwise dosing from 40 to 160 mg/day) or matching placebo was administered BID for 28 weeks."( Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Honda, D; Hosoya, T; Kimura, K; Narita, K; Okui, D; Sakamoto, R; Sasaki, T; Wada, T, 2018
)
1.92
" His uric acid was 11 mg/dL despite maximal dosing of febuxostat."( Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease.
Case, R; Jester, G; Wentworth, B, 2018
)
1.4
" The main management issues are related to patient adherence, because gout patients have the lowest rate of medication possession ratio at 1 year, but they also include clinical inertia by physicians, meaning XOI dosage is not titrated according to regular serum uric acid level measurements for targeting serum uric acid levels for uncomplicated (6."( Gout: state of the art after a decade of developments.
Lioté, F; Pascart, T, 2019
)
0.69
"Present study was undertaken to investigate the dose-response relationship of berberine in SMW between the articular concentration and anti-inflammatory effect in the knee joint under the lower-guiding of ABR."( Achyranthis bidentatae radix enhanced articular distribution and anti-inflammatory effect of berberine in Sanmiao Wan using an acute gouty arthritis rat model.
Cheng, W; Li, J; Li, W; Sun, B; Wu, J; Xie, J; Zhang, Q, 2018
)
0.48
" The dose-response relationship of berberine between the enhanced articular concentration and improved anti-inflammatory effect in the knee joint under the lower-guiding of ABR was observed for the first time."( Achyranthis bidentatae radix enhanced articular distribution and anti-inflammatory effect of berberine in Sanmiao Wan using an acute gouty arthritis rat model.
Cheng, W; Li, J; Li, W; Sun, B; Wu, J; Xie, J; Zhang, Q, 2018
)
0.48
" 67% abdominal obesity was found, decreasing at 53% after drinking the established dosage of juice."( Effect of consumption of tree tomato juice (Cyphomandra betacea) on lipid profile and glucose con centrations in adults with hyperlipidemia, Ecuador.
Barahona, A; Bermeo, B; Chtivez, C; Freire, P; Mndez, J; Ortiz, K; Salas, H; Salazar-Lugo, R; Santamaria, M, 2016
)
0.43
"To review the extent of treatment success or failure with the xanthine oxidoreductase inhibitors allopurinol and febuxostat and indicate how the dosage of urate-lowering therapy (ULT) may be modified to increase the response in the majority of patients with gout."( Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
Day, RO; Graham, GG; Kannangara, DRW; Stocker, SL, 2018
)
0.48
" Multiple regression analyses remained significant for women with a positive association with baPWV across SUA quintiles in a dose-response manner (P < ."( Association between serum uric acid and arterial stiffness in a low-risk, middle-aged, large Korean population: A cross-sectional study.
Ahn, JK; Chung, SM; Hwang, J; Hwang, JH; Kwon, MJ, 2018
)
0.78
" The use of allopurinol has been researched extensively and newer strategies for safer effective dosing are now recommended."( Gout - An update of aetiology, genetics, co-morbidities and management.
Robinson, PC, 2018
)
0.48
"Allopurinol dosing has frequently been limited based on creatinine clearance (CrCL), resulting in failure to achieve target serum urate (SU)."( How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose.
Barclay, ML; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2018
)
0.48
" However, the dose-response effects of serum uric acid (SUA) on the prevalence of MetS and electrocardiographic left ventricular hypertrophy (LVH) are unclear."( The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals.
Chang, WC; Chen, KH; Hwang, JJ; Liu, CW; Tseng, CK; Wu, YW, 2019
)
1.06
"We demonstrated that the dose-response effects of SUA are associated with the prevalence of MetS and electrocardiographic LVH in healthy individuals from Taiwan."( The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals.
Chang, WC; Chen, KH; Hwang, JJ; Liu, CW; Tseng, CK; Wu, YW, 2019
)
0.81
" Following-up for 1 year,the dosage of febuxostat decreased to 40 mg once daily, and the patient didn't have gout attack again, some of the tophus diminished, and the urate acid level ranged from 400 to 500 μmol/L."( [A case of gout secondary to primary myelofibrosis].
Hao, YJ; Ji, LL; Zhang, ZL, 2018
)
0.48
" Dosage of urate-lowering therapy is often too low to reach target urate levels, and adherence to therapy is poor."( Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression.
Cleophas, MCP; Crişan, TO; Dinarello, CA; Hoogerbrugge, N; Joosten, LAB; Klück, V; Netea, MG; Netea-Maier, RT, 2019
)
0.51
"We conducted an imaging study of a 2-year randomized clinical trial that compared immediate allopurinol dose escalation to SU target with conventional dosing for 1 year followed by dose escalation to target, in gout patients who were receiving allopurinol and who had an SU level of ≥0."( Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
Aati, O; Allan, J; Billington, K; Dalbeth, N; Doyle, A; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2019
)
0.51
"001), and a positive dose-response relationship was observed."( Dose-response relationship between higher serum calcium level and higher prevalence of hyperuricemia: A cross-sectional study.
Ding, X; He, H; Liu, Z; Tian, J; Wang, Y; Wu, J; Wu, Z; Xie, D; Yang, Z, 2019
)
0.51
" Midazolam, caffeine, and TMU concentrations were assessed at baseline and following dosing of rifampicin (300 mg daily) for 7 days."( Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.
Hopkins, A; Marshall, JC; Miners, JO; Rowland, A; Sorich, MJ; van Dyk, M; Wood, LS, 2019
)
0.78
" Mean sU decrement by dosing per CKD groups was determined by CKD stage."( Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.
Crittenden, DB; Fisher, MC; Keenan, RT; Krasnokutsky, S; Modjinou, DV; Oh, C; Pillinger, MH; Toprover, M, 2019
)
0.51
" Lead and cadmium exposure had a positive association with serum uric acid levels in a dose-response manner in the nationally representative Korean population."( Associations between blood lead, cadmium, and mercury levels with hyperuricemia in the Korean general population: A retrospective analysis of population-based nationally representative data.
Jung, W; Kang, J; Kim, Y; Lihm, H, 2019
)
0.75
"To test the influence of oral fructose and glucose dose-response solutions in blood glucose (BG), glucagon, triglycerides, uricaemia, and malondialdehyde in postprandial states in type 1 diabetes mellitus (T1DM) patients."( Postprandial metabolic effects of fructose and glucose in type 1 diabetes patients: a pilot randomized crossover clinical trial.
Dantas, JR; Lima, ÉDS; Rodacki, M; Rosado, EL; Souto, DL; Zajdenverg, L, 2019
)
0.51
" In this study, the main pharmacodynamics of different dosing methods and dosages of P-b4 was firstly investigated."( LC-MS Analysis of Serum for the Metabolomic Investigation of the Effects of Pulchinenoside b4 Administration in Monosodium Urate Crystal-Induced Gouty Arthritis Rat Model.
Ding, R; Feng, Y; Liu, P; Lyu, S; OuYang, H; Rao, Y; Yang, S, 2019
)
0.51
" Multiple-adjusted spline regression analyses further confirmed the dose-response relationship between UA levels and HT."( Serum Uric Acid and Risk of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke.
Cheng, Y; Liu, J; Liu, M; Song, Q; Wang, Y; Wei, C, 2020
)
1.04
"Higher intake of dairy products was associated with lower serum UA levels in both sexes, with a statistical dose-response gradient."( Intake of selected foods and beverages and serum uric acid levels in adults: ELSA-Brasil (2008-2010).
Barreto, SM; Coelho, CG; Diniz, MFHS; Silva, MTD; Telles, RW; Vidigal, PG, 2020
)
0.81
" Dose-response analysis was also carried out."( Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants.
Bellissimo, N; Hekmatdoost, A; Maroofi, M; Rahimi-Sakak, F; Rahmani, J, 2019
)
0.99
"Our analysis indicates a positive dose-response association between SUA and CVD mortality risk."( Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants.
Bellissimo, N; Hekmatdoost, A; Maroofi, M; Rahimi-Sakak, F; Rahmani, J, 2019
)
0.99
"Twenty-four male Wistar-Kyoto rats (220-240 g, 12 weeks old) were dosed with 50 μL of 10 nm GNPs administered intraperitoneally with or without 200 mg/kg/day Vit E or 200 mg/kg/day α-Lip."( The Protective Roles of Vitamin E and α-Lipoic Acid Against Nephrotoxicity, Lipid Peroxidation, and Inflammatory Damage Induced by Gold Nanoparticles.
Abdelhalim, MAK; Al-Mohy, YH; Ghannam, MM; Qaid, HA, 2020
)
0.56
" Dose-response relationship between SUA changing trajectories and NAFLD risk was evaluated through the testing of trajectory groups as a continuous variable."( Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study.
Guo, X; Kang, X; Li, H; Ma, Z; Tao, L; Xu, C; Yang, X; Zhang, S; Zheng, D, 2020
)
0.84
" Allopurinol, a urate synthesis inhibitor, is generally administered at a reduced dosage to patients with renal impairment."( Recent approaches to gout drug discovery: an update.
Anzai, N; Hisatome, I; Kudo, H; Otani, N; Ouchi, M; Tsuruoka, S, 2020
)
0.56
" The lower risk of incident HTN after xanthine oxidase inhibitors exhibited a significant dose-response trend."( Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.
Hsu, CC; Hwu, CM; Li, HL; Lin, KH; Wei, JC; Yang, CC; Yen, FS, 2021
)
0.62
" Further investigations are required to confirm the present results following multiple dosing with febuxostat."( A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects.
Carland, JE; Day, RO; Graham, GG; Kamel, B; Liu, Z; Pile, KD; Stocker, SL; Williams, KM, 2020
)
0.56
" Dose-response analyses revealed a novel linear trend between the risk of hyperuricaemia and total, animal-derived retinol intake separately."( Association between retinol intake and hyperuricaemia in adults.
Guo, Y; Han, M; Sun, J; Sun, Y; Yang, F; Zhang, P, 2021
)
0.62
" A restrictive cubic spline method was used to estimate the dose-response relationship between SUA and fundus arteriosclerosis."( Gender-Specific Association between Serum Uric Acid and Incident Fundus Arteriosclerosis in Chinese Population: A Retrospective Cross-Sectional Study.
Cao, J; Gao, Y; Jiang, Y; Liu, C; Liu, Q; Tang, Z; Wang, Y; Yi, N; Zhang, X, 2020
)
0.82
" The effect of uricosuric agents on the decrease in hospitalized stroke risk indicated a dose-response relationship."( Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Hsu, CC; Hwu, CM; Li, HL; Wei, JC; Yen, FS, 2020
)
0.56
"Febuxostat is initiated in chronic kidney disease (CKD) patients to lower uric acid but without any renal dosing scheme."( A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
Aoun, M; Chelala, D; Dfouni, A; Salloum, R; Sleilaty, G, 2020
)
0.79
" And as febuxostat dosage increased, more patients achieved the target SU level."( Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan, M; Gu, J; Li, X; Liu, J; Schlesinger, N; Wu, X; Zhao, B, 2021
)
0.62
" And as febuxostat dosage increased, more patients achieved the target SU level."( Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan, M; Gu, J; Li, X; Liu, J; Schlesinger, N; Wu, X; Zhao, B, 2021
)
0.62
" Natural cubic spline models were conducted to investigate the dose-response association of SUA with incident hypercholesterolaemia and hypertriglyceridaemia."( Serum uric acid and risk of incident hypercholesterolaemia and hypertriglyceridaemia in middle-aged and older Chinese: a 4-year prospective cohort study.
Jia, C; Li, Y; Tian, L; Zheng, H, 2020
)
1.04
"After full adjustment, we observed a positive linear dose-response relationship between SUA and hypercholesterolaemia and hypertriglyceridaemia."( Serum uric acid and risk of incident hypercholesterolaemia and hypertriglyceridaemia in middle-aged and older Chinese: a 4-year prospective cohort study.
Jia, C; Li, Y; Tian, L; Zheng, H, 2020
)
1.04
" KEY MESSAGES The natural cubic spline model showed a positive linear dose-response relationship between serum uric acid levels and hypertriglyceridaemia."( Serum uric acid and risk of incident hypercholesterolaemia and hypertriglyceridaemia in middle-aged and older Chinese: a 4-year prospective cohort study.
Jia, C; Li, Y; Tian, L; Zheng, H, 2020
)
1.25
" A restricted cubic spline model was used to analyze the dose-response relationship between SUA/Cr and MS morbidity."( [Association of serum uric acid/creatinine ratio and metabolic syndrome in euthyroid population].
Liu, S; Peng, J; Song, J; Tang, Z; Zhang, J; Zhang, L, 2020
)
0.87
" The correlation intensity between SUA/Cr value and MS showed a linear dose-response relationship in euthyroid population(P<0."( [Association of serum uric acid/creatinine ratio and metabolic syndrome in euthyroid population].
Liu, S; Peng, J; Song, J; Tang, Z; Zhang, J; Zhang, L, 2020
)
0.87
"Our results explore the promising evidences that SUA level showed a positive correlation with AAC score in a dose-response manner."( Clinical relevance of serum uric acid and abdominal aortic-calcification in a national survey.
Chen, WL; Li, YW, 2020
)
0.85
" A significant dose-response relationship existed between UA level and stroke, and between UA level and IS for females but not for males."( The contribution of plasma uric acid to the risk of stroke in hypertensive populations.
Cao, L; Chen, H; Hu, F; Li, X; Ma, J; Peng, X; Shi, J; Wang, C; Wang, R; Yan, G; Zhang, Y; Zhao, S,
)
0.43
" The dosage of allopurinol to accomplish full control of gout and to lower serum uric acid to normal or near-normal levels varies with the severity of the disease, and needs to be flexible to permit precise, customized dose titration for individual patients."( Physicochemical Stability of Compounded Allopurinol Suspensions in PCCA Base, SuspendIt.
Bostanian, LA; Graves, RA; Le, G; Mandal, TK; Morris, TC; Pramar, YV,
)
0.36
" A restrictive cubic spline method was used to estimate the dose-response relationship between uric acid and high IOP."( Gender-Specific Association Between Serum Uric Acid and Incident High Intraocular Pressure in Chinese Population: A Cross-Sectional Study.
Huang, W; Hui, J; Ji, X; Liu, D; Liu, Q; Tang, Z; Yan, D, 2020
)
1.04
" In addition, uric acid had an inverse U-shaped nonlinear dose-response relationship with high IOP in women."( Gender-Specific Association Between Serum Uric Acid and Incident High Intraocular Pressure in Chinese Population: A Cross-Sectional Study.
Huang, W; Hui, J; Ji, X; Liu, D; Liu, Q; Tang, Z; Yan, D, 2020
)
1.18
"5% without dose-response relationship."( Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.
Burnier, M; Dingemanse, J; Flamion, B; Gueneau de Mussy, P; Guérard, N; Iglarz, M; Maillard, MP; Sidharta, PN; Wuerzner, G, 2021
)
0.62
"Both BMI and urate are independent predictors of dementia, and there are inverse monotonic and dose-response associations of BMI and urate with dementia."( Associations of BMI and Serum Urate with Developing Dementia: A Prospective Cohort Study.
Cao, Z; Li, S; Wang, Y; Xu, C; Xu, F; Yang, H; Zhang, Y, 2020
)
0.56
" Our study revealed a dose-response relationship between uric acid levels and kidney function."( Uric acid level and kidney function: a cross-sectional study of the Korean national health and nutrition examination survey (2016-2017).
Choi, DW; Joo, HJ; Joo, JH; Kim, GR; Park, EC, 2020
)
2.25
" Every 3 weeks, the dosage of the drug was increased by 50 mg to 300 mg per day under the control of the level of serum uric acid (sUA)."( [Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout].
Gromova, MA; Kislyak, OA; Malysheva, NV; Tsurko, VV, 2020
)
0.77
" The dose-response relationship between SUA trajectories and MetS risk was examined by treating trajectory groups as a continuous variable."( Dose-response relationship between distinct serum uric acid trajectories and metabolic syndrome risk: A 5-year prospective cohort study.
Guo, X; Han, Y; Li, Q; Liu, J; Ma, Z; Tao, L; Yang, X; Zhang, J; Zhang, S, 2021
)
0.87
" Also, a quantitative assessment of the dose-response association between them has not been reported."( Serum uric acid and risk of prehypertension: a dose-response meta-analysis of 17 observational studies of approximately 79 thousand participants.
Han, M; Hong, F; Li, Q; Liu, L; Qie, R; Zhan, S; Zhang, C; Zhang, J; Zhang, L; Zhang, X, 2022
)
1.2
" Simulations based on the uric acid model were performed to assess dose-response of verinurad in combination with XOI, and to investigate the impact of covariates."( A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases.
Aksenov, S; Eriksson, UG; Johansson, S; Leander, J; Parkinson, J; Rekić, D; Sunnåker, M, 2021
)
1.13
"We aimed to evaluate the UA lowering effectiveness and provider adherence to the institutional protocol, as well as the cost-efficiency of this dosing strategy."( A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
Hossain, S; Naber, M; Yacobucci, MJ, 2022
)
0.72
" Restricted cubic spline regression was used to estimate the dose-response association between UPF consumption and risk of hyperuricemia."( Association between consumption of ultra-processed foods and hyperuricemia: TCLSIH prospective cohort study.
Gan, S; Gu, Y; Jia, Q; Jiao, H; Liu, L; Meng, G; Niu, K; Song, K; Sun, S; Wang, X; Wang, Y; Wu, H; Wu, Y; Ye, M; Zhang, Q; Zhang, S; Zhang, T; Zhou, M, 2021
)
0.62
" Logistic regression and restricted cubic spline were performed to assess the association and dose-response relationship between eating-out frequency and hyperuricemia."( Association of eating out frequency and other factors with serum uric acid levels and hyperuricemia in Chinese population.
Cui, N; Dong, X; Hou, J; Huo, W; Li, L; Li, X; Li, Y; Liao, W; Liu, X; Mao, Z; Wang, C; Xue, Y, 2022
)
0.96
" A non-linear positive dose-response relationship between eating-out frequency and hyperuricemia was observed."( Association of eating out frequency and other factors with serum uric acid levels and hyperuricemia in Chinese population.
Cui, N; Dong, X; Hou, J; Huo, W; Li, L; Li, X; Li, Y; Liao, W; Liu, X; Mao, Z; Wang, C; Xue, Y, 2022
)
0.96
"We showed a dose-response effect of SUA on incident MetS independent of BMI, BRI and BSI in healthy individuals."( Serum uric acid is associated with incident metabolic syndrome independent of body shape index and body roundness index in healthy individuals.
Chen, CC; Liu, CW; Tseng, GS; Tu, CM; Wei, TE, 2021
)
1.1
"022), while arsenic levels showed a positive and linear dose-response relationship with HUA risk (p for non-linearity = 0."( Associations of plasma multiple metals with risk of hyperuricemia: A cross-sectional study in a mid-aged and older population of China.
Chen, G; Cheng, J; Huang, H; Huang, S; Liu, N; Liu, R; Lv, Z; Peng, C; Wang, T; Wen, Y; Yu, S; Zhang, Y; Zheng, S; Zhong, D; Zhou, G; Zou, X, 2022
)
0.72
"Higher plasma levels of zinc and arsenic might increase HUA risk and showed positive dose-response relationships."( Associations of plasma multiple metals with risk of hyperuricemia: A cross-sectional study in a mid-aged and older population of China.
Chen, G; Cheng, J; Huang, H; Huang, S; Liu, N; Liu, R; Lv, Z; Peng, C; Wang, T; Wen, Y; Yu, S; Zhang, Y; Zheng, S; Zhong, D; Zhou, G; Zou, X, 2022
)
0.72
" The dosage used and the effect of allopurinol in this population, either or not undergoing therapeutic hypothermia (TH), were evaluated."( Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Allegaert, K; Annink, KV; Bakkali, LE; Benders, MJNL; Chu, WY; Dorlo, TPC; Franz, AR; Hagen, A; Huitema, ADR; Maiwald, CA; Nijstad, AL; Schroth, M; van Bel, F; van Weissenbruch, MM, 2022
)
0.92
" The dosing regimen applied in the ALBINO trial leads to the targeted XO inhibition in neonates treated with or without TH."( Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Allegaert, K; Annink, KV; Bakkali, LE; Benders, MJNL; Chu, WY; Dorlo, TPC; Franz, AR; Hagen, A; Huitema, ADR; Maiwald, CA; Nijstad, AL; Schroth, M; van Bel, F; van Weissenbruch, MM, 2022
)
0.92
" Drug selection is based on patient characteristics such as sex, age, and comorbidities, and pediatric dosage is based on usage experience in adults."( Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
Honda, M; Horiuchi, H; Iijima, T; Ito, S; Murano, H; Nakajima, A; Torii, T; Yamanaka, H, 2021
)
0.62
" In multiple logistic regression analysis, the favipiravir dosage (adjusted OR = 1."( Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir.
Hanai, Y; Ishii, Y; Mabuchi, T; Matsuo, K; Miyazaki, T; Nishimura, K; Nishizawa, K; Ohashi, H; Tateda, K; Uekusa, S; Yoshio, T; Yoshizawa, S, 2022
)
1.01
" The linear dose-response analysis revealed that the risk of DKD increased by 24% for each 1 mg/dl increase of SUA."( Serum uric acid levels and diabetic kidney disease in patients with type 2 diabetes mellitus: A dose-response meta-analysis.
Feng, J; Ji, P; Li, H; Qin, H; Wei, L; Yu, Q; Zhang, J; Zhu, J, 2022
)
1.2
"The association between serum uric acid (SUA) and the components of dyslipidaemia and their dose-response relationships have not been thoroughly explored."( The dose-response relationship of serum uric acid with Dyslipidaemia and its components: a cross-sectional study of a Chinese multi-ethnic cohort.
Hong, F; Liu, L; Ma, L; Ma, N; Nie, C; Peng, L; Wang, Z; Xu, D; Xu, Y; Yang, F; Yang, T; Zeng, Q, 2022
)
1.28
" The dose-response associations between SUA and various dyslipidaemias were investigated using restricted cubic spline regression."( The dose-response relationship of serum uric acid with Dyslipidaemia and its components: a cross-sectional study of a Chinese multi-ethnic cohort.
Hong, F; Liu, L; Ma, L; Ma, N; Nie, C; Peng, L; Wang, Z; Xu, D; Xu, Y; Yang, F; Yang, T; Zeng, Q, 2022
)
0.99
" A positive dose-response but nonlinear association was found between SUA and total dyslipidaemia, high total cholesterol, and low HDL, whereas an inverse U-shaped association was found between SUA and high LDL-C ( P-nonlinear< 0."( The dose-response relationship of serum uric acid with Dyslipidaemia and its components: a cross-sectional study of a Chinese multi-ethnic cohort.
Hong, F; Liu, L; Ma, L; Ma, N; Nie, C; Peng, L; Wang, Z; Xu, D; Xu, Y; Yang, F; Yang, T; Zeng, Q, 2022
)
0.99
" A nonlinear dose-response relationship was found between SUA levels and dyslipidaemia and its components."( The dose-response relationship of serum uric acid with Dyslipidaemia and its components: a cross-sectional study of a Chinese multi-ethnic cohort.
Hong, F; Liu, L; Ma, L; Ma, N; Nie, C; Peng, L; Wang, Z; Xu, D; Xu, Y; Yang, F; Yang, T; Zeng, Q, 2022
)
0.99
" Moreover, the PRS also revealed a dose-response trend between AH rates and quartile scores."( Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses.
Chang, JG; Chang, SJ; Chang, YS; Chen, YC; Chung, CC; Huang, CM; Lin, CY; Liu, TY; Tsai, FJ, 2023
)
0.91
" The current study indicated that tea consumption may have a mitigating effect on the HUA population and provided a basis for further research on the efficacy of tea on the dosage and mechanism of uric acid-lowering effects in humans."( Tea (
Cao, F; Chen, R; Lai, X; Li, Q; Sun, L; Sun, S; Wen, S; Wu, D; Zhang, Z, 2022
)
0.91
" In addition, the dose-response curve was also used to discuss the relationship between SUA and pSS-HT."( Relationship between serum uric acid and hypertension in patients with primary Sjögren's syndrome: A retrospective cohort study.
Luo, Q; Qin, L; Wang, H; Yang, X; Zhang, Y, 2022
)
1.02
" The top hit Spartinin F2 exhibited inhibition percentages at 10 μM dosage as high as 84."( Discovery of derivatives from Spartina alterniflora-sourced moiety as xanthine oxidase inhibitors to lower uric acid.
Jiao, QC; Liu, J; Qin, P; Wang, B; Yang, YS; Zhou, KM, 2022
)
0.93
" There was a nonlinear dose-response between TG, HDL-C, and serum uric acid (SUA)."( Association between dyslipidaemia and the risk of hyperuricaemia: a six-year longitudinal cohort study of elderly individuals in China.
Dong, H; Ma, Q; Sun, H; Xu, Y; Zhang, B; Zhang, J, 2022
)
0.96
" Drug dose titration (DT) is the process by which dosage is progressively adjusted to the patient till a steady dose is reached."( Modelling and assessing one- and two-drug dose titrations.
Alonso, JR; Kamišalić, A; Pečnik, Š; Riaño, D, 2022
)
0.72
" For 137 sessions, in 36 patients the total daily dosage of UV-absorbing drugs was less than 500 mg, and for 6 sessions 3 patients received additional UV-absorbing drugs."( Treatment with Paracetamol Can Interfere with the Intradialytic Optical Estimation in Spent Dialysate of Uric Acid but Not of Indoxyl Sulfate.
Adoberg, A; Arund, J; Dhondt, A; Fridolin, I; Glorieux, G; Holmar, J; Lauri, K; Leis, L; Luman, M; Paats, J; Pilt, K; Tanner, R; Uhlin, F, 2022
)
0.94
" However, more randomized controlled trials are needed in the future to determine the efficacy and optimal dosing design of probiotics."( Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.
Chen, H; Deng, Y; He, Q; Li, J; Liu, H; Xiang, W; Yang, K; Zeng, L; Zhu, X, 2022
)
0.72
" However, other cardiometabolic markers were not improved by magnesium supplementation at the above dosage and duration."( Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.
Amini, M; Aminorroaya, A; Feizi, A; Salehidoost, R; Taghipour Boroujeni, G, 2022
)
0.72
" Kaplan-Meier survival curves showed a clear dose-response relationship between C-index and all-cause mortality."( Conicity-index predicts all-cause mortality in Chinese older people: a 10-year community follow-up.
Bao, Q; Cai, S; Cheng, B; Dong, J; Li, M; Li, Y; Ma, S; Su, Y; Sun, J; Wang, S; Zhang, A; Zhang, Y; Zhu, P, 2022
)
0.72
" Possible dose-response relationships were analyzed through restricted cubic spline regression."( Associations of metal exposure with hyperuricemia and gout in general adults.
Hui, R; Shi, S; Wang, J; Xing, Y; Xu, J; Zhang, Y; Zhu, L; Zhu, X, 2022
)
0.72
" Logistic regression models were used to estimate the association between LAP and HWH risk, restricted cubic splines (RCS) were used to analyze the dose-response relationship between them."( The lipid accumulation product (LAP) association with hyperuricemic hypertension in the China Health and Nutrition Survey: A cross-sectional study.
Geng, Y; Ping, Z; Shang, Y; Wang, H; Wang, J; Yin, X; Zhou, M, 2022
)
0.72
" The dose-response relationship of SUACr and MetS was further assessed by a restricted cubic spline model (RCS)."( Association of the serum uric acid to creatinine ratio with metabolic syndrome in the middle age and older population in China.
Guo, Y; Huang, H; Huang, S; Li, L; Liu, D; Wu, F; Zhong, D, 2022
)
1.02
" Compared with the lowest uric acid quartile, each of the upper 3 quartiles were associated with an increased risk of AF in a dose-response manner."( Elevated Uric Acid Is Associated With New-Onset Atrial Fibrillation: Results From the Swedish AMORIS Cohort.
Ding, M; Gigante, B; Hammar, N; Lind, V; Modig, K; Viet, NN, 2023
)
1.63
" The data suggests that there is a dose-response relationship between the two."( Implications of serum uric acid for female infertility: results from the national health and nutrition examination survey, 2013-2020.
Chen, X; Deng, K; Huang, J; Huang, Q; Liang, J; Nie, W; Yang, Q, 2023
)
1.22
" However, information on the dose-response relationship between SUA and CVD is limited in the Chinese population."( U-shaped association of serum uric acid with cardiovascular disease risk scores and the modifying role of sex among Chinese adults.
Bi, M; Feng, A; Liu, Y; Tian, S, 2023
)
1.2
" Most guidelines recommend using a lifelong continuation treat-to-target (T2T) strategy, in which ULT is dosed or combined until a serum urate target has been reached and maintained."( Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
den Broeder, AA; den Broeder, N; Flendrie, M; Peeters, IR; Taylor, WJ; van Herwaarden, N, 2023
)
0.91
" The association between low SUA and mortality and the dose-response analysis on the non-linearity of SUA-mortality relationship were not statistically significant."( Association of serum uric acid levels with cardiovascular and all-cause mortality in hypertensive patients in China: a cohort study.
Chen, JY; Feng, YQ; Lo, K; Tang, ST; Yu, YL; Zhang, SX, 2023
)
1.23
"074), moreover, RCS results suggested an approximately linear dose-response relationship between the OBS and these 3 tests."( Association of the Oxidative Balance Score and Cognitive Function and the Mediating Role of Oxidative Stress: Evidence from the National Health and Nutrition Examination Survey (NHANES) 2011-2014.
Cen, M; Fu, X; Li, H; Song, L; Wu, J, 2023
)
0.91
" Mice group treated with the highest AR dosage showed significantly lower (p < 0."( The antihyperuricemia activity of Astragali Radix through regulating the expression of uric acid transporters via PI3K/Akt signalling pathway.
Barreira, JCM; Chen, JS; Chen, YY; Feng, CY; Guo, X; Li, NY; Liu, C; Prieto, MA; Sun, JY; Sun, KX; Zhang, JD; Zhang, MQ, 2023
)
1.13
" Dose-response relationships were analyzed using restricted cubic spline regression."( Association of N, N-diethyl-m-toluamide (DEET) with hyperuricemia among adult participants.
Cui, Q; Guan, G; Hui, R; Liu, Z; Wu, R; Xing, Y; Zhang, Y; Zhu, L; Zhu, X, 2023
)
0.91
" In addition, multivariate restricted cubic spline analysis was conducted to investigate the dose-response risk."( Elevated serum uric acid is a risk factor for progression to prediabetes in Japanese women: A 5-year retrospective chort study.
Minemura, Y; Nakayama, T; Shimodaira, M, 2023
)
1.26
" Furthermore, in women, restricted cubic spline analysis revealed the dose-response relationship between SUA and progression to prediabetes."( Elevated serum uric acid is a risk factor for progression to prediabetes in Japanese women: A 5-year retrospective chort study.
Minemura, Y; Nakayama, T; Shimodaira, M, 2023
)
1.26
" Logistic regression was used to estimate the association between hyperuricemia and nephrolithiasis, and a restricted cubic spline (RCS) model was used to explore the dose-response relationship between SUA and the risk of nephrolithiasis."( Asymptomatic hyperuricemia associated with increased risk of nephrolithiasis: a cross-sectional study.
Cheng, N; Deng, H; Hou, Z; Li, Y; Meng, Q; Song, C; Sun, Y; Wang, Q; Yin, J; Zhang, J; Zhang, X, 2023
)
0.91
" Restricted cubic spline regression analysis showed that the risk of nephrolithiasis increased with the increase of SUA, and when the level of SUA is higher than 356 μmol/L in males and higher than 265 μmol/L in females, there is a dose-response relationship between the increase of SUA and the risk of nephrolithiasis in both males and females (p for nonlinearity = 0."( Asymptomatic hyperuricemia associated with increased risk of nephrolithiasis: a cross-sectional study.
Cheng, N; Deng, H; Hou, Z; Li, Y; Meng, Q; Song, C; Sun, Y; Wang, Q; Yin, J; Zhang, J; Zhang, X, 2023
)
0.91
" A comparison of baseline blood metabolites with those obtained after the full Cy dosage (day 0) revealed a significant increase in blood glucose and uric acid levels with an associated decrease in serum calcium, sodium, and potassium levels."( Serum Electrolyte and Metabolic Changes During Conditioning of Autologous Hematopoietic Stem Cell Transplantation in Patients with Autoimmune Diseases: A Prospective Study in a Single Institution.
Gallardo-Pérez, MM; Méndez-Laureano, BJ; Minutti-Zanella, C; Ruiz-Argüelles, GJ, 2023
)
1.11
" ULT dosage is also limited by formularies and clinical inertia."( Mechanisms and rationale for uricase use in patients with gout.
Lioté, F; Pérez-Ruiz, F; Schlesinger, N, 2023
)
0.91
" And in analyses stratified by race and marital status, we similarly found a dose-response relationship between UA and hypertension among Hispanics and unmarried people."( Relationship between serum uric acid and hypertension in the general US population aged 20 years and older: A cross-sectional study based on NHANES 2007 to 2016.
Ouyang, Y; Wang, Y; Zhang, Y, 2023
)
1.21
"Studying the effects of uric acid levels on cognitive function and quantifying the dose-response relationship."( Uric acid levels and risk of cognitive impairment: Dose-response meta-analysis of prospective cohort studies.
Liu, Q; Peng, M; Si, G; Yang, T, 2023
)
2.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
uric acidAn oxopurine that is the final oxidation product of purine metabolism.
uric acidAn oxopurine that is the final oxidation product of purine metabolism.
uric acidAn oxopurine that is the final oxidation product of purine metabolism.
uric acidAn oxopurine that is the final oxidation product of purine metabolism.
uric acidAn oxopurine that is the final oxidation product of purine metabolism.
uric acidAn oxopurine that is the final oxidation product of purine metabolism.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (60)

PathwayProteinsCompounds
Transport of small molecules39295
SLC-mediated transmembrane transport13567
Transport of bile salts and organic acids, metal ions and amine compounds4928
Organic cation/anion/zwitterion transport67
Organic anion transport13
Ion channel transport4516
Stimuli-sensing channels2910
Metabolism14961108
Nucleotide metabolism89125
Nucleotide catabolism3671
Purine catabolism2051
Uricosurics Pathway, Pharmacodynamics123
Purine Metabolism3766
Adenosine Deaminase Deficiency3766
Adenylosuccinate Lyase Deficiency3766
Gout or Kelley-Seegmiller Syndrome3766
Lesch-Nyhan Syndrome (LNS)3766
Molybdenum Cofactor Deficiency3766
Xanthine Dehydrogenase Deficiency (Xanthinuria)3766
Purine Nucleoside Phosphorylase Deficiency3766
AICA-Ribosiduria3766
Azathioprine Action Pathway4782
Mercaptopurine Action Pathway4780
Thioguanine Action Pathway4781
Xanthinuria Type I3766
Xanthinuria Type II3766
Adenine Phosphoribosyltransferase Deficiency (APRT)3766
Mitochondrial DNA Depletion Syndrome-33766
Myoadenylate Deaminase Deficiency3766
Adenosine Nucleotides Degradation813
AMP Degradation (Hypoxanthine Route)413
Urate Degradation to Ureidoglycolate613
Urate Degradation to Glyoxylate714
Disease1278231
Disorders of transmembrane transporters10243
SLC transporter disorders4537
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1)02
Mitochondrial DNA Depletion Syndrome3566
inosine 5'-phosphate degradation013
guanosine nucleotides degradation II125
adenosine nucleotides degradation I327
superpathway of purines degradation in plants745
nucleobase ascorbate transport I16
ureide biosynthesis220
urate conversion to allantoin I311
superpathway of guanosine nucleotides degradation (plants)227
guanosine nucleotides degradation I226
purine nucleotides degradation I (plants)334
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
Purine metabolism1336
Organic Nitrogen Assimilation436
Metabolic Epileptic Disorders2589
salvage pathways of adenine, hypoxanthine, and their nucleosides023
Folic acid network070
Ureide biosynthesis017
Iron uptake and transport030
Selenium micronutrient network095
Biochemical pathways: part I0466
Purine metabolism and related disorders2353
Molybdenum cofactor (Moco) biosynthesis78
ureide biogenesis417
Purine metabolism938
Urate synthesis211

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 8Homo sapiens (human)Ki275.00000.04004.22979.0000AID681040
Solute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)IC50 (µMol)300.0000300.0000650.00001,000.0000AID1794831
Guanine deaminaseHomo sapiens (human)Ki4.34001.88003.63405.5500AID502390
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Glycogen phosphorylase, liver formHomo sapiens (human)Kd550.000092.0000250.0000550.0000AID977611
Chain A, glycogen phosphorylase, liver formHomo sapiens (human)Kd550.000092.0000250.0000550.0000AID977611
Chain A, Glycogen phosphorylase, liver formHomo sapiens (human)Kd550.000092.0000250.0000550.0000AID977611
Chain A, Glycogen phosphorylase, liver formHomo sapiens (human)Kd550.000092.0000250.0000550.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Homo sapiens (human)Km947.00000.42004.61839.3000AID679379
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
hexose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
urate transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
fructose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
urate metabolic processSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
proton transmembrane transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
monosaccharide transmembrane transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
allantoin metabolic processGuanine deaminaseHomo sapiens (human)
nucleobase-containing compound metabolic processGuanine deaminaseHomo sapiens (human)
guanine catabolic processGuanine deaminaseHomo sapiens (human)
deoxyguanosine catabolic processGuanine deaminaseHomo sapiens (human)
nervous system developmentGuanine deaminaseHomo sapiens (human)
amide catabolic processGuanine deaminaseHomo sapiens (human)
GMP catabolic processGuanine deaminaseHomo sapiens (human)
dGMP catabolic processGuanine deaminaseHomo sapiens (human)
guanine metabolic processGuanine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
carbohydrate:proton symporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
fructose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
urate transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
hexose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
zinc ion bindingGuanine deaminaseHomo sapiens (human)
guanine deaminase activityGuanine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
cytosolGuanine deaminaseHomo sapiens (human)
cytosolGuanine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (60)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2002Chemistry & biology, Aug, Volume: 9, Issue:8
Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase.
AID1811Experimentally measured binding affinity data derived from PDB2002Chemistry & biology, Aug, Volume: 9, Issue:8
Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase.
AID1058626Antioxidant activity assessed as DPPH free radical scavenging activity by spectroscopic analysis2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Antioxidant activities of 5-hydroxyoxindole and its 3-hydroxy-3-phenacyl derivatives: the suppression of lipid peroxidation and intracellular oxidative stress.
AID1071842Antioxidant activity assessed as t-butylhyroperoxide-induced alkylperoxyl radical scavenging activity by ESR spin trapping method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID1071844Antioxidant activity assessed as riboflavin/EDTA-induced superoxide anion radical scavenging activity by ESR spin trapping method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID1424233Antioxidant activity assessed as hydroxyl radical scavenging activity by measuring rate constant using UV irradiation by ESR spin trapping method2017European journal of medicinal chemistry, Jun-16, Volume: 133Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases.
AID389190Antioxidant activity assessed as oxygen radical absorbance capacity index value by fluorescein protection assay2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
Antioxidant capacity of human blood plasma and human urine: simultaneous evaluation of the ORAC index and ascorbic acid concentration employing pyrogallol red as probe.
AID679521TP_TRANSPORTER: inhibition of PAH uptake (PAH: 1 uM, Urate: 100 uM) in Xenopus laevis oocytes1999Biochemical and biophysical research communications, Feb-16, Volume: 255, Issue:2
Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3).
AID681749TP_TRANSPORTER: inhibition of PAH uptake (PAH: 50 uM, Urate; 1000 uM) in Xenopus laevis oocytes1997The Journal of biological chemistry, Nov-28, Volume: 272, Issue:48
Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney.
AID1071847Antioxidant activity assessed as DMSO/H2O2-induced methyl radical scavenging activity by ESR spin trapping method relative to DMPO2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID227565Percent inhibition at 100 uM against peroxidation of liposomal suspension of dilinoleoylphosphatidylcholine (DPLC) indicated by DMVN at 40 degree Centigrade1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID1071849Antioxidant activity assessed as AAPH-induced alkoxyl radical scavenging activity by ESR spin trapping method relative to CYPMPO2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID681141TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Molecular pharmacology, May, Volume: 59, Issue:5
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
AID453742Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in Hepes buffer at pH 8 by continuous spectrophotometric assay in presence of 150 mM2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID1071845Antioxidant activity assessed as H2O2-induced hydroxyl radical scavenging activity by ESR spin trapping method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID227566Percent inhibition at 100 uM against peroxidation of methyl linoleate / DMVN in TBA /methanol medium at 40 degree Centigrade1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID1725623Acid dissociation constant, pKa of the compound2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity.
AID679373TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Biochemical and biophysical research communications, Feb-16, Volume: 255, Issue:2
Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3).
AID681040TP_TRANSPORTER: inhibition of Estrone sulfate in Xenopus laevis oocytes2003Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, , Volume: 13, Issue:5
Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux.
AID613867Inhibition of N-terminal His6-tagged Trypanosoma brucei CTPS assessed as NH3-dependent CTP formation by continuous spectrophotometric assay2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Activation and inhibition of CTP synthase from Trypanosoma brucei, the causative agent of African sleeping sickness.
AID1071846Antioxidant activity assessed as rosebengal-induced singlet oxygen radical scavenging activity by ESR spin trapping method relative to 4-OH-TEMP2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID55471Binding affinity to DNA intercalator Acridine orange.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Structural basis for the binding affinity of xanthines with the DNA intercalator acridine orange.
AID326216Antioxidant activity in human plasma assessed as inhibition of cholesteryl ester hydroperoxide formation after 60 mins relative to control2008Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
Antioxidant capacity of BO-653, 2,3-dihydro-5-hydroxy-4,6-di-tert-butyl-2,2-dipentylbenzofuran, and uric acid as evaluated by ORAC method and inhibition of lipid peroxidation.
AID252794Insulin release in rat pancreatic beta-cells after 15 minutes of administration of the Na-salt of compound at 1 mM was measured2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
AID453746Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in TAPS buffer at pH 8.5 by continuous spectrophotometric assay in presence of 10 mM2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID679379TP_TRANSPORTER: uptake in OAT1-expressing S2 cells2003Kidney international, Jan, Volume: 63, Issue:1
Urate transport via human PAH transporter hOAT1 and its gene structure.
AID453743Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in TAPS buffer at pH 8.5 by continuous spectrophotometric assay in presence of 150 m2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID230361Reducing activity to scavenge 10 uM 1, 1-diphenylpicrylhydrazyl (DPPH)1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID1071851Antioxidant activity assessed as H2O2-induced hydroxyl radical scavenging activity by ESR spin trapping method relative to CYPMPO2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID1058623Antioxidant activity in human HL60 cells assessed as reduction of H2O2-induced intracellular oxidative stress at 10 uM after 1 hr using DCFH-DA by FACS analysis2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Antioxidant activities of 5-hydroxyoxindole and its 3-hydroxy-3-phenacyl derivatives: the suppression of lipid peroxidation and intracellular oxidative stress.
AID252792Insulin release in rat pancreatic beta-cells after 15 minutes of administration at 1 mM was measured2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
AID1071850Antioxidant activity assessed as riboflavin/EDTA-induced superoxide anion radical scavenging activity by ESR spin trapping method relative to CYPMPO2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID1424234Antioxidant activity assessed as singlet oxygen scavenging activity by measuring rate constant using VIS irradiation by ESR spin trapping method2017European journal of medicinal chemistry, Jun-16, Volume: 133Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases.
AID679450TP_TRANSPORTER: inhibition of benzylpenicillin uptake by Urate at a concentration of 1000uM in Oat3-expressing oocyte cells2004The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
AID252793Insulin release in rat pancreatic beta-cells after 15 minutes of administration of the K-salt of compound at 1 mM was measured2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
AID545994Inhibition of Trypanosoma cruzi dihydroorotate dehydrogenase by isothermal titration calorimetry2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
AID1058624Octanol-water partition coefficient, logKOW of the compound2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Antioxidant activities of 5-hydroxyoxindole and its 3-hydroxy-3-phenacyl derivatives: the suppression of lipid peroxidation and intracellular oxidative stress.
AID1071841Antioxidant activity assessed as DMSO/H2O2-induced methyl radical scavenging activity by ESR spin trapping method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID453745Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in Hepes buffer at pH 8 by continuous spectrophotometric assay in presence of 10 mM 2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID23266Partition coefficient (logP)1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID502390Inhibition of GDA by colorimetric assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine.
AID1071840Antioxidant activity assessed as rosebengal-induced singlet oxygen radical scavenging activity by ESR spin trapping method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID1424232Antioxidant activity assessed as superoxide anion free radical scavenging activity by measuring rate constant using UV irradiation by ESR spin trapping method2017European journal of medicinal chemistry, Jun-16, Volume: 133Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases.
AID1058625Antioxidant activity against tert-butylhydroperoxide-induced lipid peroxidation in rat liver microsomes after 20 mins by TBARS method2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Antioxidant activities of 5-hydroxyoxindole and its 3-hydroxy-3-phenacyl derivatives: the suppression of lipid peroxidation and intracellular oxidative stress.
AID389192Antioxidant activity assessed as oxygen radical absorbance capacity index value by pyrogallol red protection assay2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
Antioxidant capacity of human blood plasma and human urine: simultaneous evaluation of the ORAC index and ascorbic acid concentration employing pyrogallol red as probe.
AID678986TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Biochemical and biophysical research communications, Feb-16, Volume: 255, Issue:2
Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3).
AID679517TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Urate: 2000 uM) in Xenopus laevis oocytes1999The American journal of physiology, 01, Volume: 276, Issue:1
Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney.
AID1071848Antioxidant activity assessed as t-butylhyroperoxide-induced alkylperoxyl radical scavenging activity by ESR spin trapping method relative to CYPMPO2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID1071843Antioxidant activity assessed as AAPH-induced alkoxyl radical scavenging activity by ESR spin trapping method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
AID1424235Antioxidant activity assessed as alkoxyl radical scavenging activity by measuring rate constant by ESR spin trapping method2017European journal of medicinal chemistry, Jun-16, Volume: 133Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases.
AID678813TP_TRANSPORTER: trans-stimulation in Xenopus laevis oocytes2003Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, , Volume: 13, Issue:5
Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux.
AID239883Acid dissociation constant was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
AID681362TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997The Journal of biological chemistry, Jul-25, Volume: 272, Issue:30
Expression cloning and characterization of a novel multispecific organic anion transporter.
AID54305Tested for antioxidant activity using bovine heart mitochondria and iron(II) / dihydroxy fumaric acid (DHF) at 100 uM1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID326215Antioxidant activity assessed as oxygen radical scavenging activity in presence of human plasma by ORAC method relative to control2008Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
Antioxidant capacity of BO-653, 2,3-dihydro-5-hydroxy-4,6-di-tert-butyl-2,2-dipentylbenzofuran, and uric acid as evaluated by ORAC method and inhibition of lipid peroxidation.
AID252795Insulin release in rat pancreatic beta-cells after 15 minutes of administration of the NH4-salt of compound at 1 mM was measured2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26,478)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909844 (37.18)18.7374
1990's2514 (9.49)18.2507
2000's3617 (13.66)29.6817
2010's6962 (26.29)24.3611
2020's3541 (13.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 125.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index125.14 (24.57)
Research Supply Index10.30 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index273.45 (26.88)
Search Engine Supply Index2.28 (0.95)

This Compound (125.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,717 (6.14%)5.53%
Reviews2,369 (8.47%)6.00%
Case Studies1,414 (5.05%)4.05%
Observational296 (1.06%)0.25%
Other22,184 (79.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Relationship of Serum Uric Acid With Severity of Knee Osteoarthritis [NCT06149078]150 participants (Anticipated)Observational2023-12-10Not yet recruiting
Efficacy of Doxycycline as a Combination Therapy in the Treatment of Rheumatoid Arthritis [NCT03194204]160 participants (Actual)Interventional2019-10-01Completed
Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy [NCT03658317]150 participants (Anticipated)Interventional2018-09-30Not yet recruiting
Value of Uric Acid as Early Predictor of Lupus Nephritis in Assiut University Hospital [NCT05402735]100 participants (Anticipated)Observational2022-06-15Recruiting
A Phase 1, Single Centre, Two-Part, Open Label, Crossover Study in Healthy Volunteers Using Scintigraphy to Characterize the In Vivo Performance of ALLN-346 Enteric Coated Tablets [NCT05168683]Phase 112 participants (Actual)Interventional2022-01-11Completed
Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty [NCT02444013]Phase 4400 participants (Anticipated)Interventional2015-05-31Recruiting
The Relationship Between Uric Acid and Inflammatory Markers [NCT01323335]Phase 197 participants (Actual)Interventional2009-03-31Completed
Immunological Features of Unstable Angina Pectoris in Comorbidity With Anxiety-depressive Syndrome [NCT04599621]3 participants (Anticipated)Observational2018-11-05Recruiting
Probiotics for Gout / Hyperuricemia: A Randomized, Double-blind, Intervention, Parallel Controlled, Multicenter Clinical Trial [NCT04199325]300 participants (Anticipated)Interventional2018-11-01Recruiting
Randomized, Double Blind Study Assessing the Clinical Efficacy of Combined Treatment With Uric Acid and rtPA Administered Intravenously in Acute Ischemic Stroke Patients Within the First 4.5 Hours of Symptoms Onset [NCT00860366]Phase 2/Phase 3421 participants (Actual)Interventional2011-06-30Completed
Profile of Mother-caregivers of Children With Duchenne Muscular Dystrophy [NCT01921374]60 participants (Actual)Interventional2013-08-31Completed
the Association Between Serum Uric Acid Levels and the Risk of Metabolic Syndrome in Type 2 Diabetes Mellitus [NCT04575389]100 participants (Anticipated)Observational2020-10-01Not yet recruiting
Association of Elevated Serum Gamma Glutamyl Transferase (GGT) and Uric Acid at 9-14 Weeks Gestation With the Development of Gestational Diabetes Mellitus (GDM) [NCT04956094]200 participants (Anticipated)Observational2021-06-21Recruiting
Association of Maternal Uric Acid With Maternal Condition and Fetal Outcome in Pregnant Women With Hypertension [NCT01523327]80 participants (Anticipated)Observational2011-10-31Recruiting
The Association Between Serum Uric Acid Level and Acute Coronary Syndrome in_hospital Outcomes [NCT05770323]150 participants (Anticipated)Observational2023-03-22Not yet recruiting
Effect of Pegloticase on Reduction of Uric Acid in Patients With Tumor Lysis Syndrome: A Pilot Pragmatic Clinical Trial [NCT04745910]Phase 410 participants (Anticipated)Interventional2022-04-05Recruiting
Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia: Redefining Early Urate Disease [NCT02502565]150 participants (Actual)Observational2012-01-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]